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Table	  1.	  Physical-­‐	  chemical	  characteristics	  of	  hydrophobic	  substances	  used	  
in	  this	  thesis	  
	  
	  	  	  
 	  	  
 	  
Compound	   Formula	   Physical	  
state	  





Carvone	   C10H14O	   Oily	  liquid	   150.2	   2.7	   210	   Flavour	  
Indometacin	   C19H16ClNO4	   White	  powder	   357.7	   4.7	   270	   NSAID	  
Limonene	   C10H16	   Oily	  liquid	   136.2	   4.4	   210	   Cosmetic/fragrance	  
Linalool	   C10H18O	   Oily	  liquid	   154.2	   3.5	   210	   Cosmetic/fragrance	  
Naproxen	   C14H14O3	   White	  powder	   230.2	   3.34	   270	   NSAID	  
Nile	  Red	   C20H18N2O2	   iridescent	  powder	   318	   3.10	   210	   Lipophilic	  stain	  
Prednisolone	   C21H28O5	   White	  powder	   360.4	   1.42	   250	   Steroid	  anti-­‐Inflammatory	  
Retinyl-­‐	  
palmitate	  
C36H60O2	   Yellow	  oily	  liquid	   524.9	   15.5	   325	   Vit.	  A	  supplement	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Presentation	  of	  thesis’	  structure	  











1.	  Introduction	  	  
1.1	  	  	  	  	  	  Drug	  Delivery	  Systems:	  present	  and	  future	  	  Technology	   advance	   has	   always	   been	   driven	   by	   the	   necessity	   to	   improve	   and	  simplify	  human	  lifestyle,	  also	  to	  reduce	  economical	  costs.	  For	  any	  substance	  that	  is	  useful	   for	   process	   applications	   or	   pharmaceutical	   sciences,	   it	   is	   fundamental	   to	  arrive	  at	  the	  site	  of	  action	  with	  sufficient	  activity.	  This	  underlines	  the	  importance	  of	  effective	  delivery	  systems.	  	  	  “Delivery	  system”	  is	  a	  general	  concept	  that	  is	  constantly	  present	  in	  the	  formulation	  of	   medicines,	   agrochemicals,	   food	   products	   and	   cosmetics.	   Pharmaceutical,	  agrochemical,	   food	  and	  cosmetic	   industries	   face	  various	  problems	   in	  order	   to:	  a)	  produce	   stable	   products	   against	   chemical	   or	   physical	   degradation;	   b)	   mask	  unpleasant	   odours	   or	   taste;	   c)	   release	   of	   the	   active	   ingredients	   in	   a	   controlled	  fashion,	  with	   the	  ultimate	  aim	  of	  gaining	   the	  maximum	  customer	  satisfaction.	  To	  underline	   the	   importance	   of	   appropriate	   drug	   delivery	   systems,	   in	   the	   current	  pharmaceutical	  market	  the	  investments	  for	  new	  delivery	  systems	  can	  be	  estimated	  to	   be	   around	   $101bn	   (2009)	   worldwide,	   an	   enormous	   sum	   that	   is	   expected	   to	  double	   in	   value	   by	   2016	   (http://www.in-­‐pharmatechnologist.com/Materials-­‐Formulation/Drug-­‐delivery-­‐market-­‐to-­‐reach-­‐199bn-­‐by-­‐2016-­‐says-­‐GBI-­‐Research,	  online	  open	  source	  accessed	  on	  16/11/10)	  (Sagalowicz	  and	  Leser,	  2010;	  Madene	  et	  al.,	  2006).	  	  Often	   a	   delivery	   system	   is	   obtained	  when	   liquid	   or	   solid	   actives,	   and	   sometimes	  also	  gaseous	  ingredients,	  are	  entrapped	  in	  containing	  systems,	  which	  often	  consist	  of	  capsules	  of	  different	  dimensions.	  In	  a	  very	  simple	  way,	  capsules	  are	  formed	  by	  a	  central	  part	  called	  the	  core,	  where	  the	  active	  ingredients	  are	  localized,	  and	  a	  shell,	  sometimes	  called	  the	  coating,	  wall	  material	  or	  membrane,	  which	  contains	  the	  inner	  part.	   It	   is	   now	   sixty	   years	   since	   the	   first	   application	   of	   microencapsulation	   was	  developed	   for	   the	   production	   of	   carbonless	   copying	   paper	   (for	   a	   review,	   see	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Sagalowicz	   and	   Leser,	   2010)	   and	   almost	   twenty	   years	   since	   the	   first	   liposomal	  nanoparticle	  therapeutics	  were	  approved	  by	  FDA	  (Food	  and	  Drugs	  Administration,	  USA)	   for	   the	   treatment	   of	   AIDS	   associated	   with	   Kaposi’s	   sarcoma	   (Zhang	   et	   al.,	  2008).	  Yet,	  plenty	  of	   research	   is	   still	  being	  undertaken	   to	   improve	  aspects	   in	   the	  encapsulation	  technology.	  	  	  In	  principle,	  it	  is	  possible	  to	  encapsulate	  substances	  from	  visible	  granules	  of	  a	  few	  millimetres	   down	   to	   tiny	   particles	   in	   the	   nano	   scale.	   The	   formulation	   of	  encapsulated	  products	   in	  microcapsules,	  emulsions,	  micelles	  and	  nanoparticles	   is	  an	  effort	  commonly	  undertaken	  by	  academic	  and	  industrial	  scientists.	  	  	  Nowadays,	  microcapsules	   (1-­‐1000	   µm)	   can	   be	   produced	   as	   delivery	   systems	   by	  different	   techniques.	   The	   final	   products	   are	   solids,	   usually	   powder	   or	   granules,	  which	   are	   used	   straight	   away	   or	   further	   processed	   for	   more	   complex	   delivery	  systems	   (e.g.	   granules	   are	   compressed	   to	   form	   tablets)	   (Wise,	   2000).	   There	   are	  also	   liquid	   forms	   of	   delivery	   systems	   that	   include	   emulsions,	   micelles	   and	  liposomes/vesicles	   (Sagalowicz	   and	   Leser,	   2010).	   Emulsions	   are	   the	   uniform	  dispersion	  of	   two	   immiscible	   liquids	   and	  have	  a	  droplet	   size	   from	  100	  nm	   to	  10	  µm.	  On	   the	   contrary,	  micelles	   are	   aggregates	   obtained	   from	   the	   self-­‐assembly	   of	  amphiphilic	  molecules	  in	  water	  and	  are	  smaller	  than	  emulsions,	  with	  a	  mean	  size	  ranging	  from	  20	  nm	  to	  100	  nm	  (Soussan	  et	  al.,	  2009).	  	  	  Liposomes,	   which	   are	   generally	   constituted	   by	   monolamellar	   vesicles	   of	  phospholipids,	   are	   extensively	   used	   as	   delivery	   systems	   with	   a	   size	   range	  overlapping	   the	   micro-­‐	   and	   nano-­‐	   scale	   (from	   20	   nm	   up	   to	   1	   µm).	   In	   the	   new	  frontier	  of	  pharmaceutics	  that	  is	  usually	  defined	  as	  “nanomedicine”,	  the	  size	  range	  of	  delivery	  systems	  spans	  1	  to	  1000	  nm	  (Sagalowicz	  and	  Leser	  2010).	  This	  range	  includes	   only	   liposomes,	   polymer-­‐based	   nanocarriers	   and	   drug-­‐albumin	  conjugates,	   which	   have	   been	   approved	   and	   commercialized	   for	   various	   uses	   in	  clinical	  therapeutics	  to	  date	  (Zhang	  et	  al.,	  2008;	  Sagalowicz	  and	  Leser	  2010).	  Even	  if	   there	   is	   an	   enormous	   future	   potential	   for	   various	   applications	   of	   nano-­‐technology,	  in	  particular	  in	  delivering	  personalized	  medical	  treatment	  (Kim	  et	  al.,	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2010),	   a	   detailed	   discussion	   on	   nanoparticle-­‐based	   (as	   well	   as	   emulsion-­‐based)	  delivery	  systems	  goes	  beyond	  the	  scope	  of	  this	  thesis.	  	  The	  principal	  scope	  of	  all	  drug	  delivery	  systems	  is	  to	  allow	  hydrophobic	  drugs	  to	  be	  more	  dispersible	  in	  aqueous	  environments.	  For	  instance,	  a	  hydrophobic	  active	  ingredient	   formulated	   in	   emulsions	   is	   solubilized	   inside	   the	   liquid	   core	   of	   the	  droplet,	  while	  in	  micelles	  the	  same	  active	  is	  solubilized	  in	  the	  hydrophobic	  part	  of	  the	   surfactant.	   Conversely,	   the	   same	   active	   incorporated	   in	   liposomes	   will	   be	  concentrated	   within	   the	   phospholipid	   bilayer.	   The	   importance	   of	   obtaining	   an	  enhanced	   dispersion	   of	   active	   ingredients	   is	   that	   it	   facilitates	   their	   therapeutic	  action	  by	  reaching	  an	  appropriate	  concentration	  in	  body	  fluids,	  such	  as	  plasma.	  	  	  In	   the	   current	   technology	   of	   microencapsulation,	   there	   is	   a	   gap	   in	   the	   low	   cost	  production	   of	   capsules	   with	   size	   ranging	   between	   1	   and	   10	   μm.	   This	   is	   a	  particularly	  useful	  size	  range	  because	  the	  particles	  are	  small	  enough	  to	  go	  through	  small	   orifices,	   specifically	   nozzles	   used	   in	   processes	   such	   as	   ink-­‐jet	   printing	   and	  spray-­‐drying,	  but	  large	  enough	  not	  to	  diffuse	  away	  through	  Brownian	  movements.	  The	  topic	  of	  this	  project	  regards	  delivery	  systems	  of	  the	  same	  range.	  	  	  Microencapsulation	   can	   provide	   a	   simple	   and	   cost-­‐effective	   way	   to	   enclose	  bioactive	  materials,	   such	   as	   drugs	   and	   cells,	   within	   a	   semi-­‐permeable	   polymeric	  material.	  As	  for	  other	  delivery	  systems,	  the	  main	  purpose	  of	  this	  encapsulation	  is	  to	  protect	  the	  bioactive	  ingredients	  and	  allow	  their	  release	  in	  a	  controlled	  fashion.	  To	   this	   end,	   selected	   microorganisms	   can	   provide	   very	   efficient	   forms	   of	  microcapsules,	   because	   they	   solve	   a	   number	   of	   the	   practical	   problems	   such	   as	  chemical	   (hydrolysis)	   and	   physical	   instability	   (annealing,	   flocculation).	   Baker’s	  yeast,	   Saccharomyces	   cerevisae,	   is	   among	   the	   most	   useful	   types	   of	   natural	  microcapsules	  that	  can	  be	  exploited	  for	  drug	  delivery,	  as	  will	  be	  discussed	  below.	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1.2	   Definition	  of	  encapsulation	  	  In	   the	   biotechnology	   literature	   the	   term	   “encapsulation”	   has	   been	   used	   in	   two	  different	  contexts:	  1)	  Encapsulation	  of	  materials,	  essentially	  hydrophobic	  and	  hydrophilic	  substances,	  inside	   cells	   or	   delivery	   systems	   –	   this	   is	   the	   definition	   that	   has	   been	   followed	  through	  the	  present	  thesis;	  2)	  Encapsulation	  of	  cells	  (from	  microbial	  to	  human)	  within	  polymeric	  materials.	  	  The	  second	  definition	  encompasses	  the	  concept	  of	  artificial	  cells,	  which	  is	  intended	  as	   encapsulation	   of	   enzymes,	   proteins	   and	   other	   biological	   substrates	   within	  polymeric	  materials.	  All	   these	   systems	  will	   now	  be	  described	  here,	   starting	  with	  those	  defined	  as	  synthetic	  artificial	  cells;	  those	  containing	  whole	  animal	  cells	  will	  be	  described	  later	  in	  chapter	  1.2.1.	  	  	   	  The	   use	   and	   perspective	   of	   artificial	   cells,	   in	   pharmaceutical	   and	   therapeutic	  applications,	   have	  been	   comprehensively	   reviewed	   in	   (Chang,	   1998)	   and	   later	   in	  (Zhang	  et	  al.,	  2008).	  Interestingly,	  the	  concept	  of	  artificial	  cells	  can	  be	  traced	  back	  to	   the	   early	   work	   of	   Oparin	   in	   the	   1920’s.	   Especially	   in	   the	   last	   few	   decades,	  artificial	   cells	   have	   had	   a	   significant	   impact	   on	   the	   pharmaceutical	   and	  biotechnology	   industry,	   with	   diverse	   potential	   therapeutic	   applications	   (Chang,	  1998).	   Despite	   its	   potential,	   artificial	   cell	   technology	   is	   still	   complicated	   by	   the	  problem	  of	  what	   really	   constitutes	   an	   artificial	   cell.	   Zhang	   et	   al.	   (2008)	   describe	  two	   forms	   of	   artificial	   cells:	   (i)	   minimal	   encapsulation	   systems	   combining	  individual	   molecules	   to	   create	   complex	   cell	   functions;	   and	   (ii)	   systems	   that	  encapsulate	  living	  cells	  that	  are	  used	  to	  produce	  products	  like	  specific	  proteins,	  as	  originally	   introduced	   by	   TMS	   Chang	   in	   1964	   (Chang,	   2005)	   (see	   below	   chapter	  1.2.1).	   These	   encapsulation	   systems	   can	   be	   made	   up	   of	   different	   components,	  including	   liposomes.	   In	   biotechnological	   approaches,	   the	   use	   of	   artificial	   cells	   is	  based	   on	   the	   principle	   of	   retaining	   proteins,	   enzymes,	   cells	   or	   adsorbents.	   In	  addition,	   products	   from	   the	   enclosed	   materials	   (e.g.	   insulin	   from	   encapsulated	  pancreatic	  islets)	  can	  be	  released	  readily.	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For	   pharmaceutical	   and	   therapeutic	   applications,	   artificial	   cells	   started	   as	  microcapsules	  on	  the	  micron	  scale.	  Their	  size	  has	  now	  been	  expanded	  upwards,	  to	  the	   higher	   range	   of	   macrocapsules,	   and	   downwards	   to	   the	   nanometre	   range	   of	  nanocapsules	  (Chang,	  1998).	  	  Fig.	  1.2.1	  shows	  a	  schematic	  view	  of	  two	  approaches	  that	  are	  currently	  used	  to	  obtain	  different	  types	  of	  artificial	  cells.	  	  
	  
Figure	  1.2.	  1.	  This	  scheme	  illustrates	  two	  different	  strategies	  for	  obtaining	  artificial	  
cells	   (from	  Zhang	  et	  al,	  2008).	   In	  part	   (a),	  different	  molecules	  are	  encapsulated	   to	  
produce	  the	  essential	  components	  (6	  in	  total)	  of	  the	  artificial	  cell	  that	  are	  necessary	  
to	   respond	   to	   stimuli.	   Part	   (b)	   shows	   the	   encapsulation	   of	   cells	   in	   polymeric	  
material;	   in	   this	   way	   cells	   are	   protected	   from	   immunoreactions	   and	   produce	  
specific	  therapeutic	  agents	  under	  the	  effect	  of	  stimuli.  
 
1.2.1	   Encapsulation	  of	  cells	  
  In	   the	  biomedical	   literature,	   the	   term	  microencapsulation	   generally	   refers	   to	   the	  immobilization	  of	  live	  cells	  into	  suitable	  gels	  or	  matrices	  to	  produce	  detoxification	  devices,	   bioreactors	   and	   implantable	   cells	   (Chang,	   2005;	   Murua	   et	   al.,	   2008;	  Hernández	   et	   al.,	   2010).	  Most	   recently,	   the	   term	   ‘cell	   therapy’	   has	   been	   used	   to	  encompass	  all	  the	  approaches	  that	  have	  been	  investigated	  to	  treat	  tissue	  and	  organ	  deficiencies,	  e.g.	  type	  1	  diabetes,	  with	  the	  implantation	  of	  microcapsules	  containing	  suitable	   human	   or	   animal	   cells	   that	   can	   act	   as	   surrogates	   of	   organ	   transplants	  (Hernández	  et	  al.,	  2010).	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Current	  research	  in	  cell	  therapy	  has	  its	  roots	  in	  the	  pioneering	  work	  of	  TMS	  Chang,	  who	   introduced	   the	   concept	   and	   preparation	   of	   ‘artificial	   cells’	   	   (see	   above,	   and	  Chang	   (2005),	   for	   a	   comprehensive	   review).	   In	   biotechnology	   applications,	   the	  term	   ‘artificial	   cells’	   appears	   to	   be	   out	   of	   fashion	   nowadays	  with	   respect	   to	   the	  comprehensive	  concept	  of	  cell	  microencapsulation	  technology	  (Murua	  et	  al.,	  2008).	  This	  technology	  produces	  small	  microcapsules	  (ideally,	  with	  a	  diameter	  below	  400	  μm,	  see	  below)	  that	  entrap	   live	  animal	  cells	  within	  a	  semi-­‐permeable	  membrane,	  which	  allows	  the	  passage	  of	  nutrients	  but	  not	  of	  macromolecules,	  or	  the	  cells	  of	  the	  host.	   The	   fundamental	   clinical	   application	   of	   the	   technology	   is	   to	   introduce	   cells	  that	   can	   supplement	   missing	   enzymes	   or	   key	   bio-­‐products,	   for	   instance	   insulin,	  without	  inducing	  the	  innate	  immunological	  response	  that	  leads	  to	  tissue	  rejection,	  and	   the	   consequent	   use	   of	   the	   debilitating	   long-­‐term	   therapy	   with	  immunosuppressive	  drugs.	  	  	  Since	   the	   earliest	   ‘artificial	   cells’	   of	   Chang,	   the	   basic	   model	   of	   cell	  microencapsulation	  consists	  in	  a	  core	  of	  alginate,	  a	  natural	  polymer	  extracted	  from	  seaweeds,	   which	   forms	   a	   hydrogel	   surrounding	   the	   cells.	   The	   hydrogel	   is	   then	  coated	  with	  a	  thin	  layer	  of	  poly-­‐cations	  such	  as	  poly-­‐L-­‐lysine,	  which	  forms	  a	  semi-­‐permeable	  barrier	  with	  the	  external	  medium	  (and	  the	  host)	  and	  at	  the	  same	  time	  confers	  stability	  to	  the	  microcapsule.	  	  Several	  variations	  of	  this	  basic	  scheme	  have	  been	  studied,	  but	   the	  most	   commonly	  used	  materials	   remain	   the	  same:	  alginates	  and	   poly-­‐cations	   corresponding,	   or	   very	   similar	   to	   poly-­‐L-­‐Lysine,	   e.g.	   poly-­‐L-­‐ornithine(Murua	  et	  al.,	  2008;	  Hernández	  et	  al.,	  2010).	  	  The	  search	  for	  alternative	  biocompatible	  materials	  to	  improve	  the	  manufacturing	  of	   microcapsules	   and	   substitute	   alginates	   has	   been	   intense,	   but	   the	   results	  obtained	   so	   far	   have	   not	   been	   validated	   in	   depth	   (see	   Murua	   et	   al.,	   2008	   for	   a	  review	   of	   all	   tested	   materials),	   especially	   regarding	   the	   crucial	   issue	   of	  biocompatibility.	   Biocompatibility	   is	   defined	   as	   the	   ability	   of	   a	   biomaterial	   to	  deliver	   its	   intended	   application	  without	   inducing	   adverse	   host	   responses.	   In	   the	  case	   of	   microcapsules,	   their	   components	   need	   to	   have	   the	   maximal	  biocompatibility	   possible	   to	   ensure	   the	   long-­‐term	   efficacy	   of	   cell	  microencapsulation	   technology.	   Although	   alginates	   remain	   the	   most	   suitable	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material	   for	  cell	  microencapsulation,	   they	  suffer	   from	  a	  number	  of	  problems	  that	  regularly	   reduce	   their	   biocompatibility.	   The	   major	   problems	   derive	   from	   their	  natural	   source	   and	   their	   degree	   of	   purity.	   Alginates	   are	   unbranched	   binary	  copolymers	  of	   1	  →	  4	   linked	  β-­‐d-­‐mannuronic	   acid	   and	  α-­‐l-­‐glucuronic	   acid,	  with	   a	  wide	   variety	   of	   structures.	   The	   structural	   differences	   influence	   the	   physical	  properties	   of	   the	   alginates	   that	   are	   essential	   for	   optimal	  microencapsulation,	   for	  instance	   mechanical	   resistance	   and	   permeability.	   Being	   natural	   products	   of	  seaweeds	   harvested	   from	   wild	   marine	   sources,	   alginates	   invariably	   contain	  contaminations,	   including	   algal	   proteins	   that	   can	   elicit	   immune	   reactions	   in	  humans.	  Additionally,	  the	  performance	  of	  alginates	  is	  influenced	  by	  the	  industrial	  process	   used	   for	   their	   extraction,	   which	   can	   also	   add	   contaminants	   such	   as	  polyphenols.	   Indeed,	   several	   reports	   (reviewed	   by	   Hernandez	   et	   al.,	   2010)	   have	  shown	   that	   different	   levels	   of	   contaminants	   induce	   the	   release	   of	   inflammatory	  cytokines	  in	  host	  animals.	  One	  strategy	  to	  enhance	  the	  biocompatibility	  problems	  of	   alginates	   has	   been	   the	   chemical	  modification	   of	   their	   structure.	   However,	   the	  current	  perception	  is	  that	  the	  purity	  of	  alginates	  is	  generally	  more	  important	  than	  their	  chemical	  composition	  (Hernández	  et	  al.,	  2010).	  
A	   brief	  mention	   to	   the	   technology	   of	   cell	  microencapsulation	   is	  warranted	   here,	  also	   to	   compare	   it	  with	   the	   techniques	   for	   the	   production	   of	  microcapsules	   that	  will	  be	  described	  in	  more	  detail	   later	  (chapter	  1.2.3).	  The	  fundamental	   technique	  follows	  a	  scheme	  for	  generating	  controlled-­‐size	  droplets	  that	  are	  then	  stabilized	  by	  an	   interfacial	   process,	  which	   also	   forms	   a	   solid	  microcapsule	  membrane	   around	  the	   droplet.	   More	   recently,	   new	   techniques	   are	   emerging	   that	   reduce	   the	  manufacturing	   problems	   of	   common	   procedures.	   	   One	   example	   of	   these	   recent	  techniques	   is	   conformal	   coating,	   which	   can	   minimize	   membrane	   thickness	  (reviewed	   by	   Hernandez	   et	   al,	   2010).	   Independently	   of	   the	   technique	   used,	   cell	  microencapsulation	   technology	   still	   faces	   major	   issues	   that	   reduce	   the	   clinical	  applications	   for	   replacing	   or	   repairing	   diseased	   organs	   and	   tissues	   (Orive	   et	   al.,	  2003;	  Murua	  et	  al.,	  2008;	  Hernandez	  et	  al.,	  2010).	  	  
In	  particular,	  cell	  microcapsules	  must	  have	  the	  following	  critical	  properties:	  1)	  an	  optimal	   size	   below	   300–400	   μm,	   to	   guarantee	   sufficient	   diffusive	   transport	   of	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oxygen	   and	   nutrients	   to	   the	   cells	   within	   the	   capsule;	   2)	   sufficient	   membrane	  permeability	  to	  allow	  the	  penetration	  of	  macromolecular	  nutrients	  and	  the	  efflux	  of	  key	  bio-­‐pharmaceuticals,	  such	  as	  the	  small	  protein	  insulin,	  while	  preventing	  the	  penetration	  of	   larger	  protein	  molecules	   like	  antibodies,	  as	  well	  as	  host	  cells,	   into	  the	  capsule	  (clearly,	  the	  molecular	  weight	  cut-­‐off	  will	  have	  to	  be	  commensurate	  to	  the	  biomedical	  application	  of	  specific	  microcapsules);	  3)	  mechanical	  integrity	  and	  overall	   stability,	   to	   prevent	   no	   direct	   cell–cell	   contact	   between	   transplanted	   and	  host	  cells,	  while	  maintaining	  the	  structure	  of	  the	  microcapsules	  within	  the	  host	  for	  the	   longest	   duration	   possible;	   4)	   maximal	   biocompatibility,	   which	   implies	   the	  lowest	  level	  of	  immunogenicity;	  5)	  viability	  of	  the	  cells	  that	  are	  entrapped	  within	  the	  microcapsules.	  	  The	  issue	  of	  cell	  viability	  within	  the	  microcapsule	  is	  of	  crucial	   importance	  for	  the	  delivery	   and	  maintenance	   of	   the	   biopharmaceutical	   action	   that	   various	   types	   of	  cells	  can	  produce	  when	  implanted	  in	  the	  host.	  It	  is	  no	  point	  to	  discuss	  the	  diverse	  potential	  medical	  applications	  of	  cell	  microcapsules	  (reviewed	  by	  Chang,	  2005	  and	  Hernández	   et	   al.	   2010)	   without	   considering	   the	   biological	   effects	   that	   their	  implantation	  induces	  in	  the	  encapsulated	  cells.	  These	  cells	  require	  a	  constant	  flux	  of	   nutrients	   from	   the	   host	   tissue	   and	   bloodstream,	   the	  most	   critical	   of	   which	   is	  oxygen.	   Only	   spherical	   capsules	   with	   a	   diameter	   of	   less	   than	   400	   μm	   can	   allow	  sufficient	  flow	  of	  oxygen	  from	  the	  host	  blood	  without	  producing	  micro-­‐aerobic,	   if	  not	  anaerobic	  conditions	  for	  the	  cells	  lying	  at	  the	  centre	  of	  the	  capsule	  (Murua	  et	  al.,	  2008).	  Naturally,	  low	  levels	  of	  oxygen	  will	  induce	  cells	  to	  die,	  first	  by	  apoptosis	  and	  ultimately,	   under	   anaerobic	   conditions,	   by	   necrosis.	   Encapsulated	  dead	   cells	  are	   useless	   because	   the	   types	   of	   cells	   that	   are	   normally	   used	   for	  microencapsulation	   application	   have	   limited,	   if	   any,	   capacity	   of	   engulfment	   and	  phagocytosis,	  processes	  that	  could	  be	  of	  value	  for	  recycling	  biological	  components	  in	  the	  close	  environment	  of	  the	  microcapsule.	  	  	  Even	  under	  optimal	  size	  and	  flux	  conditions	  for	  oxygen	  circulation,	  the	  viability	  of	  the	   encapsulated	   cells	   is	   progressively	   undermined	   by	   cytotoxic	   and	  cytomodulatory	  compounds	  that	  the	  innate	  immunity	  of	  the	  host	  will	  throw	  at	  the	  foreign	  body	  of	  the	  implanted	  capsule.	  In	  vivo	  studies	  of	  implanted	  microcapsules	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have	   shown	   the	   progressive	   accumulation	   of	   granulocytes,	   macrophages,	  basophiles	   and	   mast	   cells	   around	   the	   capsule	   (Figure	   1.2.2).	   In	   particular,	  basophiles	   and	   mast	   cells	   will	   release	   small	   molecules	   such	   as	   histamine	   and	  thromboxanes,	  which	  will	  inevitably	  penetrate	  the	  microcapsule	  and	  activate	  their	  cognate	  receptors	  on	  the	  surface	  of	  the	  encapsulated	  cells,	  eliciting	  cell	  signals	  of	  stress	   and	   calcium	   overload.	   In	   the	   medium-­‐long	   term,	   these	   processes	   will	  compromise	   the	   viability	   of	   the	   target	   cells.	   In	   the	   case	   of	   diabetes,	   one	   major	  clinical	   application	   of	   cell	   therapy	   (Hernández	   et	   al.	   2010),	   the	   required	  permeability	   for	   the	   internally	   produced	   insulin	   will	   allow	   the	   penetration	   of	  cytotoxic	  small	  proteins	  like	  soluble	  TNF-­‐alpha	  and	  its	  analogue	  TRAIL,	  which	  are	  released	  by	  the	  host	  immune	  cells	  surrounding	  the	  capsule	  and	  can	  directly	  induce	  cell	  death	  via	  their	  ubiquitous	  receptors	  (Abdulghani	  and	  El-­‐Deiry,	  2010).	  Aside	  of	  transient	  immunosuppressive	  therapy	  (cited	  by	  Murua	  et	  al.,	  2008),	  very	  little	  can	  be	  done	  to	  reduce	  the	  innate	  immune	  response	  that	  the	  host	  will	  launch	  against	  the	  foreign	  microcapsules.	  	  




Figure	   1.2.2.	   Microcapsules	   of	   embryonic	   stem	   cells	   were	   implanted	   in	   the	  
peritoneal	  cavity	  of	  mice.	  A,	  image	  taken	  on	  day	  zero,	  B,	  after	  one	  month,	  C,	  after	  two	  
months,	  and	  D,	  after	  three	  months.	  Panel	  E	  and	  F	  show	  parallel	  images	  of	  the	  same	  
cell	   microcapsules	   cultivated	   in	   vitro.	   In	   panel	   F	   the	   image	   was	   obtained	   with	  
fluorescence	  microscopy	  after	  staining	  viable	  cells	  with	  the	  green	  fluorescent	  dye	  6-­‐
Carboxy-­‐Fluorescein-­‐Di-­‐Acetate	  (6-­‐CFDA,	  green)	  and	  dead	  cells	  	  with	  the	  membrane	  
impermeable	  DNA	  stain	  Propidium	  Iodide	  (PI,	  red).	  Images	  were	  adapted	  from	  Dean	  
et	  al.	  (2006),	  as	  presented	  by	  Murua	  et	  al.	  (2008).	  	  The	  problem	  of	  host	  tolerance,	  therefore,	  remains	  the	  major	  limiting	  factor	  for	  the	  present	  and	  future	  applications	  of	  cell	  therapy	  with	  microcapsules.	  	  	  	  In	   conclusion,	   the	   exciting	   possibility	   of	   producing	   cellular	   alternatives	   to	   organ	  transplantation	  with	   cells	   encapsulation	  has	  not	   lived	   to	   the	   expectations	  of	   two	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decades	  ago	  (Lanza	  et	  al.,	  1996	  cf.	  Hernández	  et	  al.,	  2010).	  This	  situation	  derives	  from	   a	   number	   of	   unsolved	   problems	   including:	   long	   term	   viability	   of	   the	  encapsulated	   cells,	   immunoreaction	   and	   limited	   stability	   of	   the	   microcapsules.	  Nevertheless,	  microencapsulated	  cells	  have	  a	  wide	  range	  of	  potential	   therapeutic	  application	   as	   “living	   drug	   delivery	   systems”,	   including	   cancer	   therapy.	   Further	  research	   and	   development	   needs	   to	   be	   undertaken	   in	   order	   to	   reduce	   all	   the	  problems	  of	  this	  biotechnology.	  	  	  
1.2.2   Micro-capsules with animal cells and yeast cells: common 
problems? 
 In	  reviewing	  the	  applications	  and	  problems	  of	  cell	  microencapsulation	  technology	  with	  human	  or	  animal	  cells,	  a	  set	  of	  problems	  has	  been	  encountered	   that	  will	  be	  found	   also	   in	   studying	   yeast	   cells	   as	   microscopic	   delivery	   systems.	   The	   first	  problem	  is	  the	  uniform	  size,	  300-­‐400	  μm	  representing	  the	  optimal	  diameter	  of	  the	  microcapsules	   to	   allow	   a	   constant	   diffusion	   of	   oxygen	   and	   nutrients	   inside	   the	  capsules	   when	   implanted	   in	   proximity	   of	   the	   host	   blood	   flow	   (Hernandez	   et	   al,	  2010;	   Murua	   et	   al.,	   2008).	   The	   second	   problem	   is	   linked	   to	   the	   permeability	  properties	   of	   the	   semi-­‐permeable	   envelope	   that	   surrounds	   the	   capsule,	  with	   the	  key	  issue	  of	  optimal	  cut-­‐off	  for	  the	  intended	  application.	  	  The	  third	  and	  most	   intriguing	  problem	  is	  related	  to	   the	  viability	  of	   the	  cells	  with	  respect	  to	  the	  loading	  and	  delivery	  processes.	  The	  encapsulation	  of	  S.cerivisae	  has	  arisen	  interest	  in	  the	  scientific	  community	  for	  various	  commercial	  applications.	  In	  one	   of	   the	  most	   recent	   studies,	   for	   example,	   yeast	   cells	   encapsulated	   in	   alginate	  microcapsules	   were	   used	   to	   hydrolyse	   urea	   to	   overcome	   renal	   failure	   uremia	  (Coussa	   et	   al.,	   2010).	   Another	   recent	   paper	   describes	   the	   application	   of	  encapsulated	   S.cerivisae	   cells	   to	   determine	   the	   oxygen	   demand	   of	   the	  microorganisms	   in	   a	   bioreactor,	   simply	   using	   a	   flow	   injection	   system	   (Seo	   et	   al.,	  2009).	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The	   next	   section	   presents	   a	   detail	   survey	   on	   the	   technological	   aspect	   of	  microencapsulation.	  This	  will	  be	  followed	  by	  a	  survey	  of	  the	  microencapsulation	  of	  actives	  into	  microorganisms,	  progressively	  focusing	  on	  baker’s	  yeast	  as	  the	  model	  biological	  system	  for	  previous	  encapsulation	  applications	  and	  the	  present	  project.	  	  	  
1.2.3	  	  	  Microcapsules	  technology	  	  	  Manufactured	   microcapsules	   can	   have	   different	   morphologies,	   size	   and	   ratio	  between	  core	  and	  coating	  materials.	  All	  these	  characteristics	  need	  to	  be	  considered	  when	  choosing	  a	  process	  to	  successfully	  produce	  the	  microcapsules	  and	  influence	  the	  stability	  and	  the	  release	  behaviour	  of	   the	  delivery	  systems.	  There	  are	  several	  types	   of	   microcapsules:	   matrix	   form,	   reservoir	   form,	   multicore,	   and	   some	  elaborates	   such	   as	   microencapsulated	   microcapsules	   and	   multi-­‐wall	   capsules,	  which	   are	   made	   by	   a	   sequence	   of	   microencapsulation	   processes.	   A	   schematic	  representation	  of	  these	  systems	  is	  illustrated	  in	  Figure	  1.2.3	  (Madene	  et	  al.,	  2006;	  Gibbs	  et	  al.,	  1999;	  Arshady,	  1993).	  	   	  	  	  	  	  
Figure	   1.2.3.	   Different	   morphology	   of	   microcapsules:	   a)	   microencapsulated	  
microcapsules,	  b)	  matrix,	  c)	  multi-­‐core,	  d)	  reservoir,	  e)	  multi-­‐wall.	  The	  illustration	  










	  Without	  doubt,	  spray	  drying	  is	  the	  most	  common	  and	  versatile	  technique	  used	  in	  the	   production	   of	   microcapsules	   with	   a	   size	   range	   of	   10-­‐100	   µm	   for	   the	  pharmaceutical	  and	  food	  industry.	  Figure	  1.2.4	  shows	  the	  massive	  apparatus	  of	  a	  spray	   dryer	   used	   for	   commercial	   scale	   production.	   Relatively	   fast,	   this	   process	  produces	  solid	  particles	  as	  a	  powder	  from	  liquids	  or	  mixture	  of	  liquids,	  in	  a	  sterile	  form	  if	  necessary.	  	  It	  consists	  mainly	  of	  four	  steps.	  
	  
Figure	  1.2.	  4.	  Spray-­‐dryer	  illustration	  from	  GEA	  Niro,	  world	  leader	  in	  the	  production	  
of	  spray-­‐dryers.	  The	  image	  is	  taken	  from	  http://www.niro.com/,	  accessed	  23	  
February	  2011.	  









Figure	  1.2.	  5.	  Images	  showing	  the	  details	  of	  different	  atomizers	  used	  in	  spray	  drying.	  
The	  images	  are	  taken	  from	  http://www.niro.com/,	  accessed	  23	  February	  2011.	  
	  The	   following	  step	   is	   the	  drying	  of	   the	   spray	  droplets	   in	   the	  hot	   chamber.	  Air	  or	  inert	  gas	  at	  high	  temperature	  100-­‐180	  ºC	  flow	  inside	  the	  chamber,	  meeting	  the	  fine	  droplets;	  the	  evaporation	  of	  solvent	  starts	  immediately	  after	  contact,	  leading	  to	  the	  formation	  of	  solid	  particles,	  which	  fall	  at	  the	  bottom	  of	  the	  chamber.	  The	  process	  of	  evaporation	   consumes	   the	   thermal	   energy	   that	   could	   destroy	   heat	   sensitive	  materials	   such	   as	   proteins.	   Therefore,	   this	   process	   may	   be	   relatively	   safe	   for	  proteins	  and	  similar	  biomolecules,	  whereas	  low-­‐boiling	  point	  aromatics	  molecules	  are	   lost	   during	   drying	   (Madene	   et	   al.,	   2006).	   The	   micro-­‐particles	   are	   then	  transported	   by	   the	   exhaust	   gas	   to	   the	   cyclone	   separator	   (C)	   for	   recovery,	   to	  complete	  the	  final	  step	  of	  the	  whole	  process.	  Only	  a	  few	  seconds	  are	  necessary	  to	  form	  the	  particles	  from	  the	  initial	  solution	  and	  their	  morphology	  is	  determined	  by	  modulating	   processing	   parameters	   and	   the	   excipients	   mixed	   in	   the	   feeding	  solution.	  	  	  As	   said	   before,	   this	   technique	   is	   widespread	   but	   has	   the	   problem	   of	   producing	  particles	   of	   limited	   uniformity.	   It	   also	   suffers	   from	   the	   difficulty	   of	   using	   highly	  concentrated	  solutions	  of	  polymeric	  material	  at	  low	  viscosity	  (Madene	  et	  al.,	  2006)	  to	  form	  the	  wall	  coating	  material.	  Moreover,	  some	  heat-­‐sensitive	  materials	  such	  as	  flavour	  are	  volatilized	  during	  the	  drying.	  In	  order	  to	  avoid	  the	  loss	  of	  these	  volatile	  materials,	  alternative	  methods	  of	  dehydration	  have	  been	  developed.	  Spray	  chilling	  and	   spray	   cooling	   are	   routinely	   used	   for	   the	   encapsulation	   of	   volatile	   aroma	  compounds.	   These	   techniques	   use	   low	   melting	   point	   substances	   to	   form	   the	  coating	   film	   on	   the	   atomized	  microdroplets,	   such	   as	   vegetable	   oil	   in	   the	   case	   of	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spray	  cooling	  and	  fractionated	  or	  hydrogenated	  vegetable	  oil,	  in	  the	  case	  of	  spray	  chilling.	   	   Firstly,	   the	   coating	  material	   and	   the	   active	   ingredients	   are	  melted,	   and	  then	  the	  dispersion	  is	  atomized	  into	  a	  vessel	  kept	  at	  low	  temperatures	  (-­‐	  50 °C	  for	  spray	  chilling,	  for	  example).	  The	  coating	  material	  solidifies	  immediately	  in	  the	  cold	  environment,	  leading	  to	  the	  formation	  of	  particles	  from	  droplets.	  Subsequently,	  the	  resulting	  powder	  of	  encapsulated	  actives	  is	  separated.	  	  Fluidised	  bed	  spray	  coating	  may	  be	  used	  to	  produce	  solid	  coated	  particles	  with	  size	  ranging	   from	   100	   µm	   to	   a	   few	   mm.	   The	   left	   part	   of	   Figure	   1.2.6	   shows	   the	  industrial	  apparatus	  to	  produce	  these	  coated	  particles,	  while	  the	  right	  part	  of	  the	  same	  figures	  shows	  a	  schematic	  of	  the	  instrument.	  	   	   	  	   	   	   	  	   	  	  
Figure	  1.2.	  6.	  Fluid	  Bed	  Processor	  for	  coating	  on	  real	  scale.	  The	  image	  on	  the	  left	  	  is	  
taken	   from	   http://www.niroinc.com/pharma_systems/fluid_bed_drying.asp	  
(accessed	  25	   February	  2011),	  while	   the	   schematic	   representation	  of	   the	   fluid	  bed	  
coater	  chamber	  right	  is	  taken	  from	  Madene	  et	  al.	  (2006).	  	  A	  fluidized	  bed	  is,	  in	  a	  very	  simple	  way,	  a	  bed	  of	  solid	  particles	  spread	  on	  a	  porous	  plate	   (Fig.	   1.2.6),	   through	  which	   a	   gas	   like	   air	   is	   passed.	   The	   voids	   between	   the	  particles	   let	   the	   fluid	   travel,	   but	  when	   the	   flow	   is	   at	   high	   rates	   the	   particles	   are	  displaced	  enough	  by	  the	  fluid	  to	  give	  the	  appearance	  of	  a	  boiling	  liquid	  (Madene	  et	  al.,	   2006).	   The	   fluid	   bed	   can	   be	   used	   to	   produce	   coated	   particles	   for	   controlled	  release	  or	  taste	  masking.	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Essentially	  the	  process	  is	  composed	  of	  three-­‐steps	  (Arshady,	  1993).	  The	  first	  step	  is	   the	   fluidisation	   of	   the	   particles	   (e.g.,	   as	   obtained	   by	   spray-­‐drying)	   in	   the	   hot	  chamber	   of	   the	   coater,	   while	   in	   the	   second	   step	   the	   coating	  material	   is	   sprayed	  through	  a	  nozzle	  into	  the	  suspended	  particles	  (Fig.	  1.2.6).	  The	  final	  step	  consists	  in	  the	  formation	  of	  the	  film	  coating	  from	  the	  coalescence	  of	  the	  sprayed	  droplets	  on	  the	   particle	   surface.	   The	   solvent	   where	   the	   coating	   polymer	   is	   solubilized	  evaporates	   in	   the	   hot	   air	   allowing	   the	   sprayed	  material	   to	   adhere	   and	   cover	   the	  particles.	  The	  coating	  and	  drying	  process	  can	  be	  repeated	  until	  the	  desired	  uniform	  coat	  is	  reached	  (Arshady,	  1993;	  Madene	  et	  al.,	  2006).	  A	  narrow	  size	  distribution	  of	  the	  particles	  is	  obtained	  and	  also	  the	  capacity	  of	  production	  is	  very	  versatile	  from	  grams	  to	  a	  ton	  per	  batch.	  	  	  Extrusion	  is	  another	  technology	  that	  is	  often	  used	  to	  prepare	  microcapsules.	  In	  this	  technique,	  the	  mixture	  of	   liquid	  substances	  is	  forced	  through	  a	  nozzle	  in	  order	  to	  be	  extruded	  or	  sprayed	  (Arshady,	  1993).	  Then,	  the	  generated	  droplets	  or	  filaments	  are	   solidified	   in	   a	   droplet-­‐hardening	   bath.	   Liquids	   to	   be	   encapsulated	   are	  mixed	  with	  the	  matrix	  polymer	  and	  an	  emulsifier	  at	  room	  temperature,	  or	  heated	  up	  at	  110	   °C	   when	   the	   polymers	   are	   carbohydrates,	   under	   vigorous	   stirring.	   The	  obtained	  dispersion	   is	   then	  sealed	   in	  a	   reactor	  and	   forced	   through	   the	  die	  under	  pressure.	   The	   microcapsules	   thus	   formed	   usually	   harden	   due	   to	   different	  mechanisms,	   such	   as	   the	   gelation	   or	   solidification	   by	   cooling	   the	   temperature	   in	  the	   bath,	   by	   chelating	   or	   cross-­‐linking	   the	   polymer	   of	   the	  micro-­‐particles	   in	   the	  presence	  of	  a	  chemical	  ingredient.	  	  	  Often	   in	  the	  hardening	  bath	  a	  stabilizer	  must	  be	  added	  to	  prevent	  aggregation	  of	  the	  particles.	  This	  methodology	  has	  been	  invented	  in	  the	  1950’s	  by	  Swisher	  and	  it	  is	   still	   used	   for	   flavours	   and	   drugs	   encapsulation	   (Arshady,	   1993).	   The	   most	  common	  polymers	  used	  for	  creating	  the	  droplet	  matrix	  are	  carbohydrates	  such	  as	  sucrose,	   corn	   syrup	   and	   maltodextrine;	   however,	   alginates	   also	   are	   used.	   The	  hardening	   liquid	   in	   the	   bath	   is	   often	   isopropyl	   alcohol,	   whereas	   a	   solution	   of	  calcium	  chloride	  is	  used	  for	  alginates.	  The	  particles	  size,	  usually	  400-­‐	  500	  µm,	  and	  their	   spheroidal	   shape	   can	   be	   modulated	   using	   different	   settings	   during	   the	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Figure	  1.2.	  7.	  	  Microencapsulator	  Electrostatis	  Process	  System.	  The	  image	  is	  taken	  
from	  NASA	  http://www.nasa.gov/mission_pages/station/research/pfms.html,	  accessed	  
25	  February	  2011.	  
	  These	   space	  microcapsules	   contained	   anti-­‐cancer	   drugs	   and	   as	   explained	   in	   the	  NASA	   web	   page	   (cf.	   Fig.	   1.2.7	   legend):	   ”These	   unique	   capsules,	   which	   resemble	  miniature	  liquid-­‐filled	  balloons	  the	  size	  of	  blood	  cells,	  are	  designed	  to	  deliver	  FDA-­‐approved,	  anti-­‐cancer	  drugs	  by	  injection	  into	  main	  arteries	  leading	  to	  tumours”.	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Chemical	  processes	  	  Among	  the	  chemical	  processes	  for	  producing	  microcapsules,	  co-­‐crystallisation	  is	  a	  simple	  and	  economical	  technique	  (Madene	  et	  al.,	  2006;	  Arshady,	  1993).	  The	  active	  ingredient	   is	   co-­‐precipitated	   and	   entrapped	   within	   the	   matrix	   material,	   usually	  carbohydrates.	  	  In	  most	  cases,	  the	  granular	  product	  is	  dried	  and	  screened	  for	  size.	  Diverse	  products	  can	  be	  encapsulated	  with	  this	  technique,	  including	  essential	  oils,	  fruit	  juices	  and	  flavours.	  The	  most	  reported	  example	  of	  microencapsulation	  by	  co-­‐crystallisation	   in	   the	   technical	   literature	   is	   that	   of	   a	   super-­‐saturated	   solution	   of	  sugar	   kept	   at	   high	   temperature	   (120°C)	   (Madene	   et	   al.,	   2006).	  When	   the	   active	  ingredient	   to	   be	   encapsulated	   is	   added	   to	   this	   saturated	   solution,	   the	  mixture	   is	  stirred	   and	   the	   temperature	   drops	   to	   the	   point	   that	   spontaneous	   crystallisation	  occurs.	  	  Coacervation	   is	   another	   chemical	   process	   for	   microencapsulation.	   It	   has	   been	  patented	  in	  1950s	  to	  produce	  pressure-­‐sensitive	  dye	  for	  the	  production	  of	  carbon-­‐	  less	  carbon	  paper.	  The	  process	  can	  produce	  particles	  with	  a	  size	  range	  between	  5	  and	   200	   µm	   but	   is	   very	   expensive	   (Arshady,	   1993;	   Madene	   et	   al.,	   2006).	  Coacervation	   (from	   the	   Latin	   cum	   +	   acervus,	   meaning	   cluster)	   is	   the	   term	  introduced	   in	   1949	   by	   the	   Dutch	   chemist	   Bungernberg	   de	   Jong	   to	   describe	   a	  phenomenon	   in	   colloidal	   solutions	  where	   fully	   solvated	  macromolecules,	   such	  as	  proteins,	   aggregate	   following	   partial	   de-­‐solvation	   (Arshady,	   1993).	   Basically,	   the	  process	  consists	  in	  the	  separation	  of	  tiny	  particles	  that	  agglomerate	  in	  a	  separate	  liquid	  phase	  called	  coacervate.	  As	  a	  general	  rule,	   the	  material	   to	  be	  encapsulated	  must	   be	   emulsified	   with	   the	   polymer	   carrier	   but	   has	   to	   be	   insoluble	   in	   the	  coacervate	   medium.	   Two	   mechanisms	   have	   been	   proposed	   for	   the	   process	   of	  microencapsulation	  by	  coacervation	  (Arshady,	  1993):	  a)	  newly	  formed	  coacervate	  nuclei	  deposit	  at	  the	  interface	  with	  the	  particle	  core	  droplets	  and	  are	  progressively	  coated;	   b)	   large	   coacervate	   drops	   are	   formed	   followed	   by	   addition	   and	  encapsulation	   of	   the	   core	   droplets.	   After	   solidification	   the	   resulting	   coated	  particles	   are	   collected	  by	   centrifugation	  or	   filtration.	  Coacervation	   can	  be	   simple	  with	   only	   one	   polymeric	   colloidal	   solution,	   or	   complex,	   when	   other	   polymeric	  compounds	  	  (e.g.	  arabic	  gum)	  are	  added	  to	  the	  mixture	  as	  shown	  in	  Figure	  1.2.8.	  





Figure	  1.2.	  8.	  Representation	  of	  the	  complex	  coacervation	  process	  –	  the	  picture	  has	  
been	  taken	  from	  the	  Gate2tech	  company:	  
http://www.gate2tech.com/article.php3?id_article=12,	  accessed	  25	  February	  2011.	  	  	  Unfortunately,	   this	   chemical	   process	   is	  more	   an	   “art”	   than	   a	   reliable	  method	   for	  producing	  microcapsules.	  Other	  problems	  include	  the	  fact	  that	  different	  polymers	  have	  different	  film-­‐coating	  capacity	  on	  different	  materials	  or	  medium,	  resulting	  in	  particles	   of	   different	   dimensions	   and	   properties.	   Moreover,	   stabilizers	   must	   be	  used	   in	   the	   medium	   to	   avoid	   coagulation	   of	   the	   resulting	   microcapsules;	  unfortunately,	  most	  stabilisers	  such	  as	  glutaraldeyde	  are	  toxic.	  	  Molecular	  inclusion	  is	  another	  chemical	  method	  to	  entrap	  actives	  at	  the	  molecular	  level	   (Rish	   and	   Reineccius,	   1995).	   Enzymatically	   modified	   starches	   are	   used	   to	  accomplish	   this	   inclusion	  process.	  Typically	  used	  are	  β-­‐cyclodextrines,	  which	  are	  ring	  shaped	  molecules	  where	  the	  length	  of	  the	  ring	  is	  due	  to	  seven	  glucose	  residues	  linked	   β	   -­‐1,4.	   The	   central	   part	   has	   a	   cavity	   with	   hydrophobic	   affinity,	   while	   the	  external	   surface	   is	   hydrophilic	   since	   it	   displays	   free	   -­‐OH	   groups	   on	   the	   outside.	  When	  mixed	  with	  β-­‐cyclodextrins,	  hydrophobic	  substances	  settle	  in	  the	  inner	  part	  of	   the	   cyclodextrin	   ring,	   with	   which	   they	   form	   a	   complex.	   This	   complex	   will	  become	  less	  soluble	  and	  precipitates	  out	  of	  the	  watery	  solution.	  The	  encapsulated	  products	  need	  the	  presence	  of	  water	  (e.g.	  animal	  mucosa)	  or	  high	  temperature	  to	  be	   released.	   Unfortunately,	   β-­‐cyclodextrines	   are	   very	   expensive	   and	   this	   limits	  their	  application	  of	  the	  methodology	  of	  microencapsulation.	  	  
	   	   	   Introduction	  
 
35	  
	  Although	   different	   materials,	   especially	   carbohydrates	   such	   as	   starches	   and	  dextrins,	   have	  been	   employed	   to	  produce	  delivery	   systems,	   lipids	   are	   commonly	  used	  to	  form	  capsules	  called	  liposomes.	  For	  instance,	  liposomal	  capsules	  have	  been	  widely	  used	  in	  the	  food	  industry	  to	  deliver	  food	  flavours	  and	  nutrients	  (Taylor	  et	  al.,	  2005).	  There	  are	  very	  many	  techniques	  to	  produce	  liposomes,	  but	  those	  most	  frequently	   used	   to	   deliver	   biopharmaceutical	   agents	   are	   based	   on	   the	   filter	  extrusion	   of	   multilamellar	   liposomes,	   which	   are	   obtained	   by	   three	   fundamental	  steps:	  solubilisation	  of	  the	  selected	  phospholipids	  in	  organic	  solvents,	  evaporation	  of	   the	  organic	   solvents	  and	   finally	   re-­‐dispersion	  of	   the	  phospholipids	   in	  buffered	  aqueous	   solutions.	   The	   latter	   technique	   produces	   mono-­‐lamellar	   liposomes,	   in	  particular	   large	  uni-­‐lamellar	  vesicles	   (LUV),	  which	  have	  a	   relatively	  homogenous	  size	  up	   to	  1	  µm	   (Soussan	  et	   al.,	   2009).	  To	   encapsulate	  water-­‐soluble	   actives,	   the	  method	   to	   produce	   LUV	   requires	   prior	   formation	   of	   monolamellar	   liposomes	  containing	   a	   high	   concentration	   of	   these	   actives,	  which	   subsequently	   need	   to	   be	  removed	   by	   filtration	   or	   centrifugation.	   Conversely,	   the	   encapsulation	   of	  hydrophobic	   actives	   such	   as	   cholesterol-­‐derived	   drugs	   is	   simply	   obtained	   by	  mixing	   them	   together	  with	   the	   phospholipid	   solution	   in	   organic	   solvents,	   before	  the	  formation	  of	  multilamellar	   liposomes.	   In	  this	  case	  the	  hydrophobic	  substance	  of	  interest	  will	  be	  incorporated	  within	  the	  membrane	  of	  the	  final	  LUV	  suspension,	  while	  the	  lumen	  of	  the	  liposome	  will	  be	  an	  empty	  bag	  of	  buffer.	  Clearly,	  there	  is	  a	  possibility	   of	   dual	   combination	   of	   hydrophobic	   and	   hydrophilic	   substances	  incorporated	   within	   the	   same	   liposome.	   Hydrophobic	   molecules	   will	   be	   hosted	  within	   the	   phospholipid	   bilayer	   of	   the	   vesicles,	  while	   the	   hydrophilic	   compound	  will	  be	  entrapped	  in	  the	  aqueous	  core	  of	  the	  vesicles.	  	  Liposomes	  are	  chemically	  not	  very	  stable	  because	  the	  unsaturated	  phospholipids	  of	  their	  bilayer	  easily	  undergo	  the	  process	  of	  peroxidation;	  additionally,	  their	  ester	  bonds	  hydrolyse	  over	   time.	   	  The	  product	   instability	   is	  not	  only	  due	   to	   these	   two	  processes,	  but	  also	  to	  annealing,	  the	  tendency	  of	  small	  liposomes	  (smaller	  than	  40	  nm)	   to	   fuse	   together	   (Soussan	  et	   al.,	   2009).	   	  Addition	  of	   anti	   aggregating	  agents,	  antioxidant	  agents	  and	  limited	  exposure	  to	  water	  can	  increase	  the	  stability	  of	  this	  delivery	  system.	  Another	  problem	  for	  liposomes	  is	  their	  ferrying	  capacity,	  which	  is	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limited	  (Kewal,	  2008).	  Unfortunately,	  they	  are	  not	  large	  enough	  to	  incorporate	  big	  quantities	   of	   hydrophilic	   macromolecules	   such	   as	   proteins	   and	   hydrophobic	  actives.	  The	   latter	   compounds	  can	  occupy	  only	  a	   small	   fraction	  of	   the	   liposomes’	  volume,	  because	  they	  can	  partition	  only	   in	  the	  phospholipid	  bilayer.	  This	  specific	  problem	   is	   the	  one	   that	   can	  be	  most	  effectively	   solved	  using	  microcapsules	   from	  microorganisms,	  as	  it	  will	  be	  discussed	  in	  chapter	  1.4	  of	  the	  thesis.	  	  	  Commercial	   applications	   of	   liposome-­‐based	   products	   are	   shown	   in	   Table	   1.2.1	  below.	   So	   far,	   the	   products	   approved	   for	   parenteral	   use	   belong	   to	   two	   main	  categories:	   anticancer	   and	   antifungal	   drugs	   (Storm	   and	   Crommelin,	   1998).	  Most	  recently,	   pharmaceutical	   and	   bio-­‐tech	   industries	   are	   also	   developing	   vaccines	  entrapped	  in	   liposomal	  formulations.	  These	  vaccines	  are	  for	  Hepatitis	  A,	  B	  and	  C,	  just	   to	   mention	   a	   few,	   and	   are	   being	   tested	   at	   the	   pre-­‐clinical	   stage	   (LIPOXEN,	  http://www.lipoxen.com/our-­‐technologies/imuxen.aspx,	  accessed	  18	  April	  2011).	  	  
Table	  1.2.	  1.	  Commercial	  liposome-­‐based	  pharmaceutical	  products.	  The	  list	  is	  
adapted	  from	  Storm	  and	  Crommelin	  (1998).	  	  
Product	  	   Drug	   Indication	  Ambisome	   Amphotericin	  B	   Serious	  fungal	  infection	  Abelcet	   Amphotericin	  B	   Serious	  fungal	  infection	  Amphocil	   Amphotericin	  B	   Serious	  fungal	  infection	  Doxila	  (Caelyx,	  in	  Europe)	   Doxorubicin	   Kaposi’s	  sarcoma	  DaunoXome	   Daunorubicin	   Kaposi’s	  sarcoma	  	  
1.3	  Solubility:	  the	  crucial	  parameter	  for	  drug	  delivery	  systems	  	  The	   importance	   of	   drug	   delivery	   systems	   has	   been	   recently	   reviewed	   in	   an	  editorial	   published	   in	   “Clinical	   Pharmacology	   and	   Therapeutics”	   (Smith	   and	  Uhl,	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2009).	   The	   principal	   aims	   of	   the	   vast	   field	   of	   drug	   delivery	   systems	   include	   the	  improvement	   of	   the	   ease	   of	   administration,	   the	   drug	   bioavailability,	   the	   patient	  compliance	  and,	  additionally,	  the	  reduction	  of	  the	  side	  effects	  derived	  from	  the	  use	  of	   the	   active	   ingredients.	   The	   new	   technologies	   that	   are	   developed	   for	   drug	  delivery	   revolve	   around	   not	   only	   medical	   interests,	   but	   also	   economical	   ones.	  Pharmaceutical	   industries	   extend	   the	   lifetime	   of	   their	   products	   by	   changing	   the	  formulation	  of	   their	   active	   ingredients,	  which	   allows	   launching	  new	  products	   on	  the	  market	  using	  old,	  well-­‐known	  actives	  under	  new	  packages.	  	  	  Research	   in	   drug	   delivery	   systems	   also	   involve	   improved	  ways	   of	   delivering	   the	  actives	   to	   the	   their	   desired	   targets.	   Among	   the	   various	   release	   mechanisms	   of	  these	   ingredients	  (Langer,	  1990),	  diffusion	  is	  the	  most	  pertinent	  to	  the	  project	  of	  this	  thesis.	  The	  active	  ingredients	  are	  formulated	  in	  polymeric	  systems	  that	  allow	  their	   local	   diffusion	   from	   the	   initial	   location	   to	   the	   polymer’s	   outer	   surface	   and	  then	   to	   the	   body.	   There	   are	   two	   main	   classes	   of	   diffusion-­‐controlled	   delivery	  systems:	  a)	  reservoir	  type	  (illustrated	  in	  Fig	  1.2.3d),	  where	  the	  active	  ingredients	  constitute	  the	  core	  of	  the	  system	  which	  is	  coated	  by	  a	  polymeric	  film;	  and	  b)	  matrix	  type	  (illustrated	  in	  fig	  1.2.3b),	  where	  the	  active	  ingredients	  are	  generally	  dispersed	  in	  a	  polymeric	  matrix	  that	  controls	  their	  release.	  Successful	  market	  applications	  of	  reservoir	   type	   of	   diffusion-­‐controlled	   systems	   are	  Ocusert	  ®	   and	   LGN-­‐20®.	   The	  former	   is	   an	   ophthalmic	   delivery	   system	   used	   for	   the	   constant	   release	   of	  pilocarpine,	   which	   lasts	   for	   one	   week,	   while	   the	   latter	   is	   an	   intrauterine	   device	  used	  for	  the	  constant	  release	  of	   levonorgestrel,	  a	  progesterone-­‐like	  drug	  (Langer,	  1990),	  which	  can	  last	  for	  one	  year.	  	  Nowadays	  it	  is	  possible	  to	  formulate	  matrices	  of	  different	  size,	  from	  nano	  to	  micro	  dimensions,	  but	  also	  macroscopic	  devices.	  The	  transport	  of	   the	  actives	   inside	  the	  delivery	   systems	   and	   their	   release	   depends	   on	   the	   geometry	   of	   the	   delivery	  system,	   on	   the	   physico-­‐chemical	   properties	   of	   the	   polymeric	   film	   or	  matrix	   and	  those	  of	   the	  actives,	  as	  well	  as	  on	   the	  conditions	  of	   the	   local	  environment	  where	  the	  release	  has	  been	  targeted	  (Wise,	  2000).	  Two	  of	  the	  most	  important	  factors	  that	  control	   the	   mechanism	   of	   mass	   transport	   into/from	   the	   vehicle	   in	   diffusion	  controlled	  systems	  are:	  a)	  the	  passive	  diffusion	  process	  of	  the	  matrix	  or	  polymeric	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film	  to	  water	  and	  actives;	  b)	  the	  solubility	  of	  the	  drug	  in	  the	  matrix	  or	  polymeric	  film	   and	   in	   the	   local	   environment	   (Langer,	   1990;	   Wise,	   2000).	   Therefore,	   the	  passive	   permeability	   of	   any	   substance	   is	   regulated	   by	   the	   combination	   of	   its	  diffusion	   and	   its	   solubility	   (through	   the	  partition	   coefficient)	   across	   the	  medium	  and	  the	  matrix	  or	  polymeric	  film	  of	  the	  vehicle.	  	  	  This	   general	   principle	   applies	   also	   to	   the	   specific	   delivery	   system	   constituted	  by	  yeast	   cells	   loaded	   with	   hydrophobic	   actives	   -­‐	   the	   subject	   of	   this	   thesis	   -­‐	   which	  resemble	   a	   complex	   reservoir	   type	   of	   delivery	   system	  with	  more	   than	   one	   core	  (see	   Figure	   3.4.1,	   chapter	   3).	   The	   bioactive	   agents	   are	   entrapped	   at	   high	  concentration	   in,	   predominantly,	   yeast	   lipid	   droplets,	   lipid-­‐filled	   organelles	  dispersed	  in	  the	  cytoplasm,	  which	  will	  be	  described	  in	  detail	  later	  (chapter	  1.7.3).	  Moreover,	   the	   external	   yeast	   cell	   wall	   works	   as	   a	   semi-­‐permeable	   polymeric	  membrane	   that	   regulates	   the	  diffusion	  process.	   The	  hydrophobic	   actives	   used	   in	  the	   current	   project,	   having	   low	   molecular	   weight	   (MW),	   possess	   high	   diffusion	  properties;	  therefore,	  their	  solubility	  in	  the	  polymeric	  film	  (e.g.	  yeast	  cell	  wall)	  and	  in	   the	   aqueous	   environment	   is	   the	   modulating	   step	   of	   their	   loading	   and	   their	  release	   in	   the	   designed	   target	   (see	   later	   chapter	   3).	   Given	   the	   paramount	  importance	   of	   solubility,	   here	   the	   thermodynamic	   definition	   of	   solubility	  will	   be	  briefly	   introduced,	   followed	   by	   an	   overview	   of	   the	   solubility	   of	   molecules	   in	  polymeric	  networks	  that	  are	  directly	  relevant	  to	  this	  project.	  	  	  The	   solubility	   of	   any	   substance	   in	   water	   or	   other	   solvents	   is	   determined	   by	  thermodynamics,	  which	   establishes	   the	   number	   of	  water/solvent	  molecules	   that	  will	  surround	  each	  molecule	  of	  the	  solute	  compound	  (compound	  to	  be	  solubilized).	  In	   the	   extreme	   case	   of	   complete	   solubility,	   the	   solute	   will	   be	   completely	  surrounded	  by	  water/solvent	  molecules	   (full	  hydration	  or	  solvation),	  whereas	   in	  the	   case	   of	   complete	   insolubility	   a	   physical	   separation	   will	   occur	   between	   the	  solute	   and	   the	  water/solvent	  molecules.	   Essentially,	   the	   realisation	   of	   these	   two	  different	  scenarios	  is	  determined	  by	  a	  thermodynamic	  balance,	  namely	  the	  change	  in	  “Gibbs	  energy”	  (ΔG)	  between	  two	  contributing	  factors.	  The	  first	  factor	  expresses	  the	   variation	   in	   the	   internal	   energy	   of	   the	   system,	   enthalpy	   (ΔH),	   whereas	   the	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second	   factor	   expresses	   the	   dispersal	   of	   energy	   or	   matter	   in	   the	   system,	   i.e.	  entropy	  (ΔS)	  (Atkins	  and	  De	  Paula,	  2006).	  	  In	  mathematical	  terms,	  this	  concept	  is	  translated	  into	  the	  following	  expression:	  	  
STHG Δ−Δ=Δ 	  	  	  	  	  	  	  eq	  1.3.1	  	  For	   the	   process	   of	   solubilisation,	   any	   change	   in	   enthalpy	   is	   determined	   by	   the	  possibility	   to	   form	   diverse	   interactions	   (hetero-­‐interactions)	   between	   the	  molecules	  of	  solvent	  and	  those	  of	  the	  solute.	  Predominantly,	  these	  interactions	  are	  hydrogen	   bonds,	   dipole-­‐dipole	   and	   Van	   der	  Waals	   (induced	   dipole)	   interactions.	  Taken	  separately,	   the	  molecules	  of	  solvent	  and	  those	  of	   the	  solute	  have	  a	  certain	  internal	   energy	   due	   to	   the	   same	   types	   of	   interactions	   (homo-­‐interactions).	   By	  mixing	   the	   solute	   in	   the	   solvent,	   there	   is	   a	   competition	   between	   these	   homo-­‐	  interactions	  and	  hetero-­‐interactions.	  If	  the	  hetero-­‐interactions	  prevail,	  the	  internal	  energy	  of	  the	  system	  decreases,	  resulting	  in	  a	  final	  ΔH	  <0	  (exothermic	  process).	  On	  the	   contrary,	   if	   the	   homo-­‐interactions	   prevail,	   the	   internal	   energy	   of	   the	   system	  increases,	  resulting	  in	  a	  final	  ΔH	  >0	  (endothermic	  process).	  As	  dictated	  by	  eq	  1.3.1,	  the	  fate	  for	  a	  solute	  dissolved	  in	  a	  chosen	  solvent	  is	  determined	  also	  by	  the	  change	  in	   the	   entropy	   of	   the	   system	   at	   constant	   temperature	   and	   pressure.	   Entropy	  represents	   the	   measure	   of	   a	   disorderly	   distribution	   of	   energy	   and	   matter	   in	   a	  system,	  which	  has	  associated	  a	  certain	  total	  energy	  established	  by	  temperature.	  	  	  In	   the	   context	   of	   solubility,	   the	   molecules	   of	   solvent	   and	   those	   of	   solute,	   when	  taken	  as	  separate	  entities,	  are	  distributed	  in	  energetic	  “microstates”	  that	  suddenly	  change	  when	  they	  are	  mixed	  together.	  In	  the	  process	  of	  solubilisation,	  the	  mixing	  of	   solvent	   and	   solute	   molecules	   improves	   the	   disorder	   of	   the	   system,	   i.e.	   the	  dispersal	  of	  matter	  and	  thus	  has	  favourable	  entropy	  (Atkins	  and	  De	  Paula,	  2006).	  	  Any	   spontaneous	  process	   in	   chemistry,	   at	   constant	   temperature	   and	  pressure,	   is	  driven	  towards	  a	  decrease	  in	  Gibbs	  energy	  value,	  which	  means	  that	  ΔG	  <	  0	  (Atkins	  and	  De	  Paula,	  2006).	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In	   conclusion,	   during	   a	   solubilisation	   process	   Gibbs	   energy	   decreases	   and	  therefore	   the	   process	   is	   spontaneous.	   Nevertheless,	   there	   is	   a	   restriction	   to	   this	  generalization.	   Even	   the	  most	  water-­‐soluble	   substance	   has	   a	   concentration	   limit	  for	   its	   solubility,	  which	   is	   around	  4-­‐5	  M	   for	   chaotropic	   substances	   like	  urea	   (Lee	  and	  Lahti,	  1972).	  On	  the	  other	  hand,	  the	  great	  majority	  of	  drugs	  are	  poorly	  soluble	  in	   water;	   this	   is	   a	   fundamental	   problem,	   which	   the	   delivery	   system	   may	   solve.	  Notably,	   animal	  biological	   fluids	  are	   rich	   in	  natural	   carrier	   systems,	   in	  particular	  serum	   albumins	   and	   lipoproteins,	   which	   reversibly	   bind	   and	   transport	   any	  hydrophobic	   substance	   (He	   and	   Carter,	   1992).	   However,	   these	   natural	   carriers	  usually	   sequester	   the	   actives	   and	   therefore	   prevent	   an	   efficient	   delivery	   to	   the	  desired	  targets	  in	  the	  body.	  	  	  In	  the	  specific	  context	  of	  this	  thesis,	  it	  is	  particularly	  important	  to	  describe	  how	  the	  solubility	  of	  hydrophobic	  substances	  is	  evaluated.	  In	  1949,	  Hildebrand	  published	  a	  classical	   paper	   in	   which	   he	   evaluated	   the	   factors	   that	   determine	   the	   solubility	  among	  non-­‐polar	  molecules	  and	  rationalized	  them	  in	  a	  mathematical	  model.	  This	  model	   introduces	   a	   new	   parameter	   called	   “δ”	   that	   contributes	   to	   the	   enthalpic	  factor	  represented	  in	  the	  general	  eq	  1.3.1.	  The	  introduction	  of	  this	  parameter	  was	  necessary	   in	   order	   to	   calculate	   the	   variation	   in	   internal	   energy	   of	   non-­‐ideal	  solutions	  during	  mixing.	  Specifically,	  δ	  is	  an	  energetic	  value	  related	  to	  the	  energy	  of	  vaporization	   (normalized	   for	   volume)	   of	   each	   substance	   that	   needs	   to	   be	  solubilized	   and	   is	   easily	   obtainable.	   	   These	   δ-­‐values	   are	   commonly	   called	  “Hildebrand	   solubility	   parameters”	   to	   underline	   their	   important	   role	   played	   in	  determining	  solubility	  (Hildebrand,	  1950).	  Non-­‐polar	  compounds	  easily	  dissolve	  in	  solvents	  according	  to	  similar	  “solubility	  parameters”.	  	  It	   is	  worth	  noting	   that	   the	   solubility	  of	  hydrophobic	  actives	  within	   the	  matrix	  or	  the	   polymeric	   film	   of	   the	   delivery	   system	   does	   not	   depend	   only	   upon	   the	  “Hildebrand	  solubility	  parameters”,	  but	  also	  on	  purely	  physical	  parameters	  such	  as	  their	   molecular	   dimensions.	   Cross-­‐linked	   polymers	   have	   spaces	   between	   their	  chains	   through	  which	  only	  molecules	  with	   appropriate	   size	   can	   freely	  move	   and	  pass.	   Therefore,	   in	   a	   polar	   polymeric	  material	   such	   as	   the	   yeast	   cell	  wall	   (cross-­‐linked	  polymer	  chains	  and	  water	  molecules),	  a	  physical	  limit	  has	  been	  found	  in	  the	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diffusion	  of	  hydrophilic	  molecules,	  c.a.	  800	  Da	  (Scherrer	  et	  al.,	  1974),	  whereas	  only	  recently	  the	  diffusion	  of	  hydrophobic	  compounds	  has	  been	  investigated	  (Kilcher	  et	  al.,	   2008).	   In	   the	   work	   of	   Kilcher	   et	   al.	   (2008),	   the	   solutes	   used	   to	   study	   the	  permeation	   mechanism	   of	   the	   yeast	   cell	   wall	   were	   hydrophobic	   polymers.	   The	  thermodynamic	  consideration	  discussed	  above	  assumes	  different	  connotations	  for	  polymeric	  solutes.	  In	  particular,	  the	  theory	  elaborated	  by	  Flory	  and	  Hugging	  needs	  to	  be	  used	   (Hildebrand,	  1950)	   for	   cases	   in	  which	  molecules	  of	  different	   size	  and	  shape	   are	  mixed	   together.	   In	   essence,	   the	   principle	   of	   Flory	   and	   Huggins	   in	   the	  treatment	  of	  polymer	  solubilisation	  is	  that	  an	  increase	  in	  the	  molecular	  weight	  of	  the	   polymer	   correspondingly	   decreases	   the	   entropy	   contribution	   to	   the	   Gibbs	  energy	  of	  the	  solubilisation	  process	  (cf.	  eq.	  1.3.1.).	  Kilcher	  et	  al.	  (2008)	  applied	  this	  principle	   to	  evaluate	   the	  permeability	  of	  a	  series	  of	  hydrophobic	  polymers	   in	   the	  yeast	   cell	   wall	   considered	   as	   a	   hydrophilic	   solution	   of	   infinite	   viscosity.	   	   The	  solubility	   of	   these	   hydrophobic	   polymers	   decreases	   in	   the	   polar	   cell	   wall	   by	  increasing	  their	  molecular	  weight	  (MW).	  Therefore,	   the	  permeation	  of	   these	  high	  MW	   polymers	   inside	   the	   yeast	   cell	   wall	   is	   thermodynamically	   unfavourable.	  Hydrophobic	   compounds	   with	   a	   MW	   larger	   than	   1000	   Da	   cannot	   diffuse	   easily	  inside	   the	   yeast	   cell	  wall	   because	  of	   their	   reduced	   solubility	   in	   the	  hydrogel-­‐like	  structure	   of	   the	   cell	   wall	   and	   not	   on	   the	   presence	   of	   size-­‐selective	   pores	   in	   the	  external	  mannoprotein	  layer	  of	  the	  cell	  wall	  (Kilcher	  et	  al.,	  2008;	  see	  also	  section	  1.7.2	  below).	  On	  the	  contrary,	  hydrophobic	  compounds	  smaller	  than	  1000	  Da	  first	  permeate	  passively	  through	  the	  cell	  wall	  as	  single	  molecules	  and	  then	  enter	  the	  cell	  forming	  aggregates,	  originally	  defined	  as	  “round	  bodies”	  (Kilcher	  et	  al.,	  2008).	  	  	  One	  of	  the	  objectives	  of	  this	  thesis	  was	  to	  identify	  the	  cellular	  structures	  producing	  these	  round	  bodies,	  which	  appear	  to	  correspond	  to	  the	  lipid	  droplets	  of	  yeast	  cells	  (see	  chapter	  1.7.3).	  Notably,	  hydrophilic	  compounds	  also	  have	  a	  similar	  cut-­‐off	   in	  their	   diffusion	   through	   the	   cell	   wall,	   at	   least	   under	   normal	   circumstances.	  (Scherrer	   et	   al.,	   1974).	   The	   main	   difference	   between	   the	   internalization	   of	  hydrophobic	   and	   hydrophilic	   substances	   regards	   the	   involvement	   of	   endocytic	  processes	  or	  active	  transport	  through	  the	  plasma	  membrane	  of	  the	  yeast	  cell.	  Only	  hydrophilic	   compounds,	   in	   general,	   are	   taken-­‐up	   by	   endocytic	   pathways	   and	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ultimately	  reach	  the	  yeast	  vacuole	  (Makarow,	  1985;	  Riezman,	  1985).	  This	  part	  will	  be	  discussed	  further	  in	  section	  1.7.2.	  	  
1.4 Yeast as microcapsule: an advantageous delivery system 	  The	  necessity	  of	  new	  cost-­‐effective	  delivery	  systems	  for	  hydrophobic	  compounds	  in	   the	   micron	   range	   is	   the	   foundation	   of	   this	   project,	   which	   is	   based	   on	   the	  microencapsulation	  of	  active	  substances	  in	  baker’s	  yeast.	  The	  encapsulation	  of	  an	  active	   ingredient	   	   in	   yeast	   permits	   its	   isolation	   and	   protection	   from	   an	   external,	  degrading	   environment	   that	   could	   irreversibly	  damage	   the	   chemical	   structure	  of	  the	   active.	   It	   also	   allows	   to	   mask	   and	   deliver	   the	   content	   in	   a	   site	   of	   required	  interest,	  where	  electric	  or	  mechanical	   stimuli	   could	   release	   the	   content	   from	   the	  yeast	   microcapsules.	   Yeast	   microcapsules	   with	   an	   average	   size	   of	   8	   µm	   are	   of	  particular	   interest	   for	   food	   processing,	   agrochemicals,	   printing	   processes,	  pharmaceutical	  technology	  and,	  more	  recently,	  in	  cellular	  encapsulation	  (Nelson	  et	  al.,	  2006).	  	  The	   research	   paper	   of	   Bishop	   et	   al.	   (1998)	   summarizes	   the	   importance	   of	   using	  yeast	   cells	   to	   encapsulate	   actives,	   especially	   aroma	   and	   flavours,	  with	   respect	   to	  liposomes.	  The	  relatively	  high	  cost	  of	  phospholipids	  and	  the	   laborious	  process	  to	  produce	  liposomes	  (see	  section	  1.2.3	  above)	  is	  an	  economical	  effort	  that	  the	  food	  industry	   cannot	   sustain	   (Bishop	   et	   al.	   1998).	   Moreover,	   liposomes	   lack	   a	   rigid	  structure	  that	  could	  prevent	  the	  annealing	  or	  fusing	  process	  between	  them.	  A	  valid	  alternative	   would	   be	   the	   use	   of	   yeast	   cells,	   which	   could	   mimic	   the	   liposome	  structures	   inasmuch	   that	   they	   have	   preformed	   bilayer	   membranes	   and,	  additionally,	  they	  possess	  a	  thick	  cell	  wall	  that	  stabilizes	  the	  encapsulated	  material	  inside	   the	   yeast	   microcapsules.	   In	   particular,	   baker’s	   yeast	   is	   well	   tolerated	   by	  humans	   in	   the	   gastro-­‐intestinal	   tract	   and	   on	   the	   skin,	   and	   has	   the	   capacity	   to	  incorporate	   hydrophobes	   within	   the	   cell	   (Bishop	   et	   al.,	   1998).	   Notably,	   the	  majority	   of	   available	   commercial	   products	   are	   hydrophobes,	   such	   as	   perfumes,	  flavouring,	  drugs	  and	  agrochemicals.	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The	  advantages	  of	  yeast	  as	  a	  microcapsule	  include	  wide	  availability	  at	  low	  cost,	  the	  homogeneous	  size	  and	  the	  complete	  biodegradability.	  Moreover,	  baker’s	  yeast	  can	  be	  massively	  produced,	  consequently	  generating	  a	  great	  number	  of	  microcapsules	  of	  uniform	  size	  in	  a	  fast	  and	  reproducible	  manner,	  using	  minimal	  equipment.	  These	  properties	   make	   yeast	   a	   valuable	   “carrier	   bag”	   for	   loading	   food	   ingredients,	  pesticides	  and	  other	  hydrophobes,	  once	  the	  process	  of	  encapsulation	  is	  effectively	  completed.	  Moreover,	  yeast	  microcapsules	  can	   in	  principle	   circumvent	   several	  of	  the	  problems	  that	  are	  associated	  with	  other	  microencapsulated	  delivery	  systems,	  which	  have	  been	  mentioned	  before	  and	  are	  summarized	  in	  Table	  1.4.1	  below.	  	  
Table	   1.4.	   1.	   This	   table	   lists	   the	   problems	   with	   various	   systems	   of	  
microencapsulation	   and	   possible	   solutions	   provided	   by	   using	   yeast	  
microcapsules	  (Imran	  et	  al.,	  2010).	  Some	  problems	  have	  become	  objectives	  
for	  the	  research	  of	  this	  thesis,	  as	  discussed	  in	  chapter	  2.	  	  	  
Microcapsules	  made	  with	   	  	  	  	  	  	  	  	  	  	  Problems	   	  Yeast	  as	  solution	  SPRAY	  DRYING	   Limited	  uniformity	  Thermolability	  	   Yes	  Perhaps	  EXTRUSION	   Size	  (too	  big)	  Industrial	  scaling	  Asymmetric	  morphology	  
Yes	  Yes	  Yes	  MOLECULAR	  INCLUSION	   Expensive	  material	  Limited	  loading	  capacity	   Yes	  Perhaps	   –	   one	  objective	   of	   this	  thesis	  COACERVATION	   Unreliable	  methodology	  Size	  variation	  Coagulation	   and	   toxic	  stabilizers	  
Yes	  Yes	  Yes	  
LIPOSOMES	   High	  costs	  of	  production	  Poor	  loading	  capacity	   Yes	  Perhaps	   –	   one	  objective	   of	   	   	   this	  thesis	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In	  the	  context	  of	  the	  biological	  application	  of	  yeast	  microcapsules	  for	  hydrophobic	  substances	  such	  as	  those	  used	  in	  this	  thesis,	  it	  is	  also	  relevant	  to	  consider	  how	  the	  whole	   microcapsules	   of	   yeast	   cells	   are	   taken	   up	   by	   animal	   cells	   in	   the	   gastro	  intestinal	  tract,	  particularly	  where	  pathological	  conditions	  of	  chronic	  inflammation	  allow	  the	  contact	  between	  cells	  of	  the	  immune	  system	  and	  ingested	  yeast	  cells,	  e.g.	  Crohn’s	  disease	  and	   Inflammatory	  Bowel	  Disease.	  This	  aspect	   refers	   to	   the	  much	  larger	  biocompatibility	  of	  yeast	  microcapsules	  as	  compared	  with	  artificial	  ones,	  as	  previously	   discussed	   in	   chapter	   1.2.2.	   Yeast	   cells	   are	   naturally	   eaten	   up	   by	  macrophages	  and	  neutrophils,	  which	  are	  specialized	  phagocytic	  cells	  (Aderem	  and	  Underhill,	   1999).	   Phagocytosis	   is	   a	   complex	   process	   used	   by	   these	   cells	   to	  internalize	   and	   destroy	   pathogenic	   agents	   such	   as	   viruses,	   bacteria,	   yeasts,	   and	  also	  to	  remove	  damaged	  or	  apoptotic	  cells	  in	  tissues	  and	  fluids	  of	  the	  same	  body.	  A	  common	   feature	   in	   the	   process	   of	   phagocytosis	   is	   the	   interaction	   between	  receptors	  on	  the	  surface	  of	  phagocytes	  and	  specific	  ligands	  on	  the	  surface	  of	  target	  cells,	   or	   particles.	   These	   interactions	   lead	   to	   local	   actin	   polymerization	   in	   the	  phagocytic	  cells	  driving	   the	   internalization	  of	   target	  particles	  or	  microorganisms.	  In	   the	   case	   of	   yeast	   cells,	   the	   activation	   of	   the	   macrophage	   receptors	   can	   be	  mediated	   by	   the	   mannose	   receptor	   (MR)	   that	   recognise	   mannans,	   as	   well	   as	  humorally	   by	   mannose	   binding	   proteins	   coating	   the	   targets	   (Aderem	   and	  Underhill,	  1999).	  Once	   internalized,	  yeast	  cells	  are	  progressively	  degraded	   in	   the	  endo-­‐lysosomal	  compartment	  of	  the	  macrophages,	  without	  leading	  to	  extracellular	  signalling	   of	   inflammation	   or	   other	   immune	   responses	   (Aderem	   and	   Underhill,	  1999).	   Consequently,	   after	   ingestion	   by	   macrophages	   yeast	   cells	   become	   ideal	  microcapsules	  in	  terms	  of	  biocompatibility	  with	  the	  immune	  system	  of	  animals.	  	  	  
1.5	   Evolution	   of	   microencapsulation	   using	   microorganisms	  
including	  yeast	  	  Encapsulation	  of	  bioactive	  substances	  into	  microorganisms	  has	  been	  around	  since	  the	  1970’s	  (Laboratoires	  Serozym,	  1973;	  Shank,	  1977);	  however,	  problems	  remain	  in	   the	   understanding	   of	   the	   qualitative	   and	   quantitative	   aspects	   of	   the	  encapsulation	   process.	   The	   relevant	   scientific	   information	   regarding	   the	   topic	   of	  this	  project	  is	  predominantly	  present	  in	  international	  file	  patents.	  As	  highlighted	  in	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a	   relatively	   recent	   patent	   (Crothers	   and	   Nelson,	   2002),	   which	   provides	   an	  extensive	   overview	   of	   the	   development	   of	   the	   field	   of	   encapsulation	   in	  microorganisms,	  the	  entire	  field	  was	  opened	  by	  the	  seminal	  work	  of	  Shank	  (Shank,	  1977).	   For	   the	   first	   time,	   Shank	   introduced	   the	   idea	   of	   exploiting	   the	   naturally	  predefined	  micro	  dimensions	  of	  microorganisms	  such	  as	  fungi,	  yeast	  and	  protozoa	  to	   vehicle	   substances,	   instead	   of	   making	   microcapsules	   by	   artificial	   techniques	  (like	   those	   presented	   in	   chapter	   1.2.3).	   Previously,	   the	   term	  microencapsulation	  referred	   to	  abiotic	   techniques	  used	   to	  produce	   carbonless	   carbon	  paper	   (e.g.	   the	  coacervation	  process	  of	  salting	  out	  a	   lyophilic	  sol	   into	   liquid	  droplets,	   cf.	   chapter	  1.2.3).	  	  The	  innovation	  introduced	  by	  Shank’s	  patent	  (1977)	  included	  the	  following	  points:	  •	  Decreased	  cost	  of	  microencapsulated	  products;	  •	   The	   possibility	   to	   control	   the	   delivery	   of	   actives	   (e.g.	   odours	   confined	   within	  capsules	  until	  the	  desired	  time	  of	  their	  release);	  •	  The	  possibility	  to	  introduce	  two	  or	  more	  actives	  into	  a	  single	  biological	  capsule;	  •	   The	   option	   of	   growing	   biological	   organisms	   with	   different	   properties	   by	  modifying	   the	   culture	   medium	   to	   facilitate	   the	   incorporation	   of	   liposoluble	  products	   such	   as	   dyes,	   condiments,	   flavours,	   aromas,	   pharmaceuticals	   and	  vitamins.	  	  The	   original	   commercial	   background	   and	   major	   technical	   applications	   of	   the	  innovative	   microencapsulation	   process	   invented	   by	   Shank	   (1977)	   regarded	   the	  area	  of	  carbonless	  carbon	  paper	  manufacturing.	  However,	  Shank	  (1977)	  opened	  a	  novel	   vast	   field	   of	   potential	   applications	   of	  microencapsulation	   in	   areas	   such	   as	  food	  processing	  (indeed,	  example	  IV	  of	  the	  original	  patent	  described	  encapsulation	  of	   flavouring	   into	   baker’s	   yeast)	   and	   drug	   delivery	   (example	   V	   of	   the	   original	  patent	  described	  the	  incorporation	  of	  aspirin	  into	  baker’s	  yeast).	  Consequently,	   it	  can	  be	  said	  that	  this	  work	  is	  the	  originator	  of	  the	  whole	  field	  of	  microencapsulation	  using	   microorganisms,	   and	   developed	   approaches	   that	   are	   still	   being	   used	   in	  different	  industries	  for	  diverse	  areas	  of	  biotechnology.	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1.5.1	   Evolution	  in	  the	  process	  of	  microencapsulation	  in	  microorganisms	  
 The	   original	   patent	   of	   Shank	   (1977),	   which	   can	   be	   considered	   one	   of	   the	   first	  practical	  methods	  of	  microencapsulation,	  was	  based	  on	  the	  encapsulation	  of	  lipid-­‐soluble	  actives	  within	  microorganisms	  that	  naturally	  have,	  or	  can	  be	  modulated	  to	  have	   a	   high	   content	   of	   fats	   in	   their	   cells.	   Examples	   of	   these	   organisms	  were	   the	  following	  olageneous	  yeast	  species:	  Endomyces	  vernalis	  (which	  can	  produce	  about	  42%	   fat	   when	   grown	   under	   proper	   conditions),	   Torulopsis	   lipophila	   and	  
Rhodotorula	  gracilis	  (which	  can	  produce	  as	  much	  as	  60%	  fat	  by	  weight	  in	  cultures	  with	   media	   having	   low	   nitrogen	   but	   high	   sugar).	   The	   advantage	   of	   using	   these	  organisms	   was	   that	   fat-­‐soluble	   actives	   like	   a	   leuco	   dye	   (Crystal	   violet)	   rapidly	  diffused	  into	  the	  yeast	  cells	  by	  contact	  (as	  in	  example	  I	  of	  Shank,	  1977).	  It	  is	  to	  be	  noted	  that	  the	  actives	  to	  be	  encapsulated	  had	  to	  be	  soluble	  in	  the	  natural	  fats	  of	  the	  microbes,	  a	  principle	  which	  has	  limited	  the	  application	  of	  this	  patent	  because	  some	  substances	  are	  not	  effectively	  soluble	  in	  cellular	  fats.	  The	  proposed	  mechanism	  of	  encapsulation	   in	   these	   fat-­‐rich	   organisms	   has	   been	   assumed	   to	   be	   passive	  diffusion,	  presumably	  driven	  by	  the	  partition	  coefficient	  into	  the	  lipid	  fractions	  of	  the	  microorganisms.	  	  The	   patent	   of	   Shank	   (1977)	   was	   later	   modified	   (German	   and	   Morris,	   1983)	   to	  extend	  various	  useful	  applications	  of	  microencapsulation	  to	  other	  microorganisms	  having	   a	   natural	   fat	   content	   of	   less	   than	   40%	   per	   weight,	   for	   example	   Candida	  
curvata	   and	   Saccharomyces	   cerevisiae.	   This	   novel	   method	   employed	   ‘lipid-­‐extending	   substances’,	   in	  which	   the	   actives	  were	   dissolved	   and	   then	  mixed	  with	  the	  cells.	  Lipid-­‐extending	  substances	  included	  aliphatic	  alcohols	  (C9-­‐C15)	  and	  their	  esters	   (with	   the	  alcoholic	  part	   longer	   than	  C3),	  as	  well	  as	  aromatic	  hydrocarbons	  (e.g.	  xylene).	  Both	   lipid-­‐extending	  substances	  and	  the	  actives	  have	  been	  assumed	  to	  be	  incorporated	  passively	  in	  the	  microbes.	  Again,	  the	  mechanism	  proposed	  for	  the	   encapsulation	   facilitated	   by	   these	   lipid-­‐extending	   substances	   has	   been	  diffusion,	  with	   additional	   cell	   deformation	   due	   to	   a	   large	   “globule”	   visible	   under	  the	  microscope	  (German	  and	  Morris,	  1983).	  It	  is	  to	  be	  noted	  that	  the	  most	  effective	  lipid-­‐extending	  substances	  were	  found	  to	  be	  aliphatic	  and	  aromatic	  compounds	  of	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strong	   hydrophobicity,	   which	   most	   likely	   were	   incorporated	   into	   the	   microbial	  lipid	  membranes	  and	  then	  produced	  this	  swollen	   ‘globule’,	  occupying	  most	  of	  the	  cytoplasmatic	  volume.	  However,	  it	  is	  noteworthy	  that	  the	  use	  of	  solvents	  as	  those	  described	  in	  the	  original	  patent	  by	  German	  and	  Morris	  (1983)	  produces	  biological	  effects	   comparable	   to	   those	   found	   in	   the	   course	   of	   the	   research	   for	   the	   present	  project	   (see	   later	   chapter	   3.4.5),	   especially	   in	   regard	   to	   the	   encapsulation	   of	  hydrophobes	   in	   the	   presence	   of	   DMSO	   (see	   later	   chapter	   4).	   The	   possible	  mechanisms	   accounting	   for	   this	   phenomenon	  will	   be	   subsequently	   elaborated	   in	  light	  of	   the	   current	  understanding	  of	   yeast	  membrane	  biology	   (see	   chapter	  1.5.1	  below).	  	  	  Besides	   solvents	   and	   hydrophobic	   alcohols,	   other	   systems	   have	   been	   used	   to	  facilitate	  the	  encapsulation	  of	  active	  ingredients	  in	  yeast.	  An	  alternative,	  and	  even	  earlier,	  method	  of	  encapsulation	  of	  certain	  types	  of	  water-­‐soluble	  actives	  utilized	  the	  treatment	  of	  yeast	  with	  a	  plasmolyser	  such	  as	  propylene	  glycol	  (Laboratoires	  Serozym,	   1973).	   When	   pre-­‐treated	   with	   these	   cell-­‐modifying	   agents,	   yeast	   cells	  loose	  their	  cytoplasmic	  fluid	  by	  exosmosis;	   this	  cell	  emptying	  is	  then	  followed	  by	  infusion	  of	  hydrophilic	  material	  back	  into	  the	  ‘ghost’	  cell	  structures	  (Laboratoires	  Serozym,	  1973).	  	  Another	  example	  of	   the	  encapsulation	  process	   in	  yeast	   is	   the	  procedure	   that	  has	  been	  introduced	  in	  1991	  by	  recycling	  yeast	  refuses	  containing	  dead	  cells	  and	  their	  empty	  ghosts	  or	  shells	  using	  alkaline	  conditions.	  As	  described	  in	  the	  original	  1992	  patent	  (Greenshields	  et	  al.,	  1992),	  these	  cell	  ghosts	  are	  prepared	  and	  then	  added	  to	  mixtures	   of	   various	   substances	   to	   produce	   formulations	   of	   cosmetic,	  pharmaceutical	  and	  food	  application.	  	  	  	  The	  method	  described	   in	   the	  Mitsubishi	  Paper	  Mills	  Patent	  EP	  453316	  (Inoue	  et	  al.,	  1991)	   is	   likely	   to	  be	  today’s	  most	  widely	  employed	  procedure	  to	  enhance	  the	  encapsulation	   of	   ingredients	   in	   yeast	   cells,	   especially	   in	   the	   recent	   published	  literature.	   The	   procedure	   is	   based	   upon	   a	   two-­‐step	   process	   that	   employs	   yeast	  cells	  with	  a	  low	  lipid	  content	  (less	  than	  10%	  by	  weight,	  e.g.	  S.	  cerevisae	  or	  C.	  utilis).	  In	  the	  first	  step,	  cells	  are	  treated	  with	  polar	  organic	  solvents,	  in	  particular	  acetone	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and	  ethanol,	  to	  extract	  intracellular	  components	  such	  as	  proteins,	  amino	  acids	  and	  nucleic	  acids.	  Cells	  are	  thus	  killed	  with	  extensive	  damage	  to	  their	  membranes	  (and	  possibly	  the	  cell	  wall	  too),	  but	  retain	  a	  large	  part	  of	  their	  internal	  lipid	  components,	  even	  if	  their	  organelles	  have	  been	  destroyed.	  In	  the	  second	  step,	  these	  dead	  (ghost)	  cells	   are	   mixed	   with	   a	   previously	   prepared	   hydrophobic	   liquid	   containing	   the	  actives	  to	  enclose	  the	  same	  actives,	  within	  the	  cell	  microcapsules	  using	  heating	  and	  stirring	   (Inoue	   et	   al.,	   1991).	   Among	   the	   various	   articles	   that	   followed	   this	  procedure	  are	  the	  works	  of	  (Normand	  et	  al.,	  2005)	  and	  (Dardelle	  et	  al.,	  2007).	  	  	  The	  effect	  of	   this	  encapsulation	  procedure	  on	  the	  yeast	   intracellular	  structures	   is	  shown	  in	  Figure	  1.5.1.	  Live	  yeast	  cells	  are	  characterized	  by	  a	  large	  internal	  vacuole	  and	  contain	  all	  the	  organelles	  that	  are	  found	  in	  other	  eukaryotic	  cells,	  as	  shown	  in	  Fig.	   1.5.1A.	   Before	   encapsulation	   pre-­‐treated	   yeasts	   resemble	   a	   balloon	   with	   an	  empty	  volume	  filled	  sporadically	  with	  lipid	  ‘blobs’	  (Fig.	  1.5.1B);	  it	  is	  not	  possible	  to	  distinguish	  any	  of	  the	  internal	  organelles	  that	  were	  visible	  before	  the	  treatment	  (cf.	  Fig.	  1.5.1A).	  After	  the	  loading	  with	  flavour	  compounds	  such	  as	  limonene,	  the	  yeast	  cells	   appear	   to	   have	   their	   internal	   volume	   completely	   occupied	   by	   the	  encapsulated	  material	  (Fig.	  1.5.1C).	  	   	   	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   1.5.	   1.	   Structural	   changes	   in	   yeast	   cells	   after	   treatment	   and	   encapsulation	  
according	  to	  the	  method	  of	  Inoue	  et	  al.,	  (1991).	  A)	  Transmission	  Elecron	  Microscopy	  
(TEM)	  image	  of	  untreated	  Candida	  albicans	  cells:	  M=	  Mitochondria;	  N=Nucleus;	  CW=	  
cell	  wall;	  CM=	  cell	  membrane;	  V=	  vacuole;	  the	  image	  was	  taken	  from	  (Osumi,	  1998).	  
B.	   TEM	   image	   of	   pre-­‐treated	   yeast	   (S.cerevisiae)	   cells	   before	   the	   encapsulation	  
according	  to	  the	  method	  of	  Inoue	  et	  al.,	  (1991).	  C).	  TEM	  image	  of	  yeast	  cells	  as	  in	  B	  
after	   encapsulation	   of	   limonene	   by	   the	   method	   of	   Inoue	   et	   al.,	   (1991).	   The	   dark	  
material	   represents	   indigested	   cytoplasm	   whereas	   the	   grey	   material	   represents	  
lipid	  organelles.	  Images	  B	  and	  C	  were	  taken	  from	  Normand	  et	  al.,	  (2005).	  	  
The heating procedure was identical to the one used for the thermo-
gravimetric experiment.
Phase Transition Analysis (PTA). Dry unflavored yeast samples
were mixed with various amounts of water and homogenized using a
high-speed mixer (Schweizer, Lausanne, Switzerland). The mixer
ensured a homogeneous distribution of the water in the sample.
Two grams of yeast sample was introduced into the phase transition
analyzer compression chamber (PTA 240, Wenger, Sabetha, KS) for
determination of the powder’s collapse temperature. The phase transition
analyzer consists of a sealed chamber that is subject d to both a constant
pressure and a linear increase in temperature. The piston displacement
measures the compaction of the powder. Initial conditions were as
follows: the pressure was preset to 120 bar for 15 s at 20 °C and then
reduced to 100 bar for the time of the experiment. The temperature
range was from 20 to 140 °C, and the temperature heating rate was 5
°C/min. The resulting displacement was fitted with a simple sigmoidal
curve, and the collapse temperature was determined as the temperature
for which the inflection of the sigmoid occurs.
Dynamic Vapor Sorption (DVS). The principle of the DVS system
is to record the weight changes of a sample exposed to various RHs at
isothermal conditions. Weight increase corresponds to water uptake,
which will stabilize when the product reaches the equilibrium. DVS
from Surface Measurement Systems (London, United Kingdom) was
used in this study. A mass of approximately 10 mg was deposited on
the microbalance plate. The initial RH was 40%, and the sample was
left for 2 h prior to changing the RH. The temperature of the atmosphere
surrounding the sample and the microbalance was accurately controlled.
The measurement temperatures were 20 (70, 80, 85, and 90% RH), 30
(70, 80, 85, and 90% RH), and 40 °C (60, 70, 75, and 80% RH).
Drying experiments were conducted at 20, 30, and 40 °C. The sample
was left at 40% RH for 2 h for equilibration. Then, the similar protocol
as previously used was imposed in the reverse order, starting at high
RH.
Atomic Force Microscopy (AFM). AFM was performed on a
Nanoscope IV (Digital Instruments, Veeco group, Santa Barbara, CA),
in the tapping mode in air and at ambient temperature. Dry yeasts
(around 2 µm diameter) were spread on a mica slide. A similar
procedure was carried out for yeasts mixed with a large amount of
water left for 2 h at room temperature to allow removal of the excess
water from the surface. The height imaging was achieved by using
silicon nitride tips with a resonance frequency of about 250 kHz.
RESULTS
Morphological Characterization of the Yeast. Microscopy
of the Yeast. The characterization of yeasts before and after
loading was performed using TEM imaging. Images are shown
in Figure 1a,b for empty yeasts and limonene-loaded yeasts,
respectively. In TEM images shown in this paper, the dark
material represents the undigested part of the cytoplasm while
the gray material is characteristic of a lipid phase.
For unflavored yeasts, the proportion of empty cells as
compared to filled cells is very high, thus demonstrating the
efficiency of plasmolysis. The shape of the cells is spherical
with a diameter slightly higher than 2 µm. A gray shell of around
a few nanometers thickness delimits the cells. For loaded yeasts,
a single large droplet of flavor (lipid) occupies most of the
internal volume of the yeast.
Microscopy of the Yeast Cell Wall. The cell wall of S.
cereVisiae consists of !(1f3)glucans, mannoproteins, and a
small amount of chitin. A structural model, combining proteins
linked by disulfide bridg s and glucan nd mannan units, in
equivalent amounts, linked by phosphates in a bed shape, was
described (8). It is understood that !(1f3)glucans maintain the
rigidity (9) and mannoproteins maintain the porosity of the cell
wall (10). In other words, mannoproteins are a filler for the
skeleton of the !(1f3)glucan network. The drying process used
in the preparation of the yeasts forces water to evacuate the
entire cell volume resulting in the shrinkage of the cell walls.
The typical protein content of dead cells is 30% in weight of
dry matter whereas the polysaccharide fraction is around 50%.
A structural model proposed by Zlotnik et al. (11) places the
major mannoproteins both at the surface and in deeper layers
of the wall, shielding the cell wall !(1f3)glucan from external
enzymatic attack. Figure 2 shows detailed TEM images of the
dead yeast cell in similar preparation conditions for observation
than in Zlotnik et al. (11). The preparation process (by
proteolysis) of the yeasts does not affect the structure of the
wall to a large extent, and two layers are still clearly distin-
guishable.
Similar to living cells, the structure of dead cells is composed
of a thin protein layer that sits on a !(1f3)glucan layer. The
external protein layer is 15 ( 2 nm thick whereas the inner
!(1f3)glucan layer is 130 ( 17 nm thick. According to the
average diameter f the dry cells (2 µm), the protein phase
occupies around 10% of the volume of the cell wall as compared
Figure 1. (a) TEM image of unflavored yeasts. (b) TEM image of flavored
yeasts.
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were mixed with various amounts of water and homogenized using a
high-speed mixer (Schweizer, Lausanne, Switzerland). The mixer
ensured a homogeneous distribution of the water in the sample.
Two grams of yeast sample was introduced into the phase transition
analyzer compression chamber (PTA 240, Wenger, Sabetha, KS) for
determination of the powder’s collapse temperature. The phase transition
analyzer consists of a sealed chamber that is subjected to both a constant
pressure and a linear increase in temperature. The piston displacement
measures the compaction of the powder. Initial conditions were as
follows: the pressure was preset to 120 bar for 15 s at 20 °C and then
reduced to 100 bar for the time of the experiment. The temperature
range was from 20 to 140 °C, and the temperature heating rate was 5
°C/min. The resulting displacement was fitted with a simple sigmoidal
curve, and the collapse temperature was determined as the temperature
for which the inflection of the sigmoid occurs.
Dynamic Vapor Sorption (DVS). The principle of the DVS system
is to record the weight changes of a sample exposed to various RHs at
isothermal conditions. Weight increase corresponds to water uptake,
which will stabilize when the product reaches the equilibrium. DVS
from Surface Measurement Systems (London, United Kingdom) w s
used in this study. A mass of approximately 10 mg was deposited on
the microbalance plate. The initial RH was 40%, and the sample was
left for 2 h prior to changing the RH. The temperature of the atmosphere
surrounding the sample and the microbalance was accurately controlled.
The measurement temperatures were 20 (70, 80, 85, and 90% RH), 30
(70, 80, 85, and 90% RH), and 40 °C (60, 70, 75, and 80% RH).
Drying experiments were conducted at 20, 30, and 40 °C. The sample
was left at 40% RH for 2 h for equilibration. Then, the similar protocol
as previously used was imposed in the reverse order, starting at high
RH.
Atomic Force Microscopy (AFM). AFM was performed on a
Nanoscope IV (Digit l Instruments, Veeco roup, Santa Barbara, CA),
in the tapping mode in air and at ambient temperature. Dry yeasts
(around 2 µm diameter) were spread on a mica slide. A similar
procedure was carried out for yeasts mixed with a large amount of
water left for 2 h at room temperature to allow removal of the excess
water from the surface. The height imaging was achieved by using
silicon nitride tips with a resonance frequency of about 250 kHz.
RESULTS
Morphological Characterization of the Yeast. Microscopy
of the Yeast. The characterization of yeasts before and after
loading was performed using TEM imaging. Images are shown
in Figure 1a,b for empty yeasts and limonene-loaded yeasts,
respectively. In TEM images shown in this paper, the dark
material represents the undigested part of the cytoplasm while
the gray material is characteristic of a lipid phase.
For unflavored yeasts, the proportion of empty cells as
compared to filled cells is very high, thus demonstrating the
efficiency of plasmolysis. The shape of the cells is spherical
with a diameter slightly higher than 2 µm. A gray shell of around
a few nanometers thickness delimits the cells. For loaded yeasts,
a single large droplet of flavor (lipid) occupies most of the
internal volume of the yeast.
Microscopy of the Yeast Cell Wall. The cell wall of S.
cereVisiae consists of !(1f3)glucans, mannoproteins, and a
small amount of chitin. A structural model, combining proteins
linked by disulfide bridges and glucan and mannan units, in
equivalent amounts, linked by phosphates in a bed shape, was
described (8). It is understood that !(1f3)glucans maintain the
rigidity (9) and mannoproteins maintain the porosity of the cell
wall (10). In other words, mannoproteins are a filler for the
skeleton of the !(1f3)glucan network. The drying process used
in the preparation of the yeasts forces water to evacuate the
entire cell volume resulting in the shrinkage of the cell walls.
The typical protein content of dead cells is 30% in weight of
dry matter whereas the polysaccharide fraction is around 50%.
A structural model proposed by Zlotnik et al. (11) places the
major mannoproteins both at the surface and in deeper layers
of the wall, shielding the cell wall !(1f3)glucan from external
enzymatic attack. Figure 2 shows detailed TEM images of the
dead yeast cell in similar preparation conditions for observation
than in Zlotnik et al. (11). The preparation process (by
proteolysis) of the yeasts does not affect the structure of the
wall to a large extent, and two layers are still clearly distin-
guishable.
Similar to living cells, the structure of dead cells is composed
of a thin protein layer that sits on a !(1f3)glucan layer. The
external protein layer is 15 ( 2 nm thick whereas the inner
!(1f3)glucan layer is 130 ( 17 nm thick. According to the
average diameter of the dry cells (2 µm), the protein phase
occupies around 10% of the volume of the cell wall as compared
Figure 1. (a) TEM image of unflavored yeasts. (b) TEM image of flavored
yeasts.
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maximum fidelity (Osumi et al., 1989c; Osumi et al., 1990). 
This instrument is used to detect the ultrastructural confor- 
mation of the uncoated specimens and is a valuable addition 
to the TEM for such studies. 
C. Atomic force microscopic observation o f  yeast cells 
In recent years he atomic force micr scope (AFM), a 
scanning probe microscope, has rapidly developed as a use- 
ful imaging tool in biological research. It is utilized for struc- 
tural biology, with emphasis on high-resolution imaging, and 
illustrates these applications with images of cell membranes, 
DNA and soluble and membrane proteins. The AFM can be 
used to image the 'beads-on-a-string' (Ris and Malecki, 
1993) chromatin structure in a normal water environment 
following adsorption onto a cover glass substrate. The reso- 
lution of AFM is such that individual nucleosome cores and 
linker DNA can be seen along chromatin fibers that were 
reconstituted by using istone octamers and a tandemly 
repeated 208-bp ucleosome-positioned DNA sequence 
(Allen et al., 1993). The AFM is difficult to use for large 
biological specimens such as intact yeast cells, although 
recently it was successfully used in making an image of a 
whole S. pombe cell (Ishijima, personal communication). 
III .  GENERAL STRUCTURE OF YEAST CELLS 
Figure la is an SEM image of a Saccharomyces cerevisiae 
cell with a bud scar and a birth scar (Osumi et al., 1994a; 
Osumi, 1995). A TEM image of thin-sectioned Candida 
albi ans reveals intracellular organelles (Fig. lb). In C. tro- 
picalis, a dimorphic yeast (Fig. 2a), the cells grow  in n- 
alkane as the sole carbon source show profuse microbodies 
(peroxisomes) (Fig. 2b, Osumi et al., 1974; Osumi et al., 
1975a; Osumi et al., 1975b; Osumi et al., 1975c; Osumi, 
1995). The warty projections ( *-  ) observed on the cell 
surface by SEM (Fig. 2a) were also identified in a conven- 
tional thin section (Osumi et al., 1975b) and in a negative- 
stained image of a cryo-section (Osumi, 1978) by TEM. 
Figure 3 shows freeze fracture images of yeast cells 
(Osumi et al., 1994a; Osumi, 1995). Fig. 3a is an overview 
of the fracture f ce through an S. c revisiae cell and image  
of protoplasmic fractu  (PF; Fig. 3b), exoplasmic fracture 
(EF; Fig. 3c) faces (terminology according to Branto  et 
al. (1975)) of the cell membrane (prepared by unidirection 
shadowing), showing their typical invagination (CMI, ,-- ). 
Fig. 3b,c also shows hexagonal arrays of the intramembra- 
nous particles (indicated by circles). Some of these particles 
may include t3-glucan synthetase which is a typical enzyme 
located in the yeast cell membrane. The feature of the freeze 
fracture image of the cell membrane is affected by anti- 
fungal agents. For instance, shallow trench-like invagina- 
tions and densely distributed intramembranous particles of 
the PF face of the cell membrane (prepared by rotary 
shad wing) in C. albicans are commonly observed 
Fig. 1. SEM image of surface structure of Saccharomyces cerevisiae 
(a) and TEM image of an ultrathin section of Candida albicans (b). 
Bar = 1 /zm. 	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The	   extent	   of	   the	   limonene	   loaded	   in	   these	   pre-­‐treated	   cells,	   as	   assessed	   by	  thermogravimetry,	  was	   found	   to	  be	   around	  26%	  w/w	   (Normand	  et	   al.,	   2005).	   It	  could	   be	   speculated	   that	   this	   number	   represents	   the	   maximum	   amount	   of	  hydrophobic	   substance	   that	   can	  be	   encapsulated	   inside	  yeast	   cells.	   Figure	  1.5.1C	  clearly	  shows	  a	  large	  globule	  of	  loaded	  flavour	  occupying	  the	  whole	  volume	  of	  the	  emptied	  yeast	  cell.	  This	  visual	  evidence	  will	  be	  discussed	  further	  in	  section	  1.7.3	  of	  this	  chapter.	  	  
1.5.2	   Evolution	  in	  the	  process	  of	  the	  release	  of	  the	  actives	  from	  
microorganisms	  derived	  microcapsules	  	  In	   parallel	   to	   the	   development	   of	   the	   procedures	   for	   encapsulating	   active	  substances	   into	   microorganisms,	   technologists	   and	   scientists	   have	   researched	  ways	   to	   facilitate	   the	   release	   of	   the	   encapsulated	   substances	   in	   the	   desired	  target/way.	  The	  mechanisms	  of	  the	  release	  of	  the	  encapsulated	  substances	  are	  of	  three	  types:	  1)	  Physical	  break-­‐up:	  physical	  crushing	  of	  the	  microorganisms.	  The	  first	  application	  of	  microencapsulation	  processes	  was	  the	  delivery	  of	  dye	  from	  carbonless	   carbon	   paper	   in	   a	   controlled	   way,	   which	   could	   happen	   only	   by	  disrupting	   the	   cell	   envelope	   of	   the	   microorganisms	   by	   physical	   breakage,	   i.e.	  typewriting	  or	  by	  pen-­‐pressure.	  	  2)	   Biological	   and	   chemical	   break-­‐up:	   biodegradation	   by	   enzymatic	   digestion	  operated	  by	  microorganisms.	  Pannel	  (1987)	  for	  the	  first	  time	  tried	  to	  introduce	  a	  different	   way	   to	   release	   encapsulated	   actives	   using	   biodegradation	  mediated	   by	  digestion	  with	  protease	  enzymes.	  3)	  Release	  of	  the	  actives	  without	  the	  breakage	  of	  the	  cell.	  	  In	  the	  last	  few	  years,	  innovation	  in	  this	  area	  has	  been	  introduced	  by	  Crothers	  and	  Nelson	   (2002),	   who	   discovered	   that	   the	   release	   of	   encapsulated	   actives	   from	  various	   microorganisms	   can	   occur	   without	   physical	   breakage	   or	   biochemical	  alteration	   of	   the	   cell	   wall	   when	   in	   contact	   with	   biological	   mucous	   membranes.	  Results	   obtained	   in	   this	   thesis	   have	   confirmed	   a	   similar	   rapid	   release	   of	  encapsulated	   hydrophobes	   from	   yeast	   cells	   using	   a	   simple	   new	   method	   that	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mimics	  the	  basic	  properties	  of	  body	  fluids	  (see	  chapter	  4).	  Nevertheless,	  the	  most	  comprehensive	   recent	  work	   on	   the	   release	   of	   encapsulated	   substances	   is	   that	   of	  Dardelle	   et	   al.	   (2007),	  who	  evaluated	   a	   large	   set	   of	   physical	   parameters	   in	   yeast	  microcapsules	   prepared	   with	   the	   method	   of	   Inoue	   et	   al.,	   (1991).	   The	   major	  conclusion	  of	  this	  work	  is	  that	  the	  release	  of	  hydrophobes	  from	  loaded	  yeast	  cells	  needs	   water	   to	   occur.	   Dry	   loaded	   yeast	   cells	   need	   to	   be	   hydrated	   by	   water	  molecules	  to	  relax	  and	  open	  the	  structure	  of	  the	  dried	  cell	  wall.	  This	  facilitates	  the	  diffusion	  of	  the	  hydrophobic	  substances	  encapsulated	  inside	  the	  core	  of	  the	  yeast	  cells	  to	  the	  outside.	  Remarkably,	  the	  dry	  yeast	  cells	  do	  not	  release	  the	  encapsulated	  flavour	  in	  a	  fully	  hydrophobic	  environment	  and	  show	  a	  high	  thermostability,	  up	  to	  80 °C	   for	   2	   min,	   without	   loosing	   the	   encapsulated	   compound	   (Dardelle	   et	   al.,	  2007).	  	  
1.6	   Applications	  of	  microencapsulation	  in	  yeast	  	  	  The	   European	   patent	   0242	   135	   to	   AD2	   Ltd	   is	   probably	   the	   first	   documented	  application	   of	   baker’s	   yeast	   as	   a	   single	   organism	   for	   microencapsulation	   of	  hydrophobic	  actives	  without	  cell	  alterations	  (Bishop	  et	  al.,	  1998;	  Pannell,	  1987).	  Applications	   of	   this	   innovation	   included:	   a)	   perfume	   strips;	   b)	   insecticides	   ad	  pesticides;	   c)	   products	   for	   veterinary	   uses.	   Then,	   in	   1993	   Procter	   and	   Gamble	  (P&G)	   filed	   a	   patent	   (Hardy	   et	   al.,	   1993)	   for	  microencapsulation	   applications	   of	  yeast	  regarding	  bleach	  activators	  for	  cleaning	  materials	  like	  laundry,	  dishwashing	  and	  bleaching.	  The	  previously	  discussed	  work	  of	  Bishop	  et	  al.	  (1998)	  then	  clearly	  illustrated	   the	   utility	   of	   baker’s	   yeast	   as	   biological	  microcapsules	   to	   incorporate	  high	  concentrations	  of	  different	  essential	  oils,	  which	  appear	  to	  accumulate	  in	  large	  oily	   organelles	  within	   the	   yeast	   cells.	  Work	   shown	   in	   chapter	   3.4.1	  will	   indicate	  that	  these	  organelles	  most	  likely	  correspond	  to	  enlarged	  lipid	  droplets.	  	  Subsequently,	  Nelson	  et	  al.	  (2006)	  described	  the	  application	  of	  microencapsulation	  into	   textiles	   for	   a	   variety	   of	   actives	   including	   durable	   fragrances,	   skin	   softeners,	  insect	   repellents,	   dyes,	   vitamins,	   antimicrobials,	   antibiotic,	   hormones	   and	   drugs	  (Nelson	   et	   al.,	   2006).	   Moreover,	   a	   yeast-­‐cell-­‐based	   microencapsulation	   of	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chlorogenic	   acid	   has	   been	   reported	   as	   a	   water-­‐soluble	   antioxidant	   (Shi	   et	   al.,	  2008).	   Most	   recently,	   the	   encapsulation	   of	   curcumin	   inside	   yeast	   cells	   has	   been	  described	   (Paramera	   et	   al.,	   2011).	   This	   last	   work	   is	   marginally	   related	   to	   the	  subject	   of	   this	   thesis,	   which	   fundamentally	   deals	   with	   the	   encapsulation	   of	  hydrophobic	  actives	   in	   intact	  yeast	  cells,	  as	   in	   the	  previous	  study	  of	  Bishop	  et	  al.	  (1998).	  	  
1.7	   Biology	  of	  Saccharomyces	  cerevisae	  relevant	  to	  
microencapsulation	   	  	  
1.7.1	   Basic	  properties	  of	  yeast	  cell	  wall	  and	  plasmamembranes	  	  The	   previous	   overview	   of	   the	   evolution	   of	   encapsulation	   methods	   with	  microorganisms	   (chapter	   1.5.1)	   has	   indicated	   alternative	   strategies	   that	   exploit	  diverse	  biological	   aspects	   of	   the	  microorganisms	  used.	  These	   aspects	   need	   to	   be	  discussed	  in	  detail	  here	  for	  the	  model	  organism	  studied	  in	  this	  project,	  the	  yeast	  S.	  
cerevisiae.	  The	  basic	  properties	  of	  the	  external	  envelope	  that	  surrounds	  yeast	  cells	  will	   be	   examined	   first;	   this	   envelope	   is	   normally	   called	   the	   cell	  wall,	   by	   analogy	  with	  similar	  structures	  present	  in	  plant	  and	  procaryotic	  cells.	  	  	  	  Yeasts	   and	   fungi	   are	   covered	   with	   a	   cell	   wall	   that	   can	   be	   considered	   as	   a	  semipermeable	   barrier	   (a	   sponge-­‐like	   filter)	   controlling	   the	   interaction	  with	   the	  environment.	  It	  accounts	  for	  20-­‐30%	  of	  the	  cell	  dry	  weight	  (Smits	  et	  al.,	  1999)	  and	  is	   normally	   100-­‐200	   nm	   thick,	   occupying	   between	   25%	   to	   50%	   of	   the	   cellular	  volume.	  The	  cell	  wall	  has	  a	  heterogeneous	  composition,	  in	  which	  polysaccharides	  and	   proteins	   contribute	   85%	   and	   15%	   of	   the	   overall	   dry	   weight,	   respectively	  (Lesage	  and	  Bussey,	  2006).	  Among	  the	  polysaccharides,	  the	  most	  important	  are	  β-­‐1,3	  and	  β-­‐1,6	  glucans,	  which	  account	  for	  50%	  and	  10%	  of	  wall	  mass,	  respectively,	  and	  chitin,	  accounting	  for	  1-­‐3%	  of	  wall	  mass	  (Lipke	  and	  Ovalle,	  1998).	  The	  major	  proteins	   are	   mannoproteins,	   i.e.	   heavily	   glycosylated	   proteins	   that	   are	   either	  anchored	   to	   the	   wall	   by	   glycosyl-­‐phosphathydyl-­‐inositol	   (GPI-­‐CWPs,	   cell	   wall	  proteins)	  or	  repeat	  inner	  proteins	  (Pir-­‐CWPs),	  cumulatively	  accounting	  for	  40%	  of	  the	  wall	  mass	  (Lipke	  and	  Ovalle,	  1998).	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  Table	  1.7.1.	   lists	   the	  major	   components	   of	   the	   yeast	   cell	  wall.	   Two	   layers	   can	  be	  distinguished	  in	  the	  wall	  structure.	  The	  inner	  layer	  is	  a	  skeleton	  framework	  formed	  by	  a	  three	  dimensional	  network	  of	  β-­‐1,3	  glucans	  with	  a	  degree	  of	  polymerization	  of	  1,500	   for	   yeast	   in	   the	   stationary	   phase	   (Klis	   et	   al.,	   2006).	   This	   sugary	   web	  surrounds	   the	   entire	   cell	   and	   is	   strengthened	  by	   chitin	   chains,	  which	   are	  mainly	  found	  close	  to	  the	  plasma	  membrane	  (Fig.	  1.7.1).	  	  	  
Table	   1.7.	   1.	   List	   of	   macromolecules	   that	   constitute	   the	   cell	   wall	   of	   S.	  
cerevisiae.	  (Table	  adapted	  from	  Klis	  et	  al.,	  2006).	  	  
Macromolecule	   %	  of	  wall	  mass	   Mean	  MW	  (kDa);	  DP	  Mannoproteins	   30–50	   Highly	  variable	  1,6-­‐β-­‐Glucan	   5–10	   24	  (150)	  1,3-­‐β-­‐Glucan	   30–45	   240	  (1500)	  Chitin	   1.5–6	   25	  (120)	  











Figure	  1.7	  1.	  Model	  for	  the	  structure	  of	  the	  cell	  wall	  of	  S.cerevisiae.	  A,	  zoom	  into	  the	  
modular	  components.	  B,	  overall	  structure	  including	  the	  plasmamembrane.	  Images	  
are	  taken	  from	  Lipke	  and	  Ovalle	  (1998).	  
	   	   	   Introduction	  
 
53	  
	  The	  structure	  of	  the	  cell	  wall	  determines	  its	  permeability,	  a	  fundamental	  property	  for	  the	  interaction	  of	  yeast	  with	  the	  external	  world	  and	  also	  for	  the	  encapsulation	  of	  external	  actives	  in	  biotechnological	  applications.	  In	  regard	  to	  the	  permeability	  of	  the	  cell	  wall,	  the	  pioneering	  work	  of	  Gerhardt	  and	  Judge	  initially	  estimated	  a	  cut–off	  of	  4500	  Da	  (corresponding	  to	  a	  pore	  diameter	  of	  approximately	  3.6	  nm)	  for	  the	  porosity	   of	   the	   cell	   wall	   isolated	   from	   yeast	   using	   polyethylene	   glycols	   and	  dextrans	  (Gerhardt	  and	  Judge,	  1964).	  Later	  work	  (Scherrer	  et	  al.,	  1974)	  reported	  a	  cut-­‐off	   of	   760	  Da	   (corresponding	   to	   an	   hydrodynamic	   radius	   of	   0.85	   nm	   for	   the	  diffusing	  substance)	  for	  the	  intact	  cell	  wall,	  which	  was	  essentially	  confirmed	  three	  years	   later	   by	   Arnold	   and	   Lacy	   (Arnold	   and	   Lacy,	   1977),	   who	   measured	   an	  exclusion	   size	   of	   620	   Da	   by	   osmotic	   approaches.	   Subsequently,	   Zlotnik	   and	  colleagues	  showed	  that	  just	  the	  external	  layer	  of	  the	  cell	  wall	  determined	  the	  wall	  porosity	  (Zlotnik	  et	  al.,	  1984).	  By	  removing	  the	  mannoproteins	  from	  the	  yeast	  cell	  wall	   by	   a	   protease,	   the	   porosity	   of	   the	   cell	   wall	   was	   strikingly	   increased.	  Concomitantly,	  a	  loss	  of	  the	  dark	  stained	  outer	  layer	  of	  the	  cell	  wall	  was	  visible	  by	  electron	   microscopy.	   Moreover,	   the	   same	   work	   found	   that	   treatment	   with	   2-­‐mercaptoetanol,	   digitonin	   and	   salts	   –	   compounds	  which	  did	  not	   lead	  per	   se	   to	   a	  release	  of	  mannoproteins	  from	  the	  cell	  -­‐	  increased	  the	  permeability	  of	  the	  cell	  wall	  to	  the	  action	  of	  a	  glucanase	  enzyme	  that	  specifically	  degraded	  β-­‐1,3	  glucans,	  thus	  digesting	   polysaccharides	   in	   the	   inner	   layer	   of	   the	  wall	   (Zlotnik	   et	   al.,	   1984).	   Of	  note,	   2-­‐mercaptoethanol	   reduces	   the	   disulfide	   or	   thioester	   linkages	   between	   the	  mannoproteins	   and	   thus	   gives	   rise	   to	   a	   more	   open	   structure	   by	   modifying	   the	  protein	  compartments	  of	  the	  cell	  wall,	  allowing	  the	  permeation	  by	  large	  molecules.	  Finally,	   more	   recent	   measurements	   have	   shown	   that	   in	   exponentially-­‐growing	  yeast	   the	  wall	   can	   be	   penetrated	   by	   a	   globular	   protein	   (α-­‐amilase,	   55	   KDa)	   and	  fluorescent	  dextrans	  up	  to	  400	  KDa	  (Makarow,	  1985)	  with	  a	  hydrodynamic	  radius	  of	   5-­‐8	   nm	   (De	  Nobel	   and	   Barnett,	   1991).	   Therefore,	   the	   permeability	   of	   the	   cell	  wall	  appears	  to	  decrease	  with	  the	  aging	  of	  the	  yeast	  culture,	  a	  property	  that	  will	  be	  exploited	  experimentally	  in	  some	  research	  aspects	  of	  this	  thesis	  (see	  chapter	  3.4.4	  below).	  Notably,	   all	   probes	   studied	   to	   establish	   the	  MW	  cut-­‐off	  were	  hydrophilic	  (polyethylene	   glycols	   and	   fluorescent-­‐dextrans)	   or	   amphiphilic	   (proteins);	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hydrophobes	   have	   not	   been	   studied	   for	   this	   purpose,	   with	   the	   exception	   of	   the	  recent	  work	  in	  Tirelli’s	  lab	  	  (Kilcher	  et	  al.,	  2008).	  	  
	  
Figure	  1.7.	  2	  Simplified	  model	  of	  the	  cell	  wall,	  focusing	  on	  the	  di-­‐sulfur	  bonds	  
(Zlotnik	  et	  al.,	  1984). 	  The	   structure	   and	   maintenance	   of	   the	   cell	   wall	   depends	   upon	   the	   growth	   and	  metabolic	   state	   of	   yeast	   cells	   and	   their	   interaction	   with	   the	   environment.	   For	  example,	  high	  osmolarity	   induces	  alteration	   in	  both	  the	  cell	  wall	  and	  the	   internal	  cytoskeleton	  of	  yeast	  cells	  (Slaninová	  et	  al.,	  2000).	  Moreover,	  there	  is	  an	  intimate	  link	   between	   structural	   elements	   of	   the	   cell	   wall,	   the	   interstitial	   space	   and	   the	  plasmamembrane	   structures,	   which	   are	   dynamically	   connected	  with	   each	   other.	  The	   plasmamembrane	   of	   the	   yeast	   cell	   resembles	   in	   many	   aspects	   that	   of	  mammalian	   cells,	   since	   it	   contains	   high	   levels	   of	   sterols	   (ergosterol)	   and	  glycolipids,	  as	  well	  as	  GPI-­‐anchored	  proteins	  [mostly	  en	  route	  to	  the	  wall	  or	  in	  part	  residents	   on	   the	   surface	   (Kapteyn	   et	   al.,	   1999)]	   with	   respect	   to	   internal	  membranes	   (Munn,	   2001;	   Beh	   and	   Rine,	   2004).	   	   The	   plasmamembrane	   has	   the	  same	   functions	   as	   in	   other	   cells	   and	   is	   in	   dynamic	   turnover	   with	   internal	  membranes	   via	   traffic	   routes	   that	   appear	   to	   be	   universal	   to	   all	   eukaryotic	   cells.	  These	   traffic	   routes	   include	   the	   constitutive	   pathways	   of	   endocytosis	   and	  exocytosis.	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Today	  much	   is	   known	   on	   the	   endocytosis	  machinery	   that	   is	   present	   in	   budding	  yeast	  like	  S.	  cerevisiae,	  which	  shares	  similarities	  with	  the	  more	  complex	  endocytic	  pathways	  present	  in	  mammalian	  cells	  but	  also	  has	  its	  own	  peculiarities	  (Souza	  and	  Pichler,	  2007;	  Pelham,	  2002;	  Toret	  and	  Drubin,	  2006).	  The	  major	  differences	  with	  respect	   to	  mammalian	   cells	   include	   the	   lack	  of	   a	  prominent	   recycling	  endosomal	  compartment	  and	  the	  presence	  of	  a	  unique	  terminal	  organelle,	  the	  vacuole,	  which	  combines	   degradative	   (e.g.	   lysosome-­‐like)	   and	   storage	   functions	   (Pelham	   2002;	  Souza	  and	  Pichler,	  2007).	   In	  yeast,	   there	  seems	   to	  be	  at	   least	  one	  direct	   route	  of	  internalization	   of	   exogenous	   substances	   towards	   the	   vacuole	   (Pelham	   2002).	  Moreover,	   there	   are	   recycling	   routes	   of	   membrane	   lipids	   that	   follow	   yet	  uncharacterized	  endocytic	  pathways,	  which	  are	  possibly	  equivalent	  to	  the	  clathrin-­‐independent	  pathways	  constitutively	  active	  in	  mammalian	  cells.	  Detailed	  scientific	  studies	   on	   the	   endocytosis	   of	   commercially	   important	   actives	   are	   still	   missing	  (Parveen	  et	   al.,	   2004).	  As	   in	   the	   studies	   to	   evaluate	  MW	  cut-­‐off,	   it	   is	  noteworthy	  that	   the	  probes	  used	   to	  evaluate	  endocytosis	   in	  yeast	   cell	  were	  amphiphiles	   (e.g.	  Lucifer	  yellow,	  Riezman,	  1985)	  or	  hydrophilic	  (e.g.	  FITC-­‐dextrans,	  Makarow	  et	  al,	  1985).	  	  	  One	  of	  the	  initial	  aims	  of	  the	  present	  research	  was	  to	  use	  a	  hydrophobic	  compound	  for	  evaluating	  the	  possible	  contribution	  of	  endocytosis	  in	  its	  encapsulation	  within	  yeast	  cells.	  However,	  in	  agreement	  with	  previous	  work	  (e.g.	  Bishop	  et	  al.,	  1998),	  it	  turned	  out	  that	  the	  active	  process	  of	  endocytosis	  may	  play	  only	  a	  minor	  part	  at	  the	  beginning	  of	   the	  encapsulation	  process	  of	  hydrophobic	  actives	   like	   terpenes	   (see	  later,	  chapter	  3.4.2).	  
1.7.2	   Mechanism	  of	  incorporation:	  passive	  permeability	  versus	  
endocytosis,	  or	  their	  combination?	  	  	  	  The	   original	  works	   of	   Shank	   (1977)	   and	  German	   et	   al.	   (1983)	   assumed	   that	   the	  incorporation	  of	  actives	  into	  microorganisms	  followed	  a	  simple	  process	  of	  passive	  diffusion,	   governed	   by	   mass	   law	   equilibrium	   and	   liposolubility.	   Most	   of	   the	  subsequent	  studies	  seem	  to	  have	   followed	  the	  assumption	  that	  yeasts	  suspended	  in	   aqueous	   media	   are	   able	   to	   internalize	   both	   hydrophilic	   and	   hydrophobic	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compounds,	  which	  are	  dissolved	   in	  the	  same	  media	  (Sikkema	  et	  al.,	  1994;	  1995).	  The	  permeation	  of	  these	  substances	  through	  the	  cell	  wall	  is	  a	  passive	  process,	  for	  both	  hydrophilic	  and	  hydrophobic	  compounds	  (Kilcher	  et	  al.,	  2008).	  As	  discussed	  earlier,	   a	  molecular	   cut-­‐off	   around	  1000	  Da	  exists	   for	   all	   permeating	   substances,	  under	  normal	  conditions	  in	  aqueous	  solution,	  and	  is	  also	  modulated	  by	  the	  age	  of	  the	  yeast	  cell	  culture	  (Kilcher	  et	  al.,	  2008;	  Zlotnik	  et	  al.,	  1984;	  Scherrer	  et	  al.,	  1974).	  However,	   hydrophobic	   substances	   are	   limited	   in	   their	   permeation	   by	   their	   poor	  solubility	  in	  the	  matrix	  environment	  of	  the	  cell	  wall	  (Kilcher	  et	  al.,	  2008),	  which	  is	  essentially	  hydrophilic,	  being	  mostly	  composed	  of	  mannoproteins	  and	  β-­‐1,4/β-­‐1,6	  polysaccharides	   (Lipke	   and	   Ovalle,	   1998).	   Indeed,	   Kilcher	   et	   al.	   (2008)	   have	  recently	  demonstrated	  that	  hydrophobic	  substances	  of	  size	  exceeding	  the	  normal	  cut-­‐off	  of	  the	  cell	  wall	  are	  able	  to	  penetrate	  yeast	  cells	   in	  the	  presence	  of	  organic	  solvents	  like	  dimethylsulfoxide	  (DMSO).	  DMSO	  changes	  the	  polarity	  of	  the	  cell	  wall,	  i.e.	   its	  Hildebrand	  parameters,	  apparently	  without	  major	  structural	  changes	  in	  its	  mesh	   size	   (Kilcher	   et	   al.,	   2008).	   Consequently,	   the	   DMSO-­‐swollen	   cell	   wall	  increases	   the	   solubility	   of	   hydrophobic	   substances	   in	   it,	   thus	   allowing	   the	  permeation	  of	  these	  molecules	   inside	  the	  yeast	  cells.	  This	   important	  topic	  will	  be	  described	  in	  more	  detail	   in	  chapter	  4	  along	  with	  the	  experimental	  results.	  On	  the	  other	   hand,	   organic	   solvents	   like	   DMSO	   also	   disrupt	   the	   cellular	   membranes	   of	  yeast	   cells	   and	   in	   so	   doing	   they	   alter	   the	   permeability	   and	   partitioning	   of	  encapsulated	  substances.	  	  	  The	   passive	   transport	   of	   a	   non-­‐electrolyte	   molecule	   (H)	   across	   biological	  membranes	  of	  a	  certain	  thickness	  l	  is	  described	  by	  eq	  1.7.1,	  in	  the	  approximation	  of	  steady-­‐state	  (Atkins	  and	  De	  Paula,	  2006):	  
J = DKD H[ ] Sl 	  	  	  	  	  	  eq	  1.7.1	  
	  Where	  J	  is	  the	  flux	  of	  H	  through	  the	  membrane,	  D	   is	  the	  diffusion	  coefficient	  of	  H	  through	  the	  membrane,	  KD	  is	  the	  partition	  ratio	  defined	  as	  KD= [H ]0[H ]S ,	  where	  [H]0	  	  is	  the	   concentration	   of	   H	   at	   the	   solution-­‐membrane	   interface	   and	   [H]S	   is	   the	  concentration	  of	  H	  in	  the	  aqueous	  solution.	  At	  steady	  state,	  the	  rate	  of	  the	  process	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that	  produces	  a	  certain	  concentration	  of	  the	  permeating	  hydrophobe	  (indicated	  as	  [H]	  =[H]0)	  on	  one	  side	  of	  the	  membrane	  is	  perfectly	  balanced	  at	  the	  opposite	  side	  of	   the	   same	   membrane	   by	   the	   process	   that	   consumes	   completely	   the	   same	  hydrophobe.	  	  	  Equation	  1.7.1	  applies	  also	  to	  the	  hydrophobes	  loaded	  into	  yeast	  cells,	  as	  it	  will	  be	  elaborated	  in	  more	  detail	  in	  chapter	  3.2.	  Hydrophobic	  substances	  enter	  the	  cellular	  microcapsules	   via	   a	   kinetic	   process	   regulated	   by	   diffusion	   and	   their	   flux	   is	  dependent	  also	  on	  the	  geometry	  of	  the	  permeable	  membrane	  formed	  by	  the	  whole	  cell	  (Atkins	  and	  de	  Paula,	  2006).	  However,	  the	  flux	  is	  always	  generated	  in	  response	  to	   the	   thermodynamic	   force	  arising	   from	   the	   concentration	  gradient	  of	   the	   same	  hydrophobes	   outside	   vs.	   inside	   the	   cells	   (Atkins	   and	   de	   Paula,	   2006).	  Consequently,	   the	   process	   of	   encapsulation	   ultimately	   is,	   in	   essence,	   solubility	  dependent.	  	  	  With	  regard	  to	  the	  diffusion	  of	  hydrophobes	  from	  the	  external	  bulk	  solution	  to	  the	  interior	  of	  the	  yeast	  cell,	  a	  couple	  of	  assumptions	  should	  be	  considered.	  First,	  the	  solubility	  of	  the	  permeating	  substance	  of	  size	  below	  1000	  Da	  in	  the	  yeast	  cell	  wall	  could	  be	  assumed	  to	  be	  more	  or	  less	  the	  same	  as	  in	  water,	  because	  the	  cell	  wall	  is	  an	  hydrophilic	  environment.	  Secondly,	  the	  solubility	  of	  hydrophobic	  substances	  in	  the	  cell	  membrane	  and	  in	  the	  yeast	  lipid	  droplets,	  which	  are	  the	  ultimate	  target	  in	  the	  intracellular	  loading	  process	  (see	  later	  chapter	  3.4.2),	  could	  be	  estimated	  using	  the	  partition	  coefficient	  of	  the	  same	  substances	  in	  membranes	  (P	  in	  octanol/water,	  usually	  expressed	  as	  LogP)	  (Sikkema	  et	  al.,	  1995).	  These	  assumptions	  offer	  only	  an	  approximation	  of	  the	  real	  solubility	  in	  the	  yeast	  cell	  because,	  as	  stated	  by	  Sikkema	  et	   al.	   (1995)	   	   “…	   the	   specific	   lipid	   composition	   of	   a	   lipid	   bilayer	   can	   strongly	  influence	   the	   partitioning	   behaviour	   of	   a	   compound…“.	   The	   hydrophobicity	  parameter	  expressed	  by	  LogP	  is	  fundamental	  for	  determining	  the	  incorporation	  of	  molecules	  in	  lipid	  membranes	  and	  consequently	  estimate	  their	  permeability	  across	  the	  biological	  systems	  (Leo	  et	  al.,	  1971).	  With	  this	  in	  mind,	  three	  different	  terpenes	  having	  widely	  different	  LogP	  values	   	   (2.7	   for	  carvone,	  3.5	   for	   linalool	  and	  4.4	   for	  limonene	  –	  Griffin	  et	  al.,	  1999)	  will	  be	  tested	  here	  to	  measure	  how	  the	  kinetics	  of	  the	   encapsulation	   process	   correlates	  with	   LogP.	   These	   substances,	  which	   have	   a	  
	   	   	   Introduction	  
 
58	  











Figure	  1.7.	  3.	  Model	  for	  constitutive	  endocytosis	  and	  secretion	  in	  yeast	  cells	  (taken	  
from	  Riezman,	  1985).	  Abbreviations:	  ER,	  endoplasmic	  reticulum;	  SV,	  secretory	  
vesicle;	  PM,	  plasma	  membrane;	  End,	  endocytic	  vesicle;	  Vac.	  Vacuole.	  	  
	  	  The	   approach	   that	   has	   been	   used	   to	   evaluate	   the	   contribution	   of	   cellular	   active	  processes	   to	   the	   encapsulation	   of	   hydrophobic	   actives	   is	   metabolic	   poisoning,	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classically	   with	   respiratory	   inhibitors	   like	   sodium	   azide	   (Bishop	   et	   al,	   1998).	   In	  baker’s	   yeast,	   which	   can	   naturally	   switch	   between	   aerobic	   metabolism	   to	  anaerobic	   fermentation,	   growth	   in	   the	   presence	   of	   high	   concentrations	   of	  substrates	   is	   likely	   to	   cause	   fermentative	   ATP	   production,	   thereby	   allowing	  survival	   also	   in	   the	   absence	   of	   mitochondrial	   respiration.	   This	   may	   explain	   the	  small	   increase	   in	   the	  encapsulation	  of	   terpenoids	   into	  baker’s	   yeast	   treated	  with	  sodium	  azide	  as	   reported	  by	  Bishop	  et	  al.	   (1998).	  This	  potential	  problem	  will	  be	  experimentally	  addressed	  in	  chapter	  3	  (cf.	  Fig.	  3.4.5).	  	  In	   general,	   different	   mechanisms	   are	   involved	   in	   the	   subsequent	   permeation	   of	  actives	  in	  the	  yeast	  cell	  membrane	  not	  treated	  with	  organic	  solvents.	  Hydrophilic	  or	  amphiphilic	  compounds	  are	  taken	  up	  through	  active	  transport	  via	  endocytosis	  and	   then	  sequestered	   in	   the	  vacuole,	  whereas	  hydrophobic	  compounds	  passively	  diffuse	  into	  the	  membranes	  (unless	  they	  interact	  with	  specific	  carriers	  or	  receptors	  on	   the	   surface).	   Often,	   the	   accumulation	   of	   lipophilic	   compounds	   into	   the	   lipid	  bilayer	   leads	   to	   cellular	   toxicity	   (Uribe	   et	   al.,	   1985).	   The	   partitioning	   of	   these	  substances	   in	   the	   membrane	   is	   regulated	   thermodynamically	   by	   the	   lipid	  composition	   of	   the	  membrane,	   in	   particular	   the	  degree	   of	   saturation	   of	   the	   fatty	  acids	   in	   phospholipids	   (Sikkema	   et	   al.,	   1995).	   Different	   studies	   have	   been	  undertaken	  to	  correlate	   the	  partition	  coefficient	  of	  hydrophobic	  compounds	  with	  their	   biological	   effects	   on	   membranes.	   In	   general,	   a	   good	   correlation	   has	   been	  obtained	   using	   the	   partition	   coefficient	   of	   these	   compounds	   in	   octanol/water	  (o/w),	  even	  if	  precise	  quantitative	  evaluations	  are	  very	  difficult	  due	  to	  the	  variable	  composition	   of	   the	   membranes	   (Sikkema	   et	   al.,	   1994).	   Historically,	   the	   o/w	  partition	   coefficient	   of	   hydrophobic	   substances	   has	   been	   used	   to	   attempt	  rationalizing	   the	   action	   of	   anaesthetic	   drugs	   on	   different	   tissues	   (Hansch	   and	  Dunn,	   1972).	   	   However,	   the	   importance	   of	   lipid-­‐water	   partitioning	   has	   been	  investigated	  only	  scantly	  in	  regard	  to	  the	  encapsulation	  of	  hydrophobic	  substances	  in	  yeast	  cells,	  e.g.	  (Dardelle	  et	  al.,	  2007).	  Research	  conducted	  here	  will	  fill	  this	  gap	  of	  knowledge.	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1.7.3	  Lipid	  droplets	  and	  physical	  limit	  for	  lipophilic	  storage	  in	  yeast	  cells	  	  As	  already	  mentioned	  and	  will	  become	  evident	   in	   the	  course	  of	   the	  experimental	  part	   of	   the	   current	   project	   (chapter	   3),	   lipid	   droplets	   are	   important	   organelles	  involved	  in	  the	  incorporation	  of	  hydrophobes	  within	  yeast	  cells.	  These	  organelles	  have	  never	  been	  considered	  before	   in	   the	   studies	   regarding	   the	  encapsulation	  of	  hydrophobes	   inside	   microroganisms.	   Consequently,	   a	   brief	   description	   of	   these	  organelles	  needs	  to	  be	  presented	  here.	  	  	  Lipid	  droplets	  are	  ubiquitous	  storage	  organelles	  formed	  by	  a	  surface	  monolayer	  of	  phospholipids	  and	  a	  core	  of	  tightly	  packed	  neutral	  lipids,	  such	  as	  triglycerides	  and	  esters	  of	   ergosterol	   (in	   yeast)	   of	   cholesterol	   (in	  mammalian	   cells)	   (Greenspan	  et	  al.,	   1985).	   These	   small	   rounded	   structures	   constitute	   the	   fat	   reserve	   of	   the	   cells	  (for	  both	  mammalian	  and	  fungi)	  and	  their	  synthesis	  is	  increased	  approaching	  the	  stationary	  phase	  in	  yeast	  cell	  culture	  (Werner-­‐Washburne	  et	  al.,	  1993).	  A	  few	  years	  ago,	  Larebell	  and	  Le	  Gros	  (2004)	  undertook	  a	  detailed	  study	  of	  the	  internal	  cellular	  structures	  of	  S.cerevisiae.	  This	  work	  produced	  accurate	  3D	  reconstructions	  of	  yeast	  cells	   that	  were	   generated	   by	   X-­‐ray	   tomography,	   a	   beautiful	   example	   of	  which	   is	  presented	  in	  Fig	  1.7.4.	  	  (Larabell	  and	  Le	  Gros,	  2004).	  	  	  
images were collected at 4° intervals through 180° degrees of
rotation for each reconstruction. All 45 images were then
aligned to a common axis of rotation using 60-nm-diameter
gold particles as fiducial markers (arrows, Figure 1) and a
fiducial marker alignment routine which is part of the
“SPIDER” software suite of programs (Frank et al., 1996). A
single projection image of a typical field of view showing
one budding yeast and portions of several nearby yeast is
shown in Figure 1A. Although it is possible to see numerous
overlapping vesicles and organelles inside of the yeast (Fig-
ure 1A, small white circles), it is difficult to distinguish the
precise boundaries of these organelles because this image is
a superimposition of all structures located in the 5-!m-thick
yeast. The simplest way for the eye to interpret the 3-D
nature of the raw data is to animate the entire series of 45
projection images, which immediately provides depth to the
data set (Video Sequence 1).
Although the yeast appears more 3-D in the animation, it
is still difficult to distinguish distinct organelle boundaries in
any one of the projection images because of the degree of
overlapping information. Tomographic reconstruction re-
trieves the 3-D information and reveals the internal struc-
tures of the cell. Two of the 110 computer-generated sections
through the yeast, each of which is!30 nm thick, are shown
in Figure 1, B and C, and all 110 sections, slicing longitudi-
nally through the capillary, can be played back as a video
(Video Sequence 2). Several centrally located large vacuoles
are clearly seen along with numerous smaller organelles
around the periphery of the cell. These cortical organelles
are most likely endoplasmic reticulum and mitochondria,
based on their position and previous data obtained from
electron micrographs, but specific labeling is being con-
ducted to definitively identify these structures as seen in
X-ray tomography.
The X-ray microscope images were collected at X-ray en-
ergies of 514 eV, which lies within what is referred to as the
“water window” wavelength range where organic material
absorbs approximately an order of magnitude more than
water. This produces a quantifiable natural contrast of bio-
logical material and eliminates the need for contrast en-
hancement procedures to visualize cellular structures of the
yeast. Once a 3-D map of the X-ray absorption coefficient has
been obtained, volume processing and visualization tech-
niques can be used to analyze the data. One such visualiza-
tion algorithm was used to extract the surface of the same
yeast (Figure 2A and Video Sequence 3), whereas edge
enhancement algorithms reveal numerous internal or-
ganelles of varying sizes (Figure 2B). The surfaces of or-
ganelles are seen in each of the individual images which,
when played back as a movie, assume a very 3-D nature and
illustrate the overall structural organization of the entire
yeast (Video Sequence 4).
Because we are using absorbance contrast X-ray micros-
copy, we can color-code the cellular structures based on
their density as determined by the volume-reconstructed
X-ray absorption coefficient (Figure 2C). The lipid droplets,
which are the densest structures, were color-coded white,
the least dense vacuoles were color-coded gray, and numer-
Figure 3. Cryo X-ray tomography of whole
yeast, S. cerevisiae, viewed using several pro-
cessing algorithms after reconstruction. (A)
Combination of translucent outer surface and
opaque surfaces that demark internal or-
ganelles; arrow points to nucleus that has
been color-coded blue; (B) surfaces from A
combined with volume rendering; arrow
points to nucleus that is colored blue, lipid
droplets appear white, and the surface of a
large vacuole in the center of the yeast is
color-coded pink; (C) 0.5-!m-thick section
that had been volume-rendered according to
the amount of X-ray absorption; lipid droplets are white, the internal structures of the vacuole and nucleus (arrow) appear red, and other
cytoplasmic structures appear green and orange. Yeast cell, 5 !m diameter.
Figure 4. Computer-generated sections through
the nucleus of the yeast seen in Figure 3. Six sections
through the nucleus show internal organization of
the nucleoplasm; dense lipid vesicles (white structures)
are also seen adjacent to the nucleus. Bar, 0.5 !m.
X-ray Tomography of Yeast Cells
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Figure	   1.7.	   4.	  Cryo	   X-­‐ray	   tomography	   of	   whole	   yeast	   cells	   viewed	   using	   different	  
reconstruction	  methods.	   (A)	   Translucent	   outer	   surface	   define	   internal	   organelles;	  
(B)	  volume	  rendering,	  highlights	  the	  internal	   lipid	  droplets,	  which	  appear	  whitish,	  
and	   the	   large	   central	   vacuole,	  which	   is	   coloured	   in	  pink;	   (C)	   in	  another	   rendering	  
procedur ,	   lipid	   dropl ts	   are	   in	   white,	   while	   large	   intern l	   structures	   such	   the	  
vacuole	  and	  nucleus	  appear	  red.	  Other	  cytoplasmi 	  organelles	  are	  coloured	  in	  green	  
and	  orange.	  In	   ll	  panels	  the	  arrow	  points	  to	  the	  nucl us	  that	  is	  coloured	  in	  different	  
ways.	  Images	  are	  reproduced	  from	  Larebell	  and	  le	  Gros	  (2004).	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Yeast	  cell	  resemble	  a	  spheroid	  sac	  in	  which	  the	  internal	  volume	  is	  occupied	  in	  the	  large	  part	  by	  the	  vacuole	  and	  the	  nucleus.	  Among	  the	  various	  internal	  organelles,	  lipid	  droplets	  are	  clearly	  visible	  (Fig.	  1.7.4B,C).	  Of	  note,	  lipid	  droplets	  are	  spread	  all	  over	   the	   cytoplasm,	   occupying	   a	   significant	   proportion	   of	   the	   internal	   volume	  of	  the	   cells.	   Although	   this	   volume	   is	  minimal	  when	   cells	   grow	   in	   their	   exponential	  phase,	  it	  increases	  substantially	  when	  cells	  are	  in	  their	  stationary	  phase,	  reaching	  a	  maximum	  around	  10%	  of	  the	  entire	  volume	  of	  yeast	  cells	  (Willison	  and	  Johnston,	  1985;	   Veehuis	   et	   al.,	   1987).	   This	   value	   may	   represent	   the	   physical	   limit	   of	   the	  storage	  capacity	  of	   intact	  yeast	   cells	   for	   lipophilic	   (hydrophobic)	   substances	   that	  accumulate	   in	   the	   lipid	   droplets.	   In	   contrast,	   Normand	   et	   al.	   (2005)	   published	   a	  paper	   in	  which	   empty	   yeast	   cells	  were	   loaded	  with	   limonene	   for	   the	   delivery	   of	  flavour.	   In	   this	   work,	   already	   described	   in	   section	   1.5.1,	   yeast	   cells	   were	   pre-­‐treated	  with	  a	  plasmolyser,	  which	  facilitated	  the	  release	  of	  the	  whole	  cytoplasmic	  content;	  then,	  the	  resulting	  ghost-­‐cells	  were	  loaded	  with	  limonene	  (Fig	  1.5.1C).	  The	  extent	   of	   limonene	   loaded	   in	   these	   pre-­‐treated	   cells,	   assessed	   by	  thermogravimetry,	  resulted	  to	  be	  around	  26%	  w/w	  (Normand	  et	  al.,	  2005).	  	  	  Different	   procedures	   of	   encapsulation	   can	   therefore	   yield	   different	   levels	   of	  maximal	  loading	  of	  hydrophobic	  agents	  in	  yeast	  cells,	  which	  are	  related	  to	  the	  bio-­‐physical	  properties	  of	  the	  same	  cells.	  The	  work	  presented	  in	  this	  thesis	  will	  clarify	  the	   biological	   and	   physical	   limits	   of	   encapsulation,	   and	   subsequent	   release,	   of	  commercially	  valuable	  hydrophobes	  in	  intact	  yeast	  cells	  –	  the	  most	  economic	  way	  of	  using	  this	  organism	  as	  a	  delivery	  system	  for	  commercial	  applications.	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2.	  Aims	  and	  Objectives	  	  
2.1	  Aims	  	  The	  scientific	  frame	  of	  this	  project	  has	  been	  the	  work	  of	  Kilcher	  et	  al.	  (2008),	  which	  has	   suggested	   a	   new	   hypothesis	   for	   the	   mechanism	   of	   encapsulation	   in	   baker’s	  yeast	  cells.	  The	  hypothesis	  can	  be	  formulated	  as	  follows:	  the	  cell	  wall	  solubility	  of	  hydrophobic	  compounds	  smaller	  than	  1000	  Da	  (normal	  cut-­‐off	  of	  yeast	  cell	  wall)	  is	  the	  limiting	  step	  in	  the	  process	  of	  encapsulation.	  	  The	  current	  project	  has	  been	  articulated	  in	  a	  series	  of	  aims	  and	  objectives	  to	  test,	  validate	  and	  eventually	  evolve	  this	  hypothesis.	  Specifically,	  the	  following	  aims	  have	  been	  addressed:	  	  	   1. Visualization	   and	   localization	   of	   hydrophobes	   encapsulated	   in	   yeast	   cells	  and	  determination	  of	  how	  yeast	  cells	  viability	  is	  affected	  by,	  and	  eventually	  influences	  the	  encapsulation	  process;	  2. Understanding	   the	   physical-­‐chemical	   parameters	   that	   regulate	   the	   yeast	  encapsulation	   processes	   of	   hydrophobes	   in	   water	   and	   in	   DMSO	   and	  quantification	  of	  the	  hydrophobes	  loading	  with	  both	  processes;	  3. Preliminary	   kinetic	   evaluation	   on	   the	   release	   of	   hydrophobes	   from	   yeast	  cells.	  	  In	   the	   course	  of	   the	  experimental	  work	  undertaken	   for	   the	  project,	  new	   findings	  led	   to	   re-­‐formulate	   the	   hypothesis	   regarding	   the	   mechanism	   of	   loading	  hydrophobes	  from	  aqueous	  media	   into	  yeast	  cells.	  Namely,	   the	  hydrophobicity	  of	  the	   substance	   to	   encapsulate	   in	   yeast	   cells	   and	   the	   extent	   of	   loading	   are	   not	  directly	   proportional	   to	   each	   other.	   This	   extent	   is	   instead	   proportional	   to	   the	  solubility	   of	   the	  hydrophobes	   in	   the	   encapsulating	  media.	   	   Subsequent	  work	  has	  been	   carried	   out	   to	   experimentally	   verify	   this	   hypothesis,	  which	  provides	   a	   new	  understanding	  of	  the	  fundamental	  aspects	  of	  the	  loading	  of	  hydrophobes	  in	  yeast	  cells.	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2.2	  Objectives	  	  In	  order	  to	  achieve	  the	  aims	  of	  the	  project,	  the	  experimental	  work	  used	  a	  variety	  of	  approaches	  that	  have	  progressively	  formed	  a	  series	  of	  technical	  and	  experimental	  objectives	  guiding	  the	  progression	  of	   the	  research	  activities.	  These	  objectives	  are	  summarized	  below	  with	  reference	  to	  the	  three	  major	  aims	  of	  the	  project	  described	  above	  (chapter	  2.1).	  	  	   1. For	  Aim	  1,	  the	  first	  objective	  was	  to	  visualize	  the	  hydrophobic	  compounds	  internalized	   in	   yeast	   cells;	   this	   was	   obtained	   predominantly	   using	  fluorescence	   microscopy	   after	   selective	   staining	   of	   lipid	   membranes	   of	  yeast	   cells.	   In	   particular	   the	  work	   has	   used	  Nile	   Red	   (9-­‐diethylamino-­‐5H-­‐benzo[α]phenoxazine-­‐5-­‐one,	   NR),	  which	   is	   a	   lipophilic	   dye	  well	   known	   to	  stain	   intracellular	   lipid	   droplets	   (Greenspan	   et	   al.,	   1985).	   With	   this	  approach,	   it	   was	   possible	   to	   identify	   the	   localization	   of	   the	   loaded	  hydrophobes	   inside	   yeast	   cells.	   The	   second	   objective	  was	   to	   evaluate	   the	  possible	   influence	   of	   yeast	   cell	   viability	   on	   the	   encapsulation	   process.	   To	  this	   end,	   a	   combination	   of	   two	   complementary	   techniques	   has	   been	  followed,	  using	  two	  different	  fluorophores:	  a)	  Propidium	  Iodide	  (PI),	  which	  is	  a	  cell	   impermeable	  DNA	  stain	  that	  produces	   intense	  red	   fluorescence	   in	  dying	   or	   dead	   cells	   and	   was	   studied	   using	   the	   LIVE/DEAD	   baclight	   	   kit	  (Molecular	  Probes),	  predominantly	  with	  flow-­‐cytometry;	  and,	  b)	  FUN-­‐1	  [2-­‐chloro-­‐4-­‐(2,3-­‐dihydro-­‐3-­‐methyl-­‐(benzo-­‐1,3-­‐thiazol-­‐2-­‐yl)-­‐methylidene)-­‐1-­‐phenylquinolinium	   iodide],	   which	   is	   a	   vital	   dye	   staining	   fungal	   cells	   with	  different	  colours	  depending	  on	  their	  metabolic	  state	  and	  was	  studied	  with	  quantitative	  cytofluorescence	  analysis,	  using	  both	  fluorescence	  microscopy	  (Millard	  et	  al.,	  1999)	  and	  spectrofluorescence	  measurements.	  	  2. For	   Aim	   2,	   it	   was	   necessary	   to	   set	   up	   a	   new	   approach	   in	   order	   to	  quantitatively	  evaluate	  also	  dynamic	  aspects	  of	   the	  encapsulation	  process.	  The	   first	   objective	  was	   then	   to	  develop	   an	   indirect	  method	  of	   quantifying	  the	  encapsulation	  of	  hydrophobes	  by	  combining	  HPLC	  measurements	  (off-­‐line)	   with	   changes	   in	   NR	   fluorescence	   in	   loaded	   yeast	   cells.	   This	   was	  systematically	   undertaken	   with	   three	   terpenes	   having	   largely	   different	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3.	  Terpene	  encapsulation	  in	  yeast:	  analytical	  methods	  
and	  internalisation	  kinetics	  	  
3.1	  Summary	  	  Yeast	  is	  a	  useful	  microcapsule	  system	  for	  delivering	  drugs	  and	  other	  compounds	  of	  commercial	  value.	  The	  parameters	  that	  govern	  yeast	  encapsulation	  of	  hydrophobic	  substances,	  which	  include	  most	  commercially	  important	  agents	  such	  as	  flavouring	  terpenes,	  were	  poorly	  understood	  so	  far.	  This	  work	  focuses	  on	  validating	  tools	  that	  allow	   to	   precisely	   determine	   the	   kinetics	   and	   yield	   of	   terpene	   internalization	   in	  baker’s	   yeast,	   S.	   cerevisiae.	   These	   tools	   include	   on-­‐line	   measurements	   with	   the	  reporter	  dye	  Nile	  Red	   and	  off-­‐line	  quantitative	  measurements	  with	  HPLC.	  Taken	  together,	   the	   results	   indicate	   that	   the	   encapsulation	   process	   is	   predominantly	  diffusion	   dependent,	   thus	   following	   a	   simplified	   scheme	   for	   the	   penetration	   and	  accumulation	  of	  hydrophobic	  substances	   into	  yeast	  microcapsules.	  Lipid	  droplets	  have	  been	  identified	  as	  the	  major	  intracellular	  containers	  of	  encapsulated	  terpens.	  Hence,	   the	   new	   evidence	   reported	   here	   clarifies	   basic	   aspects	   of	   hydrophobe	  encapsulation	  by	  intact	  yeast	  cells.	  	  	  




on	   the	  simple	  exposure	  of	  yeast	   cells	   to	   liquid	  hydrophobes	   (Bishop	  et	  al.,	  1998;	  Nelson	  et	  al.,	  2006;	  Kilcher	  et	  al.,	  2008).	  The	   permeation	   of	   most	   low	   molecular	   weight	   (<1,000	   Da)	   hydrophobic	  substances	   into	   yeast	   cells	   is	   essentially	   controlled	   by	   the	   diffusion	   of	   the	  molecules	   through	   the	   cell	   wall,	   which	   is	   a	   hydrophilic	   environment	   mainly	  composed	   of	  mannoproteins	   and	   β-­‐1,4/β-­‐1,6	   polysaccharides	   (Lipke	   and	   Ovalle,	  1998).	  Hydrophobes	  may	   then	  accumulate	   in/on	   the	   cell	  membrane,	  where	   they	  often	   show	   toxic	   effects	   (Sikkema	   et	   al.,	   1995;	   Uribe	   et	   al,	   1985),	   or	   permeate	  further	   in	   the	   cytoplasm.	   Hydrophobes	   can	   enter	   the	   cell	   wall	   from	   a	   generally	  saturated	  external	  water	  environment	  or	  from	  a	  liquid	  droplet.	  A	  rather	  simplified	  Fickian	   model	   (Figure	   3.1.1)	   can	   illustrate	   the	   role	   of	   the	   cell	   wall	   hydrophobe	  solubility	   in	   determining	   the	   two	   possible	   rates	   of	   permeation,	   which	   can	   be	  expressed	  as:	  	   Jwater = DA ([H ]w!w ![H ]w!m )d = DA ([H ]wsat Pw ![H ]m / Pm )d 	  and	  
([ ] [ ] ) ( [ ] / )w d w m d m m
droplet
H H P H PD DJ
A d A d
− −− −= = 	  where	  D	  is	  the	  diffusion	  coefficient	  of	  the	  hydrophobe	  in	  the	  wall;	  A	  and	  d	  the	  area	  and	  thickness	  of	  the	  wall,	  respectively;	  	   are	  the	  hydrophobe	  concentrations	   at	   the	   wall-­‐water,	   wall-­‐membrane	   and	   wall-­‐droplet	   interfaces,	  respectively;	   are	   the	   hydrophobe	   solubility	   in	   water,	   its	  concentration	   in	   the	   cell	   membrane	   and	   its	   concentration	   in	   the	   droplet,	  respectively;	  	  	   are	   the	   partition	   coefficients	   of	   the	   hydrophobe	   at	   	   the	  three	  interfaces	  (water-­‐wall,	  droplet-­‐wall	  and	  wall-­‐membrane).	  Both	   equations	   have	   the	   general	   form	   of	   ( [ ] / )m mP H PDJ
A d
−
= ,	   where	  
[ ]satw w dP H P P= + 	  is	  a	  constant	  representing	  the	  partition	  from	  the	  exterior.	  P	  is	  most	   probably	   dominated	   by	   the	   second	   term	   (the	   concentration	   of	   the	  hydrophobe	   in	   an	   oil	   droplet	   is	   generally	   orders	   of	   magnitude	   higher	   than	   its	  saturation	   in	   water):	   therefore,	   this	   term	   will	   be	   higher	   for	   compounds	   better	  soluble	  in	  the	  wall,	  thus	  boosting	  the	  diffusion	  kinetics	  of	  more	  polar	  hydrophobes.	  
[H ]w
sat ,[H ]m ,[H ]d





The	   second,	   negative	   term	   ([ ] /m mH P )	   is	   probably	   smaller	   for	   compounds	   better	  soluble	  in	  the	  cell	  membrane,	  favouring	  the	  transport	  of	  more	  apolar	  hydrophobes	  out	   of	   the	   wall	   towards	   the	   cytoplasm,	   but	   its	   effect	   would	   only	   modulate	   the	  overall	  diffusive	  rate.	  	  
	  
Figure	   3.1.	   1.	   The	   scheme	   depicts	   the	   key	   compartments	   for	   the	   permeation	   of	  
hydrophobes.	   In	   this	   study,	   these	   hydrophobes	   are	   limonene,	   carvone	   or	   linalool	  
encapsulated	   into	   yeast	   cells.	   The	   concentration	   of	   the	   hydrophobes	   in	   water	    is	  	  
assumed	   to	   be	   constant	   because	   of	   its	   saturation	   and	   the	   concentration	   in	   the	  
droplet	  is	  assumed	  to	  be	  unitary.	  
	  	  The	  main	  message	  of	  this	  simplified	  scheme	  (Figure	  3.1.1)	  is	  that	  compounds	  with	  higher	   solubility	   in	   the	  wall	   are	   likely	   to	   diffuse	   faster.	   A	   previous	   report	   of	   our	  group	   (Kilcher	   et	   al.,	   2008)	   has	   partially	   confirmed	   this	   effect.	   	   Hydrophobic	  compounds	   with	   identical	   structure	   but	   different	   molecular	   weight	   (MW)	   show	  decreased	  entropy	  of	  mixing	  and,	  therefore,	   lower	  solubility	  with	  increasing	  MW.	  This	  MW	  threshold	  depends	  on	  the	  polarity	  of	  environment,	  since	  the	  exchange	  of	  water	  with	  DMSO,	  thus	  increasing	  the	  solubility	  of	  high	  MW	  hydrophobes	  in	  the	  S.	  




hydrophobes	   on	   their	   permeation.	   In	   the	   last	   part	   of	   this	   study,	   we	   have	   also	  tackled	   the	   issue	   of	   whether	   cell	   viability	   may	   play	   a	   role	   in	   the	   encapsulation	  process.	  	  In	  terms	  of	  analytical	  tools,	  we	  have	  worked	  on	  the	  simultaneous	  application	  of	  an	  off-­‐line,	   quantitative	   but	   destructive	   analytical	   method	   and	   an	   on-­‐line,	   non-­‐destructive	  one.	  
	  
Off-­‐line	   (chromatographic)	  method.	  The	  level	  of	  encapsulation	  of	  hydrophobes	  can	  be	  quantitatively	  assessed	  via	  reverse	  phase	  HPLC.	  However,	  the	  critical	  step	  of	  this	  analysis	  is	  the	  efficiency	  of	  the	  extraction	  from	  the	  biological	  container.	  In	  a	  previous	   study	   (Kilcher	   et	   al.,	   2008),	   the	   extraction	   was	   accomplished	   by	   the	  enzymatic	  digestion	  of	  the	  yeast	  cell	  wall	  with	  Zymolyase.	  This	  enzymatic	  cocktail	  is	   essentially	   composed	   by	   a	   β-­‐1,3-­‐glucanase	   (Zymolyase	   A)	   and	   an	   alkaline	  protease	   (Zymolyase	   B),	   involved	   in	   the	   hydrolysis	   of	   cell	   wall	   β-­‐glucans	   and	  mannoproteins,	   respectively,	   and	   is	   commonly	   employed	   for	   the	   preparation	   of	  spheroplasts	   	   (Ovalle	   et	   al.,	   1998).	   Similarly	   to	   mammalian	   cells,	   spheroplasts	  easily	   lyse	  by	  exposure	   to	  organic	   solvents	  or	   to	  osmotic	  gradients.	   In	  our	   initial	  method,	  after	  lysis	  of	  the	  cell	  wall,	  spheroplasts	  were	  pelleted	  and	  re-­‐suspended	  in	  a	  CH3OH/CHCl3	  40:60	  mixture,	  supposedly	  releasing	  all	  the	  cellular	  contents	  in	  the	  medium	  (Folch	  et	  al.,	  1957).	  This	  extraction	  method,	  however,	  is	  time-­‐consuming.	  More	   worryingly,	   the	   heterogeneity	   of	   the	   cell	   walls	   may	   also	   lead	   to	   poor	  extraction	   yields	   in	   a	   significant	   fraction	   of	   the	   yeast	   population.	   Here	   we	   have	  compared	   the	   efficiency	   of	   the	   extraction	   after	   enzymatic	   cell	   wall	   degradation	  with	   that	  of	  mechanical	  disruption	  by	   the	  use	  of	   a	  beads	  mill.	  The	   latter	  method	  has	   been	   widely	   employed	   for	   the	   extraction	   of	   genetic	   material	   from	   bacteria,	  fungi	  and,	  more	  generally,	  environmental	  samples	  (Carlson	  et	  al.,	  1995;	  Hurt	  et	  al.,	  2001;	   	  Kuske	   et	   al.,	   1998).	  Here,	   the	  use	   of	   glass	   beads	   for	   the	  disruption	  of	   the	  yeast	   cell	   wall	   has	   been	   successfully	   validated,	   in	   accordance	   with	   earlier	   work	  (Stowers	  and	  Boczko,	  2007).	  	  




oil)	  was	  monitored	   using	   a	   phenoxazine	   lipid-­‐staining	   fluorescent	   dye,	  Nile	   Blue	  (NB).	   NB	   actually	   contains	   a	   number	   of	   oxidized	   products	   (phenoxazones)	   in	  various	   proportions,	   among	   which	   Nile	   Red	   (NR),	   9-­‐diethylamino-­‐5H-­‐benzo[α]phenoxazine-­‐5-­‐one	   (Figure	   3.1.2)	   is	   predominant.	   Both	   compounds	   are	  solvatochromic,	  with	  green	  or	  blue	  fluorescence	  in	  a	  polar	  environment,	  which	  red	  shifts	  once	  incorporated	  into	  lipid	  compartments.	  	  
	  
	  
Figure	  3.1.	  2.	  Molecular	  structures	  and	  spectral	  properties	  of	  Nile	  Blue	  (NB,	  left)	  and	  




(Kimura	  et	  al.,	   2004).	  We	  have	   therefore	   selected	  NR	  as	   the	   fluorescent	   reporter	  for	  our	  on-­‐line	  studies.	  
	  
3.3	  Experimental	  section	  	  
3.3.1	  Materials	  	  Methanol	  gradient	  grade	  for	  HPLC	  analysis,	  zymolyase	  1598	  units/mg,	  Nile	  Red,	  D-­‐glucose,	  YPD	  (1%	  yeast	  extract,	  2%	  bacteriological	  peptone	  and	  2%	  glucose),	  acid-­‐free	  glass	  beads	  (500	  µm	  diameter)	  were	  obtained	  from	  Sigma	  Aldrich,	  Gillingham,	  United	  kingdom.	  Phosphate	  Buffered	  Saline	  tablets	  (PBS)	  were	  supplied	  by	  Oxoid,	  Basingstoke,	   United	   Kingdom.	   FUN-­‐1,	   Calcofluor	   White	   M2R,	   Alexa-­‐fluor	   488-­‐conjugated	   concanavalin	   A,	   Live/Dead	   Baclight	   viability	   and	   counting	   kit	   stains	  were	   purchased	   from	   Molecular	   Probes-­‐Invitrogen	   Inc.,	   United	   Kingdom.	  Limonene,	   carvone,	   linalool,	   menthyl	   acetate	   and	   pinene	   were	   obtained	   from	  Fluka,	   Gillingham,	   United	   Kingdom.	   Antimycin	   A	   was	   kindly	   provided	   by	   Dr	   M.	  Degli	  Esposti,	  Faculty	  of	  Life	  Sciences,	  University	  of	  Manchester.	  Diploid	  wild	  type	  yeast	   strain	   BY4743	   was	   obtained	   from	   Dr.	   D.	   Del	   Neri	   of	   the	   Faculty	   of	   Life	  Sciences,	  University	  of	  Manchester.	  





3.3.3	  Cell	  counting	  	  
Turbidimetry.	   The	   evaluation	   of	   the	   concentration	   of	   cell	   suspensions	   was	  performed	  by	  turbidimetry,	  measuring	  their	  optical	  density	  (OD)	  at	  660	  nm	  (UV-­‐Vis	  Lambda	  12,	  Perkin	  Elmer,	  USA)	  	  using	  a	  coefficient	  equivalence	  of	  1.0	  OD	  units	  =	  107	  cells/mL.	  	  
Gravimetry.	  A	  complementary	  evaluation	  of	  cell	  concentration	  was	  carried	  out	  by	  measuring	   the	  wet	  weight	  of	   yeast	   suspensions	  after	   centrifugation	  at	  4500	   rpm	  for	  5	  minutes.	  Typically,	  a	  concentration	  of	  1.66	  mg/mL	  obtained	  gravimetrically	  corresponded	  to	  1.0	  OD	  at	  660	  nm.	  The	  wet	  weight	  of	  yeast	  was	  estimated	  to	  be	  12%	  larger	  than	  that	  of	  dry	  yeast	  (obtained	  by	  drying	  at	  120	  °C	  for	  24	  hours).	  




Image	  J	  plugin	  “process/subtract	  background”	  (with	  a	  routine	  setting	  of	  50	  for	  the	  roundball)	  prior	  to	  the	  application	  of	  the	  plugin	  “analyse/measure”.	  
3.3.5	  Encapsulation	  of	  hydrophobes	  in	  yeast	  cells	  	  The	   general	   protocol	   for	   the	   encapsulation	   process	   was	   adapted	   from	   the	  procedure	  described	  by	  Bishop	  et	  al.	  (1998).	  Aliquots	  of	  cells	  growth	  in	  either	  log	  phase	   (usually	   48	   hours,	   10	  mL)	   or	   stationary	   phase	   (6	   days	   or	   older,	   5	  mL)	   as	  described	  in	  chapter	  3.3.2	  were	  harvested	  by	  centrifugation	  at	  4500	  rpm	  for	  5	  min	  using	  15	  mL	  Falcon	   tubes.	  After	   removal	  of	   the	   supernatant,	   cells	  were	  weighed,	  usually	   yielding	   around	   90	  mg	   of	  wet	  weight.	   The	   pellets	  were	   re-­‐suspended	   in	  distilled	   water,	   transferred	   to	   1.5	   mL	   Eppendorf	   tubes	   and	   supplemented	   with	  different	   quantities	   of	   hydrophobes	   in	   order	   to	   obtain	   	   5%,	   10%,	   20%	  and	  30%	  w/wtotal	   of	   hydrophobes	   in	   the	   final	   suspension.	   The	   encapsulation	   process	   was	  then	  carried	  out	  by	  agitating	  these	  tubes	  in	  a	  thermomixer	  at	  900	  rpm	  for	  different	  times	  (from	  2	  to	  8	  h)	  at	  different	  temperatures	  (20	  °C	  to	  60	  °C).	  At	  the	  end	  of	  these	  incubations,	  the	  suspensions	  were	  centrifuged	  at	  10,000	  rpm	  for	  3	  min	  in	  a	  bench	  centrifuge	  (Fisher	  Scientific,	  accuSpin	  Micro).	  After	  removing	  the	  supernatant	  (oil	  and	   water),	   the	   cell	   pellets	   were	   suspended	   in	   approx.	   1	   mL	   of	   distilled	   water,	  transferred	   in	   a	   new	   1.5	   mL	   Eppendorf	   tube	   and	   rinsed	   three	   times	   with	   the	  following	  procedure.	  Each	  rinsing	  cycle	  consisted	  in	  a	  centrifugation	  step	  at	  10,000	  rpm	   for	   3	   min,	   followed	   by	   the	   complete	   removal	   of	   the	   supernatant	   and	   re-­‐suspension	  of	   the	  pellet	   in	  distilled	  water	  with	   transfer	   into	  new	  tubes.	  The	   final	  pellets	  containing	  washed	  encapsulated	  yeasts	  were	  weighed	  and	  resuspended	  in	  either	   200	  μl	   of	   appropriate	   staining	   solutions	   or	   400	  μl	   of	  methanol	   containing	  appropriate	  concentrations	  of	  the	  suitable	  internal	  standard	  for	  each	  hydrophobe	  (ISD).	   Pure	   (±)-­‐limonene,	   (+)-­‐carvone,	   (±)-­‐menthyl	   acetate,	   (α)-­‐pinene	   and	   (±)-­‐linalool	   have	   been	   used	   for	   the	   encapsulation	   process.	   Small	   variations	   of	   this	  general	  protocol	  are	  detailed	  in	  the	  captions	  to	  figures.	  	  




centrifuged	   at	   10,000	   rpm	   for	   3	  minutes	   in	   an	   Eppendorf	   bench	   centrifuge	   and	  resuspended	  in	  water	  at	  a	  final	  concentration	  of	  approximately	  108	  cells/mL.	  The	  NR	  stock	  solution	  was	  added	  to	  reach	  a	  final	  concentration	  of	  0.01	  mg/mL	  (30	  μM),	  and	  then	  incubated	  in	  the	  dark	  for	  30	  min	  at	  37°	  C	  in	  an	  Eppendorf	  Thermomixer	  set	   at	  600	   rpm.	   In	   some	  experiments,	   the	   cell	  wall	  was	  additionally	   stained	  with	  Calcofluor	  White	  (final	  concentration:	  25	  μM)	  or	  with	  Alexa-­‐fluor	  488-­‐conjugated	  concanavalin	  A	  	  (final	  concentration:	  50	  μg/mL).	  After	  incubation,	  the	  suspensions	  were	  then	  centrifuged	  at	  10,000	  rpm	  for	  3	  minutes;	  the	  supernatant	  was	  removed	  and	  the	  pellet	  was	  resuspended	  in	  fresh	  deionised	  water.	  These	  washed	  cells	  were	  used	   for	   both	   the	   procedures	   described	   below.	   For	   microscopy	   analysis,	   slides	  were	  prepared	  as	   follows:	  on	  a	   standard	  microscope	   slide,	  5	  μl	  of	  2%	  (w/v)	  Na-­‐alginate	  were	  deposited	  and	   then	  mixed	  with	  5	  μl	  of	   the	  stained	  cell	   suspension.	  Subsequently,	  5	  μl	  of	  CaCl2	  0.1	  M	  were	  added	  to	  induce	  gelification	  of	  the	  alginate	  mixture,	  which	  was	   covered	  with	   an	   18-­‐	   by	   18-­‐mm	  1.5	  mm	   cover	   slip	   and	   then	  allowed	  to	  dry	  for	  1	  h	  at	  room	  temperature	  under	  darkness.	  	  Spectrofluorimetric	  measurements	  of	  NR	  were	  carried	  out	  in	  a	  Perkin	  Elmer	  LS55	  spectrofluorimeter.	  Briefly,	  yeast	  cells	  were	  suspended	  to	  reach	  an	  optical	  of	  OD	  of	  ca.	   1	   and	   diluted	   to	   2	   mL	   with	   distilled	   water	   (or	   PBS)	   in	   disposable	   plastic	  cuvettes,	  emission	  spectra	  were	  then	  recorded	  at	  T=	  25	  ºC	  between	  500	  to	  750	  nm	  with	   excitation	   wavelength	   usually	   set	   at	   480	   nm	   and	   bandwidth	   of	   10nm.	  Emission	   spectra	   of	   NR	   suspended	   in	   ethanol	   and	   organic	   solvents	   were	   also	  measured	   using	   the	  maximal	   emission	   obtained	  with	   the	   standard	   settings	   used	  above.	  	  
3.3.7	  Extraction	  of	  encapsulated	  hydrophobes	  	  
Disruption	  of	  yeast	  cells	  in	  a	  beads	  mill	  and	  extraction	  with	  the	  HPLC	  mobile	  




extraction	   with	   500	   μl	   of	   methanol	   containing	   the	   appropriate	   ISD	   was	   then	  performed	  on	  these	  lysate.	  The	  resulting	  suspensions	  were	  incubated	  for	  3	  min	  at	  40°	  C	   in	  an	  Eppendorf	   thermomixer	   set	   at	  300	   rpm.	  The	   total	   extraction	  volume	  was	  usually	  900	  µl	  for	  all	  the	  hydrophobes.	  The	  methanol	  phase	  containing	  the	  ISD	  and	  the	  extracted	  hydrophobes	  was	  carefully	  filtrated	  with	  0.20	  µm	  RC	  membrane	  (Minisart	  RC	  15,	  Sartorium	  Stedim	  Biotech)	  and	  transferred	  in	  new	  glass	  vials	  for	  subsequent	  HPLC	  analysis.	  	  
Enzymatic	   digestion	   followed	   by	   extraction	   with	   organic	   solvents.	  Suspensions	   of	   aliquots	   of	   loaded	   yeast	   cells	   (prepared	   as	   described	   in	   section	  3.3.5)	  were	  mixed	   in	   1.5	  mL	   Eppendorf	   tubes	  with	   132	   μl	   of	   a	   Zymolyase	   stock	  solution	  (approximately	  2800	  U/mL)	  and	   incubated	   for	  15-­‐20	  min	  at	  37°	  C	   in	  an	  Eppendorf	   thermomixer	   set	   at	   600	   rpm.	   After	   incubation,	   different	   volumes	   of	  various	   organic	   solvents	   were	   added	   to	   proceed	   with	   the	   extraction	   of	  hydrophobic	   material.	   Initially,	   332	   μl	   of	   CH2Cl2	  were	   added	   to	   the	   lysate,	   but	  subsequently	  the	  solvent	  has	  been	  changed	  to	  CHCl3/CH3OH	  (HPLC	  grade)	  60/40	  (vol/vol)	  in	  order	  to	  increase	  the	  efficiency	  of	  the	  extraction	  process	  (Folch	  et	  al.,	  1957).	  In	  every	  case,	  the	  resulting	  suspension	  of	  lysate-­‐solvent	  was	  incubated	  for	  5	  min	   at	   37°	   C	   in	   an	   Eppendorf	   thermomixer	   set	   at	   600	   rpm	   and	   centrifuged	   at	  10,000	   rpm	   for	   3	   min	   in	   a	   bench	   centrifuge.	   After	   phase	   separation,	   the	   lower	  organic	   phase	   was	   carefully	   removed	  with	   a	   200	   μl	   automatic	   pipette	   and	   then	  transferred	   into	  a	  15	  mL	  glass	  vial.	  This	  extraction	  step	  was	  repeated	  four	  times.	  The	  collected	  organic	  phases	  were	  then	  combined	  together	  and	  evaporated	  for	  10	  min	  at	  40	  °C	  in	  a	  ROTAVAPOR.	  To	  resuspend	  the	  evaporated	  residues,	  100	  to	  400	  μl	  of	  the	  same	  solvent	  used	  as	  the	  mobile	  phase	  for	  HPLC	  elution	  (see	  below)	  were	  added,	  together	  with	  a	  suitable	  volume	  of	  a	  stock	  solution	  of	  internal	  standard.	  	  	  




mm	   of	   internal	   diameter).	   The	   eluent	   mixtures	   were:	   methanol	   for	   the	  determination	  of	   limonene,	   linalool	   and	  carvone;	  methanol/hexane	  90:10	   for	   the	  simultaneous	  determination	  of	  NR	  and	  the	  aforementioned	  terpenes.	  Each	  terpene	  was	  also	  used	  as	  internal	  standard	  for	  the	  others,	  e.g.	  1	  mg/mL	  limonene	  was	  used	  as	   the	   internal	  standard	   for	  carvone	  and	   linalool.	  The	  elution	  times:	   in	  methanol,	  carvone	  at	  3.39	  min,	  linalool	  at	  4.2	  min,	  limonene	  at	  5.5	  min;	  in	  methanol/hexane,	  NR	  at	  4.08	  min,	  linalool	  (standard)	  at	  3.05	  min	  and	  	  limonene	  at	  4.5	  min.	  	  
3.3.9	  Kinetics	  of	  the	  encapsulation	  process	  	  Three	   terpenes	   (limonene,	   linalool	   and	   carvone)	   dispersed	   in	   water	   at	   a	   final	  concentration	  of	  20%	  wt.	  were	  loaded	  according	  to	  the	  procedure	  described	  above	  in	  section	  3.3.5	  at	  a	  temperature	  of	  20,	  40	  or	  60°C,	  interrupting	  the	  process	  at	  3,	  7,	  10,15,	  20,	  30,	  40	  min,	  1	  h,	  2	  h.	  Washed	  loaded	  cells	  were	  resuspended	  in	  950	  µl	  of	  water	   and	   50	   µl	   of	   NR	   0.1	   mg/mL	   (dissolved	   in	   MeOH),	   to	   yield	   a	   final	  concentration	  of	  0.005	  mg/mL.	  Samples	  were	   incubated	  at	  30	   °C	   for	  20	  min	   in	  a	  Thermomixer	   at	   900	   rpm.	   For	   each	   sample,	   200	   µl	   of	   stained	   cells	   were	   then	  transferred	   into	  a	  96	  well	  plate	   in	   triplicate.	  Quantitative	  NR	  spectrofluorimetric	  measurements	   were	   recorded	   with	   a	   96-­‐well	   plate	   reader	   (Biotech	   Synergy	   2)	  equipped	  with	  a	  485/20	  nm	  excitation	  filter	  and	  620/40	  emission	  filter.	  	  
3.3.10	  Viability	  assays	  	  




A)	   Viability	   assessment	   through	  microscopy.	   Slides	   were	   prepared	   as	   described	  before	   in	   section	   3.3.6.	   Deconvolved	   pictures	   were	   analysed	   by	   three	   different	  observers	  and	  scored	  for	  the	  fraction	  of	  viable	  cells	  (defined	  as	  those	  presenting	  a	  sharp	  red	   intracellular	  element	  without	  green	  cytoplasmic	  staining).	  The	  number	  of	  cells	  was	  automatically	  determined	  for	  each	  field	  using	  the	  appropriate	  routine	  in	  the	  Image	  J	  program	  and	  a	  minimum	  of	  200	  cells	  was	  evaluated	  for	  each	  sample.	  B)	   Viability	   assessment	   through	   spectrofluorimetry.	   	   The	   fluorescence	   emission	  was	   recorded	  using	   two	  different	  plate	   readers,	   after	   transferring	  aliquots	  of	   the	  stained	  suspensions	  into	  96-­‐well	  plates	  (bottom-­‐clear,	  black	  Greiner	  Bio	  One)	  and	  incubating	  them	  in	  the	  dark	  for	  30	  min	  at	  37°C:	  i)	  a	  Biotech	  Synergy	  2	  instrument	  with	   a	  485/20	  nm	  excitation	   filter	   and	  either	   a	  528/20	  nm	   (green)	  or	   a	  620/40	  (red)	  emission	  filter;	  and	  ii)	  a	  TECAN	  Saffire	  instrument	  with	  excitation	  set	  at	  480	  nm	   and	   emission	   recorded	   in	   the	   500-­‐700	   nm	   range.	   Alternatively,	   FUN-­‐1	  fluorescence	  was	  measured	  with	  a	  Perkin	  Elmer	  LS55	  spectrofluorimeter,	  diluting	  the	   yeast	   suspensions	   in	   2	   mL	   of	   staining	   buffer	   (to	   a	   final	   concentration	   of	  approximately	  107	  cells/mL;	  i.e.	  with	  an	  OD	  of	  ca.	  1)	  in	  disposable	  plastic	  cuvettes	  (Kartell,	  4	  clear	  sides	  of	  4.5	  mL	  capacity).	  The	  excitation	  wavelength	  was	  set	  at	  480	  nm	  and	  the	  emission	  spectra	  were	  recorded	  at	  T=	  25	  ºC	  between	  500	  and	  750	  nm	  with	  a	  10	  nm	  slit.	  The	  viability	  of	   loaded	  yeast	  was	  calculated	  on	  the	  basis	  of	  the	  red/green	  emission	  ratio	  (620	  nm	  /	  528	  nm),	  as	  [Ratio	  R/G	  (terpene)-­‐	  Ratio	  R/G	  (autoclaved	   cells	   incubated	   with	   terpene)	   /	   Ratio	   R/G	   (control)-­‐	   Ratio	   R/G	  (autoclaved	  cells)]*100.	  	  	  
	  








3.4	  Results	  and	  discussion	  	  
3.4.1	  Optimization	  of	  hydrophobe	  recovery	  	  The	   method	   used	   to	   extract	   encapsulated	   hydrophobes	   was	   optimized	   using	  terpenes	   (most	   often	   limonene,	   but	   also	   carvone	   and	   linalool)	   as	   model	  hydropobes	   of	   choice.	   Initially,	   we	   have	   compared	   two	   methods	   of	   cell	   wall	  disruption,	   i.e.	   enzymatic	   with	   Zymolyase	   and	   mechanical	   with	   glass	   beads,	   on	  yeast	   grown	   in	   stationary	   phase	   (6	   days	   or	   older).	   The	   hydrophobes	   were	  extracted	  with	  60/40	  CHCl3/methanol,	  evaporating	  the	  solvents	  and	  re-­‐dissolving	  the	  material	  in	  the	  HPLC	  mobile	  phase	  (methanol).	  As	  shown	  in	  Figure	  3.4.1	  (left)	  the	   mechanical	   disruption	   provided	   a	   >3-­‐fold	   higher	   value	   of	   limonene	  encapsulation,	   possibly	   because	   of	   incomplete	   disruption	   of	   the	   cell	   walls	   with	  Zymolyase.	   The	   enzymatic	   method	   was	   therefore	   abandoned.	   Notably,	  hydrophobes	   such	   as	   terpenes	   are	   already	   volatile	   at	   room	   temperature	   and	  atmospheric	   pressure;	   therefore,	   the	   step	   of	   solvent	   evaporation	   and	   exchange	  may	   considerably	   lower	   the	   efficiency	   of	   hydrophobe	   recovery.	   We	   have	   thus	  compared	  the	  above	  method	  with	  the	  direct	  extraction	  of	  the	  yeast	  with	  methanol	  during	  the	  mechanical	  disruption	  in	  the	  beads	  mill.	  	  
	  
Figure	  3.4.	  1.	  Comparison	  of	   the	  methods	  used	   for	  cell	  wall	  disruption	  and	  solvent	  
extraction	   of	   encapsulated	   hydrophobes.	   S.	   cerevisiae	   cells	   (two	   different	   growth	  




limonene	   water	   dispersion	   at	   40	   °C.	   Histograms	   represent	   averages	   while	   error	  

















































Contact time (h) 	  
Figure	   3.4.	   2.	   Encapsulation	   yield	   for	   log	   phase	   grown	   yeast	   cells	   exposed	   to	  
different	   terpenes	   (all	  20%	  wt.	   in	  deionized	  water)	  at	  60	   °C	   for	   contact	   times	  of	  3	  
min,	  30	  min,	  2	  h,	  4	  h	  (and	  also	  6-­‐8	  h	  for	  limonene).	  Error	  bars	  refer	  to	  the	  SD	  of	  n	  =	  4	  
separate	  experiments.	  	  	  	  
3.4.2	  Nile	  Red-­‐mediated	  visualization	  and	  quantification	  of	  hydrophobe	  
encapsulation	  	  	  
NR-­‐staining	   allows	   the	   visualisation	   of	   lipid	   bodies.	   Control	   (untreated)	   S.	  






Figure	  3.4.	  3.	  Deconvolution	  microscopy	  images	  of	  S.	  cerevisiae	  cells	  growing	  in	  the	  
exponential	   phase.	   Control	   and	   limonene-­‐loaded	   log	   phase	   (48	   h	   culture)	   stained	  
with	  NR	  (0.01	  mg/mL,	  red	  fluorescence)	  and	  Calcofluor	  white	  (25	  μM,	  cf.	  Kilcher	  et	  
al.,	   2008).	   In	   the	   control	   (A)	   NR	   stains	   naturally	   occurring	   intracellular	   lipid	  
organelles,	   while	   Calcofluor	   white	   allows	   the	   identification	   of	   the	   cell	   wall	  
(crystalline	  chitin	  domains,	  stained	  blue).	  After	  treatment	  with	  a	  20%	  wt.	  limonene	  
water	  dispersion	  (B),	  the	  number	  and	  size	  of	  NR-­‐stained	  elements	  clearly	  increase.	  
Deconvolved	  fluorescence	  pictures	  were	  obtained	  by	  merging	  those	  taken	  using	  the	  
DAPI	  (blue)	  and	  theTX-­‐TRITC-­‐PE	  (red)	  filter. 








Figure	  3.4.	  4.	  	  Effect	  of	  limonene	  loading	  on	  yeast	  cells	  grown	  in	  exponential	  phase.	  
The	   images	   were	   obtained	   with	   deconvolution	   microscopy	   using	   yeast	   cells	  
harvested	  in	  log	  phase	  and	  then	  stained	  with	  NR	  (0.01	  mg/mL)	  and	  Alexa	  Fluor	  488-­‐
conjugated	  concanavalin	  A	  (50	  μg/mL).	  A)	  Untreated	  cells;	  B)	  Cells	  after	  treatment	  
with	  20%	  wt.	  limonene.	  The	  deconvolved	  images	  were	  merged	  from	  those	  obtained	  
with	  the	  FITC	  (green)	  and	  the	  TXR-­‐TRITC-­‐PE	  (red)	  emission	  filters	  keeping	  the	  same	  
excitation	  filter	  centred	  at	  480	  nm.	  The	  thin	  green	  rim	  on	  the	  surface	  of	  the	  cells	  is	  
due	   to	   the	   bright	   green	   fluorescence	   of	   the	   concanavalin	   A	   conjugate	   that	  
specifically	  stains	  the	  cell	  wall	  (Kilcher	  et	  al.,	  2008).	  Of	  note,	  cells	  stained	  only	  with	  
the	   green	   conjugate	   of	   concanavalin	   showed	   an	   exclusive	   staining	   of	   the	   cell	  wall	  
both	  before	  and	  after	  the	  encapsulation	  of	  limonene	  (results	  not	  shown).	  
 




substantially	   inactive;	  the	  reduction	  in	  NR	  incorporation	  is	  most	   likely	  due	  to	  the	  decreased	   diffusion	   coefficient,	   which	   slows	   down	   NR	   permeation	   through	   wall	  and	  membrane.	  
	  
Figure	   3.4.	   5.	   Comparison	   of	   microscopic	   and	   fluorimetric	   data	   of	   metabolically	  
poisoned	   yeast	   cells.	  Left:	   Log	   phase	   (48	   h	   culture)	  S.	  cerevisiae	   cells	   stained	  with	  
Calcofluor	  white	  (cell	  wall)	  and	  NR	  with	  and	  without	  the	  addition	  of	  antimycin	  (0.4	  
mM)	   show	   an	   indistinguishable	   staining	   of	   their	   lipid	   droplets.	   Right:	   Emission	  
spectra	   of	   NR-­‐stained	   yeast	   cell	   suspensions	   at	   0	   and	   37	   °C,	   with	   and	   without	  
antimycin.	  Cell	  samples	  were	  incubated	  in	  PBS	  without	  nutrients	  (so	  in	  the	  absence	  
of	   fermentable	  substrates)	  and	  in	  the	  dark	  for	  1	  h,	  either	  at	  37	  °C	  in	  an	  Eppendorf	  
Thermomixer	  set	  at	  600	  rpm	  or	  at	  0	  °C	  using	  a	  melting	  ice	  bath.	  	  
 
NR	   staining	   is	   a	   reliable	   monitor	   of	   the	   amount	   of	   encapsulated	  




	  In	  order	  to	  confirm	  the	  above	  hypothesis,	  NR	  was	  added	  to	  yeast	  samples	  loaded	  with	   different	   amounts	   of	   three	   model	   terpenes:	   limonene,	   carvone	   or	   linalool.	  HPLC	   analysis	   showed	   that	   NR	   and	   terpenes	   were	   incorporated	   in	   roughly	  proportional	   amounts	   (Figure	   3.4.7).	   The	   NR	   fluorescence	   followed	   exactly	   the	  same	   trend,	   confirming	   the	   suitability	   of	   NR	   as	   a	   rapid	   and	   non-­‐destructive	  reporter	   of	   hydrophobe	   encapsulation	   (Figure	   3.4.8).	   The	   NR	   emission	   intensity	  depended	  on	   the	   terpene:	   e.g.	   for	   comparable	  amounts	  of	   encapsulated	  material,	  NR	   emitted	   less	   intensely	   with	   linalool	   than	   with	   carvone.	   However,	   the	  quantification	  of	  the	  exact	  amount	  of	  encapsulated	  terpenes	  was	  corroborated	  by	  HPLC	  measurements	  undertaken	  in	  parallel	  (Fig.	  3.4.8).	  	  
	  
Figure	   3.4.	   6.	   Emission	   spectra	   of	   NR-­‐stained	   yeast	   cells.	   Data	   were	   recorded	  
without	  NR	  (yeast	  susp.,	  short	  dashed	  spectrum)	  and	  with	  NR	  staining	  before	  (long	  
dashed	  spectrum)	  and	  after	  (solid,	  larger	  spectrum)	  the	  encapsulation	  of	  limonene	  
as	   described	   in	   chapter	   3.3.5.	   The	   emission	   of	   NR	   in	   ethanol	   is	   also	   shown	   for	  
reference.	  The	  concentration	  of	  NR	  and	  the	  excitation	  wavelength	  (480	  nm)	  was	  the	  





Figure	   3.4.	   7.	   Comparison	   of	   the	   encapsulation	   of	   terpenes	   and	   the	   subsequent	  
uptake	  of	  NR	  via	  HPLC	  analysis.	  Yeast	  cells	  in	  log	  phase	  (48	  h)	  were	  exposed	  to	  20%	  
wt.	   limonene	  (left)	  or	  carvone	   (right)	  at	  60°C.	  HPLC	  analysis	  of	  NR	  was	  performed	  
under	   the	   conditions	   described	   in	   Appendix	   B	   (section	   3.8),	   using	   linalool	   as	   an	  
internal	  standard	  for	  the	  normalization	  of	  the	  absorbance	  values	  at	  210	  nm.	  The	  SD	  
(bars)	  refer	  to	  n	  =	  3	  samples.	  Note	  that	  the	  uptake	  of	  NR	  in	  the	  absence	  of	  terpenes	  
is	  nearly	  within	  the	  limits	  of	  detection.	  	  
	  
Figure	  3.4.	  8.	  Comparison	  of	   the	  encapsulation	  yield	  of	   two	  terpenes.	  Carvone,	   left,	  
and	   linalool,	   right	   were	   loaded	   for	   the	   indicated	   times	   with	   yeast	   cells	   after	   NR	  
staining	   and	   the	   fluorescence	   intensity	   was	   recorded	   in	   a	   plate	   reader	   as	   in	   the	  
experiments	   of	   Fig.	   3.4.	   7.	   HPLC	   measurements	   were	   undertaken	   in	   parallel	  
samples,	  as	  described	  for	  the	  experiment	  in	  Fig.	  3.4.7.	  	  






Figure	   3.4.	   9.	   Comparison	   of	   NR	   staining	   of	   limonene-­‐loaded	   yeast	   using	  
fluorescence	  microscopy	  imaging.	  Image	  analysis	  techniques	  	  (area	  of	  lipid	  droplets	  
and	   average	   pixel	   intensity,	   bottom	   left)	   are	   combined	   with	   HPLC/whole	   sample	  
fluorescence	  (top	  left).	  Histograms	  represent	  the	  average	  ±	  Standard	  Deviation	  (SD)	  
of	   the	  mean	   value	   of	   pixel	   intensity	   obtained	   from	  n=	   6	   randomly	   selected	   fields.	  
Note	  that	  the	  only	  slight	  incongruence	  in	  the	  results	  appears	  to	  be	  the	  average	  pixel	  
intensity	   at	   30%	  wt.	   limonene	   load	   (second	   diagram	   from	   the	   left	   in	   the	   bottom	  
row).	   This	   data	   shows	   an	   increase	   in	   encapsulation	   extent	   whereas	   all	   the	   other	  
techniques	   indicate	  that	  a	  plateau	  is	  reached	  at	  much	  lower	  loading	  concentration	  
of	   limonene.	   Yeast	   cells	   (1.35•107	   cells/mL	   in	   distilled	   water)	   were	   exposed	   to	  
limonene	   dispersions	   in	   water	   with	   increasing	   concentration	   at	   40	   °C	   and	   then	  
stained	  with	  0.01	  mg/mL	  of	  NR.	  Deconvolved	  images	  were	  acquired	  under	  identical	  
conditions	   with	   the	   FITC	   filter	   for	   excitation	   and	   the	   TXR-­‐TRITC-­‐PE	   filter	   for	  
emission.	   Note	   that	   the	   droplets	   appear	   red	   (instead	   of	   yellow	   as	   in	   Figure	   3.4.4)	  
because	  only	  the	  red	  filter	  was	  used	  here	  for	  the	  acquisition	  of	  the	  images.	  	  	  
	  
3.4.3	  	  Influence	  of	  the	  LogP	  of	  hydrophobes	  and	  temperature	  on	  the	  






Figure	   3.4.	   10.	   Kinetics	   of	   encapsulation	   of	   various	   terpenes	   in	   yeast	   at	   different	  
temperatures.	  Left:	  internalisation	  of	  limonene,	  linalool	  and	  carvone	  (all	  20%	  wt.	  in	  
water)	  was	  followed	  in	  log	  phase	  grown	  S.	  cerevisiae	  at	  20	  and	  60	  °C	  as	  a	  function	  of	  
time	   of	   contact	   with	   the	   hydrophobe;	   the	   kinetics	   was	   monitored	   through	   the	  
fluorescence	   intensity	   of	  NR	   staining	   (added	  after	   the	   encapsulation).	  Right:	   time-­‐
course	   of	   limonene	   encapsulation	  was	   followed	   at	   the	   indicated	   temperatures.	   	   A	  
mono-­‐exponential	   fit	   (dashed	   lines)	   of	   the	   form	   ( ) exp( / )F t F F t τ∞= − − 	  considerably	  
underestimated	   the	   amount	   of	   internalised	  material	   (considered	   equal	   to	   the	   NR	  
emission	   intensity)	   for	   the	  data	  points	  up	  to	  10-­‐20	  min.	  A	  bi-­‐exponential	  model	  of	  
the	   form F (t) = F
!
" F1 exp(!t / !1)! F2 exp(!t / ! 2 ) 	  (solid	   lines)	  always	   showed	  a	  much	  better	  




number	   of	   time	   points.	   The	   rate	   of	   the	   second	   phase	   (1/τ2)	   increased	   with	  increasing	   temperature	   (Figure	   3.4.11,	   right)	   for	   all	   terpenes;	   however,	   at	   any	  given	   temperature,	   carvone	   showed	   the	  most	   rapid	   internalisation	  and	   limonene	  the	   slowest	   one.	   Similarly,	   the	   increase	   in	   rate	   with	   temperature	   was	   more	  noticeable	  for	  carvone	  and	  least	  evident	  for	  limonene.	  Moreover,	  the	  temperature	  dependency	   of	   the	   internalisation	   rate	   of	   carvone	   and	   linalool	   did	   not	   follow	   a	  simple	  Arrhenius	  model	  (see	  Figure	  3.9.2	  in	  Section	  3.9,	  Appendix	  C),	  suggesting	  a	  rather	   complex	   nature	   of	   this	   passive	   diffusion	   mechanism.	   These	   results,	  nonetheless,	   clearly	   confirmed	   the	   initial	  hypothesis	   that	  polarity	   (i.e.	   LogP)	  was	  the	   major	   determinant	   for	   the	   rate	   of	   internalisation	   of	   these	   hydrophobic	  compounds	  in	  yeast	  cells,	  in	  an	  inversely	  proportional	  way.	  	  
	  
Figure	   3.4.	   11.	   Results	   of	   the	   bi-­‐exponential	   fits	   of	   the	   encapsulation	   kinetics	   of	  
limonene,	  linalool	  and	  carvone.	  All	  terpenes	  were	  used	  at	  20%wt.,	  with	  cells	  in	  log	  
phase.	  Left:	  fraction	  of	  terpene	  internalised	  through	  the	  slower	  phase	  at	  time=∞.	  In	  
all	  experiments	  at	  least	  80%	  of	  the	  loaded	  terpene	  would	  be	  taken	  up	  in	  this	  second	  
phase,	  with	  the	  exception	  of	  limonene	  at	  60°C,	  where	  the	  fraction	  decreases	  to	  about	  
65%.	   Right:	   internalisation	   rate,	   expressed	   as	   the	   reciprocal	   of	   the	   characteristic	  
time	  of	  the	  second	  phase	  (t2),	  as	  a	   function	  of	  temperature.	  Of	  note,	   the	  higher	  the	  
LogP,	  the	  lower	  is	  the	  internalisation	  rate	  of	  a	  terpene	  obtained	  at	  any	  temperature.	  	  	  
	  







the	   exponential	   (log)	   phase	   is	   more	   porous	   and	   less	   resistant	   to	   enzymatic	  degradation	   than	   that	   of	   quiescent	   cells	   in	   the	   stationary	   phase	   (de	  Nobel	   et	   al.,	  1990).	   Additionally,	   during	   the	   stationary	   phase	   yeast	   cells	   accumulate	   large	  amounts	  of	  reserve	  fats	  stored	  in	  lipid	  droplets	  (Clausen	  et	  al.,	  1974;	  Leber	  et	  al.,	  1994;	   Sandager	   et	   al.,	   2002;	   Zweytick	   et	   al.,	   2000).	   Indeed,	   morphological	  differences	   of	   the	   lipid	   organelles	   in	   the	   cytoplasm	   of	   yeast	   cells	   growing	   in	   log	  phase	   or	   stationary	   phase	   are	   easy	   to	   recognise	   with	   NR	   staining	   (Fig.	   3.4.12).	  	  However,	  previously	  presented	  data	  (Figure	  3.4.1)	  suggested	   that	   the	  differences	  in	  cell	  wall	  and	  lipid	  bodies	  number	  or	  morphology	  may	  not	  play	  a	  significant	  role	  in	   determining	   the	   final	   amount	   of	   internalised	   terpenes.	   Using	   NR	   staining	   to	  monitor	  the	  kinetics	  of	  uptake,	  we	  further	  confirmed	  that	  the	  growth	  phase	  of	  the	  cells	  did	  not	  significantly	  alter	  the	  internalisation	  kinetics	  (Figure	  3.4.13).	  
	   	  	  
 
Figure	  3.4.	  12.	  Yeast	  lipid	  droplets	  stained	  with	  NR.	  Images	  were	  obtained	  under	  the	  
same	  conditions	  as	  in	  the	  experiment	  of	  Fig.	  3.4.5.	  S.	  cerevisiae	  in	  log	  phase	  (2	  days	  
of	   culture,	   left)	   showed	   a	   larger	   number	   of	   small	   lipid	   bodies,	   while	   those	   in	  
stationary	   phase	   (6	   days	   of	   culture,	   right)	   exhibited	   a	   reduced	   number	   of	   larger	  
lipid	  bodies.	  It	   is	  noteworthy	  that,	  despite	  the	  clear	  morphological	  differences,	  our	  
measurements	   did	   not	   highlight	   any	   significant	   difference	   in	   the	   overall	  





Figure	   3.4.	   13.	   Kinetics	   of	   limonene	   uptake	   in	   yeast	   cells	   grown	   under	   different	  
conditions.	   The	   uptake	   and	   internalisation	   of	   limonene	   (20%	   wt.	   in	   water)	   was	  
measured	  using	  S.	  cerevisiae	  cells	  in	  log	  and	  stationary	  phase	  at	  40	  °C	  by	  following	  
the	  emission	  intensity	  at	  620	  nm	  after	  NR	  staining.	  	  	  	  




B)	   Using	   the	   LIVE/DEAD	   Baclight	   kit,	   all	   cells	   are	   stained	   by	   SYTO	   9,	   a	   green-­‐emitting,	   DNA-­‐binding	   and	   membrane-­‐permeable	   dye;	   instead,	   only	   dead	   cells	  with	  compromised	  membranes	  are	  stained	  by	   the	  red-­‐emitting	  propidium	   iodide	  dye	   (PI)	   (Zhang	   and	   Fang,	   2004)	   (Figure	   3.4.14,	   bottom	   row).	   Flow	   cytometry	  provides	   a	   quantitative	   estimate	   of	   the	   proportion	   of	   live	   and	   dead	   cells	   by	  computing	   the	   ratio	   between	   red-­‐	   and	   green-­‐emitting	   cells	   (Zhang	   and	   Fang,	  2004).	  	  
Figure	  3.4.	  14.	  Viability	  staining	  of	  yeast	  cells	  with	  two	  different	  fluorescence-­‐based	  
methods.	   Top:	   deconvolved	   images	   of	   the	   localization	   and	   fluorescence	   of	   FUN-­‐1;	  
cells	  were	  also	   stained	  with	  25	  µM	  Calcofluor	  white	   to	  highlight	   the	   cell	  wall.	  The	  
intensely	  red-­‐emitting	  intravacuolar	  cylindrical	  structures	  indicated	  high	  metabolic	  
activity	  (left),	  but	  in	  control	  samples	  bright	  green	  emission	  indicated	  	  the	  presence	  
of	   living	   but	  metabolically	   inactive	   cells	   (centre).	  Bottom	  left:	   fluorescence	   images	  
(not	  deconvolved)	  of	  control	  cells	  showed	  green	  fluorescence	  due	  to	  the	  membrane	  
permeable	   dye	   SYTO	   9	   (LIVE/DEAD	   BacLight);	   note	   the	   presence	   of	   some	   red	   PI	  
fluorescence	   on	   the	   surface	   of	   cells.	   Bottom	   centre:	   autoclaved	   cells	   showed	   an	  
intense	  yellow	  fluorescence	  due	  to	  the	  co-­‐localisation	  of	  the	  emission	  of	  SYTO	  9	  and	  


































Figure	  3.4.	   15.	  Time-­‐course	  of	   yeast	   cell	   viability	  was	   assessed	  with	   two	  methods.	  
Top:	  FUN-­‐1	   	   cell	   viability	  of	   stationary	  phase	  S.	  cerevisiae	   cells	  as	  a	   function	  of	   the	  
contact	   time	   with	   20%	   terpene	   dispersions	   in	   deionised	   water	   at	   40°C.	   Open	  
symbols:	  viability	  calculated	  on	  the	  basis	  of	  the	  red/green	  emission	  ratio	  of	  FUN-­‐1;	  
the	  viability	  of	  autoclaved	  cells	  was	  assumed	  0%.	  Full	  symbols:	  viability	  calculated	  
through	   cell	   counting	   by	   three	   independent	   observers;	   this	   method	   provided	   a	  
“viability”	   of	   autoclaved	   cells	   of	   ~	   10%,	   but	   this	   may	   simply	   reflect	   the	   residual	  
presence	  of	  FUN-­‐1-­‐metabolising	  enzymes	  rather	  than	  the	  viability	  state	  of	  the	  cells.	  
Bottom:	  BacLight	  assay	  of	  cell	  viability	  for	  the	  same	  systems.	  Open	  symbols:	  cells	  in	  
stationary	  phase;	  the	  maximum	  viability	  recorded	  was	  100%.	  Full	  symbols:	  cells	  in	  




confirm	  that	   the	  trend	  observed	  for	  cells	  grown	  in	  stationary	  phase	  applied	  to	   the	  
less	  robust	  cells	  growing	  in	  log	  phase.	  	  Nevertheless,	   the	   three	   assays	   qualitatively	   agreed	   that	   linalool	   internalisation	  decreased	   cell	   viability	   to	   negligible	   levels	   within	   the	   first	   30	   min	   of	   exposure,	  while	   the	   effect	   of	   limonene	  was	   less	   pronounced	   and	   slower:	   in	   one	   hour	   60%	  viability	   was	   evaluated	  with	   FUN-­‐1	   cell	   counting,	   45%	  with	   FUN-­‐1	   fluorescence	  (Figure	  3.4.15,	  top)	  but	  20%	  with	  BacLight	  (down	  from	  the	  original	  40%).	  Of	  note,	  40%	  viability	  was	   recorded	   by	   the	  BacLight	   assay	   under	   the	   same	   conditions	   of	  internalisation	   on	   cells	   in	   log	   phase	   (Figure	   3.4.15,	   bottom).	   The	   different	  behaviour	   of	   the	   two	   terpenes	   can	   be	   easily	   related	   to	   the	   faster	   internalisation	  kinetics	  of	  linalool.	  	  A	   clear	   discrepancy	  was	   observed	   for	   the	   data	  with	   carvone:	   the	  BacLight	   assay	  provided	  a	  picture	  indistinguishable	  from	  that	  of	  linalool,	  with	  negligible	  viability	  in	   both	   stationary	   and	   log	   phase	   cells	   (Figure	   3.4.15,	   bottom).	   The	   similarity	   is	  reasonable,	  considering	  that	  the	  two	  terpenes	  have	  similar	  internalisation	  kinetics	  (cf.	   Fig.	   3.4.8).	   On	   the	   other	   hand,	   the	   absence	   of	   significant	   changes	   in	   FUN-­‐1	  fluorescence	   suggested	   high	   levels	   of	   viability	   (Figure	   3.4.15,	   top);	   in	   particular,	  while	   the	   emission	   spectra	   of	   autoclaved,	   linalool-­‐	   or	   limonene-­‐containing	   S.	  





Figure	   3.4.	   16.	   Images	   and	   spectra	   of	   FUN-­‐1-­‐stained	   yeast	   cells	   after	   loading	  with	  
terpenes.	   	   Left	   and	   centre:	   Fluorescence	   microscopy	   pictures	   of	   FUN-­‐1	   stained	   S.	  
cerevisiae	  cells	  in	  stationary	  phase	  untreated	  (control),	  or	  exposed	  to	  20%	  terpenes	  
for	   30	  min	   at	   40°C.	   In	   FUN-­‐1	   cell	   counting	   assays,	   such	   images	   were	   analysed	   by	  
three	   different	   observers	   and	   scored	   for	   the	   fraction	   of	   viable	   cells	   (not	   shown).	  
Right:	   Fluorescence	   spectra	   (λ	  exc=	  480	  nm)	  of	   the	   same	  yeast	   cells	   suspensions	  as	  
above	   that	   were	   adjusted	   to	   the	   same	   final	   OD	   value.	   The	   spectral	   similarity	   of	  




well	   known	   and	   generally	   ascribed	   to	   their	   permeabilising	   effect	   on	   the	   cell	  membranes	  (Uribe	  et	  al.,	  1985;	  Belletti	  et	  al.,	  2004;	  Cox	  et	  al.,	  2000;	  Griffin	  et	  al.,	  1999).	  Our	  results	  confirmed	  early	  evidence	  of	  the	  effect	  of	  terpene	  internalisation,	  further	   showing	   that	   relative	  differences	   (limonene	  vs.	   linalool	   and	  carvone)	   can	  be	  easily	  ascribed	  to	  the	  different	  internalisation	  kinetics	  of	  the	  terpenes.	  The	  key	  point	   of	   this	   analysis	   is	   that	   the	   majority	   of	   terpene	   internalisation	   takes	   place	  under	   conditions	   of	   seriously	   impaired	   cell	   viability,	   therefore	   confirming	   the	  purely	   diffusive	   and	   non-­‐energy-­‐dependent	   nature	   of	   the	   process.	   However,	   the	  initial,	  more	  rapid	  phase	  of	  terpene	  internalisation	  takes	  place	  when	  a	  significant	  number	  of	   cells	  are	   still	   viable.	  Hence,	   it	   cannot	  be	  excluded	   that	   this	   first	  phase	  may	   have	   an	   active	   uptake	   component,	   whereas	   at	   later	   time	   points	   no	   longer	  viable	   cells	   surely	   internalise	   terpenes	   through	   purely	   passive	   diffusion.	  Alternatively,	   the	   physical	   properties	   of	   the	   cell	   wall	   and/or	   intracellular	  organelles	   may	   change	   after	   cell	   die,	   producing	   a	   different	   environment	   for	   the	  incorporation	  of	  exogenous	  hydrophobes.	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3.7	  Appendix	  A	  	  As	   illustrated	   in	   the	   image	   of	   Figure	   3.7.1,	   increasing	   the	   hydrophobicity	   of	   the	  environment	  shifts	  the	  absorbance	  of	  NR	  solutions	  from	  blue	  to	  red	  and	  then	  pale	  yellow.	   In	   parallel,	   the	   fluorescence	   emission	   blue-­‐shifts	   from	  deep	   red	   to	   green	  and	   then	   yellow,	   with	   a	   corresponding	   increase	   in	   emission	   intensity	   (Figure	  3.7.2).	  In particular, when the solvent changes from ethanol to hexane, the intensity of 
NR fluorescence increases by over two-fold together with a blue shift by over 60 nm in 
the emission maximum. This means that the colour of the emitted fluorescence changed 
from red to green-yellow in a more hydrophobic environment.	  
	  
Figure	  3.7.	  1.	  Solvatochromic	  behaviour	  of	  NR.	  NR	  was	  dissolved	  in	  (from	  left	  to	  





































Figure	  3.7.	  2	  Fluorescence	  emission	  spectra	  of	  0.1	  µg/mL	  NR	  in	  solvents	  of	  different	  
polarity.	   Note	   the	   small	   shift	   in	   emission	   maximum	   between	   ethanol	   and	   the	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3.8	  Appendix B 	  	  
	  
 
Figure	  3.8	  1.	  Chromatogram	  of	  a	  methanol	  solution	  containing	  0.05	  mg/mL	  NR,	  0.5	  
mg	   limonene	   and	   0.55	  mg/mL	   ISD	   (linalool).	   The	   peak	   at	   2.9	  min	   corresponds	   to	  
linalool,	   	  that	  at	  3.7	  min	  to	  Nile	  Red	  and	  that	  at	  4.4	  min	  to	  limonene.	  HPLC	  analysis	  
was	  performed	  using	  a	  Reprosil	  100	  C18	  (5µ),	  250	  mm	  X	  4.6	  mm	  column,	  T	  =	  40°	  C,	  
eluent:	  MeOH:	  Hex	  90:10;	  the	  UV-­‐detector	  was	  set	  at	  210	  nm.	  	  	  


















weight NR/ weight ISD (mg/ml)
R2 = 0.998
	  	  	  
Figure	  3.8	  2.	  Calibration	  curve	  of	  NR	  by	  HPLC.	  The	  analysis	  was	  performed	  using	  a	  
Reprosil	  100	  C18	   (5µ),	  250mm	  X	  4.6	  mm	  column,	   temperature	  of	   the	   column	  was	  





3.9 Appendix C 	  
	  	  
Figure	   3.9.	   1.	   Fitting	   of	   the	   kinetics	   of	   limonene	   loading	   in	   yeast.	   Using	   limonene	  
loading	  curves	  as	  an	  example,	  a	  time	  log	  scale	  (right)	  allows	  to	  better	  appreciate	  the	  
more	  accurate	  fit	  of	  the	  early	  time	  points	  offered	  by	  	  	  bi-­‐exponential	  model.	  	  	  
	  	  
Figure	  3.9.	  2.	  Arrhenius	  plot	  of	   the	  kinetic	  data	   for	  the	   internalisation	  of	   terpenes.	  
Limonene,	   linalool	  and	  carvone	  were	  added	  at	  20%	  (wt)	   to	   log	  phase	  grown	  yeast	  
cells	  and	  the	  loading	  kinetics	  were	  recorded	  as	  in	  the	  experiment	  of	  Fig.	  3.9.	  1.	  It	  is	  
apparent	   that	   the	   two	   terpenes	  with	  higher	  LogP	   (linalool	   and	   limonene)	   seem	   to	  




4.	  Enhancing	  the	  encapsulation	  of	  hydrophobes	  in	  yeast	  
microcapsules	  and	  preliminary	  studies	  on	  their	  release.	  	  	  
4.1	  Summary	  	  The	  research	  presented	  in	  this	  chapter	  addresses	  the	  possibility	  to	  encapsulate,	  for	  the	  first	  time,	  solid	  hydrophobic	  compounds	  inside	  yeast	  cells	  as	  microcapsules	  for	  drug	  delivery.	  This	  could	  be	  achieved	  by	  exposing	  yeast	  cells	  to	  organic	  solvents	  in	  which	   the	   compounds	   were	   dissolved.	   After	   a	   screening	   of	   different	   solvents,	  DMSO	   was	   chosen	   as	   an	   effective	   system	   to	   enhance	   the	   encapsulation	   of	  hydrophobes	   of	   commercial	   application.	   The	   physical-­‐chemical	   parameters	   that	  regulate	  the	  encapsulation	  process	  of	  hydrophobes	  with	  DMSO-­‐treated	  cells	  were	  then	  investigated.	  The	  results	  show	  that	  the	  hydrophobicity	  of	  the	  compound	  is	  the	  main	   factor	   driving	   their	   loading	   process,	   with	   some	   exception	   for	   ionisable	  substances.	  Conversely,	  the	  same	  hydrophobicity	  reduces	  the	  rate	  of	  release	  of	  the	  hydrophobes	   encapsulated	   in	   yeast	   cells,	   as	   verified	   by	   novel	   approaches	   to	  measure	   this	  release	  under	  conditions	   that	  are	  physiologically	  pertinent	   for	  drug	  delivery.	  	  	  








described	   in	   Inoue	   et	   al.,	   (1991).	   In	   the	   resulting	   empty,	   dead	   cells	   the	   loading	  extent	  of	  limonene	  and	  other	  hydrophobic	  substances	  is	  high	  (Dardelle	  et	  al.,	  2007;	  Fieber	  et	  al.,	  2011).	  The	  encapsulated	  substances	  fill	  most	  of	  the	  space	  inside	  the	  cell	   wall	   with	   a	   single	   droplet	   (Figure	   1.5.1),	   which	   appears	   to	   be	   formed	   by	   a	  mixture	  with	  retained	  cellular	  material	  (Normand	  et	  al.,	  2005;	  Fieber	  et	  al,	  2011).	  The	  release	  of	  flavouring	  compounds	  loaded	  into	  these	  yeast	  microcapsules	  could	  follow	  two	  mechanisms	  (Normand	  et	  al.,	  2005).	  The	  first	  mechanism,	  suggested	  by	  calorimetric	   analysis,	   implied	   a	   mechanical	   breaking	   of	   the	   cell	   wall,	   while	   the	  second	  mechanism,	   more	   relevant	   to	   physiological	   conditions	   for	   the	   release	   of	  encapsulated	  drugs,	  depended	  on	  a	  swelling	  process	  of	  the	  external	  layer	  of	  the	  cell	  wall.	  	  	  A	   recent	   study	   by	   Shi	   et	   al.	   (2008)	   has	   used	   a	   hybrid	   yeast	   capsule	   system,	  obtained	   first	  with	  plasmolysis	   as	   in	   the	  work	  of	  Dardelle	   et	   al.	   (2007)	  and	   then	  with	   the	   encapsulation	   procedure	   of	   Bishop	   et	   al.	   (1998).	   The	   release	   of	   loaded	  resveratrol,	   studied	  with	   an	   in	   vitro	   system	   that	   simulated	   the	   conditions	   of	   the	  gastric	   fluid	   (very	   low	   pH),	   was	   shown	   to	   be	   relatively	   rapid,	   with	   complete	  emptying	  of	  the	  load	  after	  2	  h	  (Shi	  et	  al.,	  2008).	  This	  rapid	  release	  was	  considered	  to	  derive	  from	  the	  physical	  damage	  that	  the	  low	  pH	  environment	  produced	  on	  the	  mannoprotein	   layer	   and	   other	   structures	   of	   the	   cell	   wall,	   resulting	   in	   loss	   of	  capsular	   integrity.	   A	   similar	   situation	   is	   supposed	   to	   occur	  whenever	   yeast	   cells	  are	   ingested	   and	   encounter	   the	   gastric	   fluids,	   which	   additionally	   have	   acid	  proteases	   and	   glycosylases	   that	  would	   destroy	   the	   cell	  wall	   integrity	   even	  more	  rapidly	  than	  the	  system	  used	  by	  Shi	  et	  al.	  (2008).	  	  Besides	   the	   abovementioned	   studies,	   information	   on	   the	   release	   of	   loaded	  hydrophobes	   from	  yeast	  microcapsules	   is	  rather	   limited,	  especially	   in	   the	  case	  of	  




compounds	   that	   could	   be	   efficiently	   loaded	   only	   after	   treating	   yeast	   cells	   with	  DMSO.	  
4.3	  Experimental	  section	  	  
4.3.1	  Materials	  	  Additional	   materials	   used	   for	   this	   chapter	   were:	   DMSO,	   DMF,	   NMP,	   acetonitrile,	  diclorometane,	   toluene	   gradient	   grade	   for	   HPLC	   analysis,	   retinyl	   palmitate,	  prednisolone,	   indomethacin,	   naproxen,	   pyrene,	   K2HPO4,	   H3PO4	   and	   30%	  BSA	   fat	  free	   (albumin	   solution	   from	   bovine	   serum	   30%±2%	   in	   0.85%	   sodium	   chloride,	  aseptically	  filled,	  essentially	  fatty	  acid	  free,	  ≥96%	  by	  agarose	  gel	  electrophoresis)	  were	  obtained	  from	  Sigma-­‐Aldrich,	  Gillingham,	  United	  Kingdom.	  
4.3.2	  Methods	  	  All	   the	  procedures	  of	   cell	   culture	  were	  undertaken	  as	  described	   in	   chapter	  3.3.2.	  	  Cell	  imaging	  and	  staining	  were	  undertaken	  as	  described	  in	  chapters	  3.3.5	  and	  3.3.7.	  	  Extraction	  of	   encapsulated	  hydrophobes	  was	   carried	  out	   as	  described	   in	   chapter	  3.3.8.	  The	  only	  variation	  was	  that	  retinyl-­‐palmitate	  was	  extracted	  with	  a	  mixture	  of	  50:50	  methanol:	   dichloromethane	   instead	   of	  methanol	   alone.	   This	   variation	  was	  necessary	  because	  of	  the	  poor	  solubility	  of	  retinyl-­‐palmitate	  in	  methanol.	  	  	  
4.3.3	  Encapsulation	  of	  hydrophobes	  in	  yeast	  cells	  facilitated	  by	  organic	  








(2008).	   By	   contrast,	   the	   quantity	   of	   yeast	   cells	   used	   here	   for	   the	   encapsulation	  process	  was	  around	  hundreds	  of	  mg.	  In	  addition,	  the	  amount	  of	  hydrophobes	  used	  for	  the	  loading	  process	  was	  not	  fixed	  at	  20%	  as	  in	  Kilcher	  et	  al.	  (2008)	  but	  included	  other	  concentrations,	  e.g.	  5%	  and	  10%.	  	  
4.3.3	  HPLC	  analysis	  of	  extracted	  hydrophobes	  	  HPLC	   analysis	   of	   extracted	   hydrophobes	  was	   performed	   as	   described	   in	   chapter	  3.3.9.	   The	   HPLC	   system	   (Laserchrome	   HPLC	   Laboratories	   Ltd,	   Rochester,	   Kent,	  England)	  and	  the	  instrument	  settings	  were	  the	  same	  as	  those	  described	  in	  chapter	  3.3.9.	  Chromatographic	  separations	  were	  obtained	  with	  a	  Reprosil	  100	  C18	  (5	  µm)	  column	   (250	  mm	  x	  4.6	  mm	  of	   internal	   diameter)	   Laserchrome.	   The	   column	  was	  kept	   at	  40	   °C	  and	  eluted	   isocratically	   at	  1	  ml/min	   in	  different	  mobile	  phases	   for	  each	  compound,	  which	  are	  listed	  in	  Table	  4.7.1	  in	  Appendix	  A.	  	  	  	  









4.4	  Results	  and	  discussion	  	  	  To	  date,	  only	  liquid	  hydrophobes	  have	  been	  encapsulated	  in	  yeast	  by	  mixing	  them	  with	  aqueous	  suspensions	  of	  cells.	  Earlier	  work	  (Bishop	  et	  al.,	  1998;	  Dardelle	  et	  al.,	  2007)	   has	   indeed	   established	   that	   the	   encapsulation	   of	   hydrophobes	   in	   yeast	  microcapsules	   is	   limited	  by	   the	  physical	   state	   of	   the	  hydrophobes	   in	   the	   loading	  solution.	   Can	   this	   limit	   be	   overcome?	   To	   answer	   this	   question	   in	   quantitative	  terms,	   we	   tested	   here	   whether	   treating	   yeast	   cells	   with	   organic	   solvents,	   as	  introduced	  by	  Kilcher	  et	  al.	  (2008),	  can	  effectively	  overcome	  this	  limit	  and	  expand	  to	  solid	  hydrophobes	  the	  application	  of	  loading	  yeast	  cells.	  	  	  The	   first	   approach	   was	   to	   screen	   a	   series	   of	   organic	   solvents	   having	   different	  dielectric	   constants,	   which	   were	   able	   to	   dissolve	   the	   hydrophobic	   substances:	  DMSO,	   DMF	   (Dimethylformamide)	   and	   NMP	   (N-­‐Methyl-­‐2-­‐pyrrolidone).	   Retinyl-­‐palmitate	   was	   the	   hydrophobe	   chosen	   for	   the	   solvent	   screening.	   It	   is	   a	   very	  hydrophobic	   substance,	   essentially	   insoluble	   in	   water	   (LogP	   =	   15.5),	   which	   is	  widely	  used	  as	  a	  vitamin	  A	  supplement	  in	  the	  food	  industry.	  	  	  
4.4.1	  Screening	  of	  different	  solvents	  to	  enhance	  the	  encapsulation	  of	  






Figure	  4.4.	  1.	  Effect	  of	  organic	  solvents	  on	  yeast	  encapsulation	  of	  retinyl-­‐palmitate.	  
A)	   Quantitative	   evaluation	   of	   extracted	   retinyl-­‐palmitate	   from	   loaded	   yeast	   in	  
different	   experiments.	   Values	   on	   the	   Y-­‐axis	   refer	   to	   determined	   levels	   of	   the	  
hydrophobe	  normalised	  to	  yeast	  in	  w/w	  tot	  and	  are	  shown	  as	  the	  average	  plus	  SD	  of	  
three	  different	  experiments.	  The	  values	  of	   the	  dielectric	   constant	   for	  each	   solvent	  
have	  been	  taken	  from	  The	  Merck	  Index:	  an	  Encyclopaedia	  of	  Chemicals,	  Drugs,	  and	  
Biologicals,	   14th	   Edition,	   2006,	   on-­‐line	   resource	   from	   University	   of	   Manchester	  
Library.	   B)	   Quantitative	   changes	   in	   the	   extent	   of	   encapsulated	   retinyl-­‐palmitate	  
from	   yeast	   cells	   obtained	   in	   5	   different	   experiments.	   The	   relative	   increase	   was	  
calculated	  as	   the	  ratio	  of	   the	  quantity	  encapsulated	  after	  solvent	  exposure	  vs.	   that	  
obtained	  under	  normal	  aqueous	  conditions,	  as	  described	   in	  chapter	  3.	   See	  section	  
4.8	   in	   Appendix	   B	   for	   typical	   experimental	   chromatograms	   of	   the	   data	   presented	  
here.	  	  
 
 Figure	   4.4.1B	   presents	   the	   average	   data	   of	   five	   different	   experiments,	   which	  indicate	   that	   all	   solvents	   tested	   clearly	   increase	   the	   level	   of	   retinyl-­‐palmitate	  incorporation	   in	   yeast	   cells	  with	   respect	   to	   the	   standard	   encapsulation	   in	  water.	  The	   concentration	   of	   the	   retinyl-­‐palmitate	   in	   the	   extract	   in	   DMF-­‐treated	   and	  DMSO-­‐treated	   cells	   was	   approximately	   66-­‐fold	   and	   58-­‐fold	   larger,	   respectively,	  than	   that	   in	  water	   far	   right	   in	  Fig.	  4.4.1B.	   	  Conversely,	   it	  was	  only	  27-­‐fold	   larger	  than	   in	   water	   with	   NMP-­‐treated	   cells	   (Fig.	   4.4.1B).	   Hence,	   DMF	   increased	   the	  encapsulation	   capacity	   of	   the	   same	   factor	   that	   has	   been	   described	  previously,	   in	  qualitative	  terms	  and	  only	  for	  DMSO	  (Kilcher,	  2007).	  	  Another	  way	  to	  visually	  appreciate	   the	  quantitative	  changes	   in	   the	  encapsulation	  of	   retinyl-­‐palmitate	  with	   different	   solvents	   is	   shown	   in	   Fig.	   4.4.2.	   Because	   of	   its	  yellowish	  colour	  due	  to	  its	  near	  UV	  absorbance,	  retinyl	  can	  be	  observed	  optically,	  





as	  well	  as	  with	  the	  naked	  eye,	  when	  it	  is	  concentrated	  in	  yeast	  cells.	  Concentrated	  pellets	  of	  untreated	  yeast	  cells	  show	  some	  pale	  creamy	  colour	  due	  to	  their	  intrinsic	  pigments;	  solvent	  treatment	  slightly	  changes	  this	  natural	  colour,	  in	  particular	  with	  DMSO	  (Fig.	  4.4.2A).	  However,	  the	  loading	  of	  retinyl-­‐palmitate	  clearly	  enhances	  the	  yellow	   colour	   of	   the	   yeast	   pellets,	   which	   becomes	   intensely	   orange-­‐yellow	   after	  treatment	  with	  all	  solvents,	  but	  especially	  DMSO	  (Fig.	  4.4.2B).	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Figure	   4.4.	   2.	   Visual	   effects	   of	   solvent	   treatment	   of	   yeast	   cells	   before	   and	   after	  
encapsulation	   of	   retinyl-­‐palmitate.	   A)	   Visual	   images	   of	   yeast	   pre-­‐treated	   with	  
different	  solvents,	  without	  encapsulation.	  B)	  Digital	  photograph	  of	  loaded	  yeast	  cell	  
samples	   after	   loading	   with	   retinyl-­‐palmitate	   using	   the	   indicated	   solvents	   (cf.	   Fig.	  
4.4.1).	  Images	  were	  taken	  for	  one	  representative	  experiment.	  	  The	  results	  of	   the	  solvent	  screening	  suggested	  that	  DMSO,	   the	  solvent	  previously	  used	   by	   Kilcher	   et	   al.	   (2008),	   could	  maximise	   the	   extent	   of	   hydrophobe	   loading	  into	   yeast	   cells	   with	   respect	   to	   the	   levels	   obtained	   under	   the	   usual	   aqueous	  conditions	  (up	  to	  approximately	  60-­‐fold,	  Fig.	  4.4.1B).	  By	  considering	  that	  DMSO	  is	  much	  better	   tolerated	   than	  DMF	  by	  cells	   (especially	  eukaryotic	  ones,	   a	  matter	  of	  concern	   for	   the	   possible	   applications	   of	   the	   implemented	   delivery	   of	   yeast	  microcapsules),	  DMSO	  was	  maintained	  as	   the	   standard	   solvent	   in	   all	   subsequent	  studies.	  	  




for	   widely	   used	   drugs	   that	   are	   powders	   at	   room	   temperature	   and	   basically	  insoluble	  in	  water:	  the	  non-­‐steroid	  anti-­‐inflammatory	  indomethacin	  and	  naproxen,	  and	   the	   steroid	   prednisolone	   (their	   relevant	   physical-­‐chemical	   properties	   are	  listed	   in	   Table	   1).	   These	   drugs,	   which	   could	   not	   be	   mixed	   with	   yeast	   cells	   in	  aqueous	  conditions,	  were	  previously	  dissolved	  in	  DMSO	  and	  then	  mixed	  with	  yeast	  cells	  progressively	  exposed	  to	  the	  same	  solvent	  	  (up	  to	  20%	  weight/overall	  weight	  of	   the	  complete	  suspension	   including	  yeast	  –	  Fig.	  4.4.3).	  After	  a	  series	  of	  washes,	  their	   intracellular	   content	  was	   determined	  with	   solvent	   extraction	   and	  HPLC,	   as	  previously	  described	  in	  chapter	  3.	  	  	  None	  of	  the	  above	  drugs	  was	  incorporated	  to	  levels	  equivalent	  to	  those	  of	  retinyl-­‐palmitate,	   even	   if	   indomethacin	   was	   consistently	   more	   efficiently	   encapsulated	  than	   the	   other	   drugs	   at	   40	   °C	   (Fig.	   4.4.3.A).	   The	   results	   thus	   suggested	   that	   the	  quantitative	   aspects	   of	   drug	   encapsulation	   after	   DMSO	   treatment	   varied	   for	  different	   drugs,	   similarly	   to	   what	   had	   been	   previously	   observed	   with	   different	  terpenes	  under	  aqueous	  conditions	   	  (e.g.	  Fig.	  3.4.2	   in	  chapter	  3).	   Intriguingly,	   the	  extent	   of	   encapsulation	   of	   the	   same	   drugs	   did	   not	   significantly	   increase	   by	  increasing	  the	  temperature	  to	  60	  °C	  (Fig.	  4.4.3.B).	  Of	  note,	  at	  60	  °C	  the	  extent	  of	  the	  loading	  of	  retinyl-­‐palmitate	  was	  lower	  than	  that	  obtained	  at	  40°C	  (Fig	  4.4.3B	  vs.	  A).	  This	  apparent	  contradiction	  most	  likely	  derived	  from	  the	  fact	  that	  retinyl	  palmitate	  is	   thermo-­‐labile	   (Carlotti	   et	   al.,	   2002).	   Given	   this,	   subsequent	   experiments	  were	  routinely	  conducted	  at	  40	  °C.	  
	   	  	  	  	   	  	  
Figure	   4.4.	   3.	   Quantification	   of	   the	   loading	   of	   hydrophobic	   drugs	   using	   DMSO	  
treatment	  of	  yeast	  cells.	  Drugs	  were	  used	  at	  a	  fixed	  concentration	  (20%),	  either	  at	  



























































	  To	  evaluate	  whether	  the	  differences	  observed	  in	  the	  extent	  of	  drug	  encapsulation	  (Fig.	  4.4.3)	  arose	  from	  a	  different	  concentration	  dependence	  of	  the	  encapsulation	  process,	   titrations	   were	   carried	   out	   in	   an	   enlarged	   series	   of	   experiments	   (Fig.	  4.4.4A).	   The	   results	   showed	   that	   the	   differences	   in	   the	   absolute	   extent	   of	   drug	  encapsulation	  remained	  at	  every	  concentration	  tested	  (Fig.	  4.4.4A).	  	  	   	   	   	  
	  	  
	  	  	   	   	   	  	  	  	   	  
	  
	  
Figure	  4.4.	  4.	  Parameters	  affecting	  the	  loading	  of	  hydrophobic	  substances	  in	  DMSO-­‐
treated	   yeast.	   A)	   Concentration	   dependence	   in	   the	   loading	   of	   hydrophobic	  
compounds,	  at	  40°C	  for	  2h	  and	  4h	  as	  in	  the	  experiment	  of	  Fig.	  4.4.3.	  B)	  Correlation	  
between	   the	   LogP	   of	   the	   hydrophobic	   substances	   and	   their	   percentage	   of	   loading	  
inside	  yeast	  cells.	  
A	  
B	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Table 4.4. 1. Percentage of hydrophobes loaded in yeast cells using different 
concentrations of hydrophobic compounds after 2 h of incubation. Results represent 
averages ± SD for n = 4 experiments. 	  
Compounds	   LogP	   %	  of	  hydrophobes	  loaded	  	   At	  5%	  loading	   At	  10%	  loading	   At	  20%loading	  Prednisolone	   1.42	   0.15	   ±0.008	  	   	  0.28	   	  	  ±0.014	  	   	  	  0.6	   ±0.1	  	  Naproxen*	   3.34	   0.06	   ±0.003	  	   	  0.16	   	  	  	  ±0.04	  	   	  	  0.67	   ±0.12	  	  Indomethacin^	   4.7	   0.17	   	  	  ±0.038	  	   	  0.35	   	  	  	  ±0.029	  	   	  	  1.38	   	  ±0.5	  	  Retinyl	  palmitate	   15.5	   1.64	   	  ±0.4	  	   	  3.38	   	  	  	  ±0.94	  	   	  	  3.8	   	  ±	  0.1	  	  	  *	  Naproxen	  has	  a	  pKa	  =	  4.8	  (Mura	  et	  al.,	  2005)	  ^	  Indomethacin	  has	  a	  pKa	  =	  4.4	  (Nokhodchi	  et	  al.,	  2005)	  	  
4.4.3	  Investigating	  other	  parameters	  that	  may	  affect	  drug	  encapsulation	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  4.4.	  5.	  Kinetics	  of	  loading	  of	  retinyl-­‐palmitate	  and	  naproxen	  in	  DMSO-­‐treated	  
cells.	  Both	  drugs	  were	  used	  at	  20%	  and	  40°C	   in	  DMSO	  during	   the	   incubation	  with	  
cells.	   Each	   time	   point	   represents	   the	   incubation	   time	   of	   DMSO-­‐treated	   cells	   and	  
hydrophobes.	   The	   hydrophobic	   substances	   encapsulated	   in	   yeast	   cells	   were	   then	  
extracted	  with	  MeOH	  or	  MeOH:	  CH2Cl2	  for	  HPLC	  determination	  as	  described	   in	   the	  
methods	  (chapter	  4.3.2).	  Cells	  were	  used	  in	  the	  log	  phase	  of	  growth.	  























































Figure	  4.4.	  6.	  Images	  of	  deconvolution	  microscopy	  of	  cells	  stained	  with	  NR	  	  (for	  lipid	  
droplets	   and	   membrane	   structures)	   combined	   with	   Alexa	   488-­‐conjugated	  
concanavalin	   A	   (for	   the	   external	   wall).	   A.	   Control	   untreated	   cells.	   The	   green	  
continuous	   rim	   surrounding	   the	   cell	   derives	   from	   concanavalin	   staining	   of	  
mannose-­‐rich	   structures	   in	   the	   cell	  wall	   (cf.	  Kilcher	   et	   al.,	   2008).	  B.	  DMSO-­‐treated	  
cells	   (without	   drug	   loading).	   	   C	   &D.	   DMSO-­‐treated	   cells	   after	   loading	   with	   20%	  
naproxen.	  E	  &F.	  DMSO-­‐treated	  cells	  after	  loading	  with	  20% retinyl	  palmitate.	  G	  &H.	  
DMSO-­‐treated	  cells	  loaded	  with	  20%	  prednisolone.	  All	  cells	  were	  used	  in	  log	  phase	  








	  Taken	   together,	   these	   results	   indicated	   that	   DMSO	   treatment	   perturbed	   intra-­‐cytoplasmatic	  organelles,	   including	   the	   lipid	  droplets,	  but	  without	  preventing	   the	  formation	  of	  hydrophobic	  globular	  structures	   incorporating	   loaded	  hydrophobes.	  These	  globules	  filled	  with	  encapsulated	  hydrophobes	  resembled	  the	  enlarged	  lipid	  droplets	  previously	  found	  in	  the	  encapsulation	  of	  limonene	  in	  water,	  and	  therefore	  may	   represent	   re-­‐organized	   storage	   organelles	   coated	   with	   phospholipids	   and	  other	  endogenous	  lipids.	  The	  finite	  structure	  of	  these	  globules	  suggested	  a	  physical	  limit	  in	  the	  maximal	  loading	  of	  hydrophobic	  substances	  in	  DMSO-­‐treated	  cells	  like	  in	   the	   cells	  maintained	   in	   aqueous	   systems.	   The	   overall	   cell	   volume	  was	   in	   fact	  retained	  by	  an	  essentially	  intact	  cell	  wall	  (Fig.	  4.4.6).	  	  	  
4.4.5	  DMSO	  treatment	  enhances	  the	  extent	  of	  loading	  of	  hydrophobes	  




exponentially	  and	  thus	  having	  a	  more	  flexible	  and	  less	  cross-­‐linked	  wall	  structure	  (Gray	  et	  al.,	  2004).	  These	  results	  also	  suggested	  that	  DMSO	  treatment	  specifically	  alters	  the	  permeability	  of	  the	  yeast	  cell	  wall	  contributing	  to	  the	  enhanced	  loading	  and	  storage	  of	  hydrophobes	  within	  cellular	  micro-­‐capsules.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	   4.4.	   7.	   DMSO	   treatment	   differentially	   affects	   the	   encapsulation	   of	  
prednisolone	  depending	  on	  the	  growth	  phase	  of	  yeast	  cells.	  	  Cells	  in	  log.	  phase	  (dark	  
histograms)	  and	  stationary	  phase	  (light	  grey	  histograms)	  were	  treated	  with	  DMSO	  
containing	  20%	  prednisolone	  for	  the	  indicated	  times	  at	  40	  °C.	  Loaded	  prednisolone	  
was	   then	   quantified	   by	   HPLC	   after	   methanol	   extraction	   as	   described	   before	  
(chapter.	  4.3.3).	  Note	  the	  much	  larger	  extent	  of	  prednisolone	  loaded	  in	  cells	  grown	  
logarithmically	  than	  in	  cells	  grown	  in	  the	  stationary	  phase.	  	  	  	  
4.4.6	  Study	  on	  the	  release	  of	  encapsulated	  drugs	  from	  yeast	  capsules	  	  To	  set	  up	  a	   sensitive	  method	   for	  determining	   the	   release	  of	  hydrophobes	   loaded	  into	   intact	   yeast	   cells,	   it	   was	   considered	   a	   simple	   aqueous	   buffer	   containing	  physiologically	   relevant	   concentrations	   of	   the	   dominant	   serum	  protein,	   albumin.	  This	  protein	   is	   the	  major	   carrier	   for	  hydrophobic	  drugs	   and	   their	  metabolites	   in	  the	   body	   and	   its	   multiple	   binding	   sites	   for	   hydrophobic	   substances	   can	  accommodate	  a	  variety	  of	  synthetic	  molecules	  as	  well	  as	   its	  natural	   ligands,	   fatty	  acids	  and	   their	  derivatives.	  The	   idea	  of	  using	  BSA	  was	  also	   inspired	  by	  earlier	   in	  vitro	   studies	   on	   the	   surface	   back	   resorption	   of	   lipid	   molecules	   like	   fluorescent	  phospholipids.	   After	   their	   delivery	   to	   live	   mammalian	   cells,	   these	   hydrophobic	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compounds	  enter	  and	   rapidly	   circulate	  within	  membrane	   traffic	   routes	   that	   then	  transiently	  expose	  them	  onto	  the	  plasmamembrane	  (Mayor	  and	  Pagano,	  2007).	  By	  analogy,	   it	   was	   considered	   that	   whatever	   fraction	   of	   previously	   loaded	  hydrophobes	   were	   to	   permeate	   the	   cell	   wall	   and	   thus	   become	   exposed	   to	   the	  surface	  of	  yeast	  microcapsules,	  this	  fraction	  would	  be	  rapidly	  bound	  to	  the	  excess	  of	  defatted	  BSA	  in	  the	  medium,	  as	  if	  the	  capsules	  were	  suspended	  in	  body	  fluids.	  	  The	  first	  hydrophobic	  compound	  that	  was	  tested	  in	  this	  system	  was	  Nile	  Red	  (NR),	  because	   its	   spectroscopic	   properties	   facilitated	   its	   real	   time	   determination	   in	  solution.	   Yeast	   cells	   were	   stained	   with	   NR	   under	   the	   same	   conditions	   as	   those	  described	   in	   chapter	   3.3.6	   and	   the	   evaluation	   of	   NR	   release	   was	   carried	   out	   by	  following	  its	  absorbance	  at	  different	  time	  points	  in	  the	  supernatant	  obtained	  from	  a	  suspension	  of	  NR-­‐loaded	  yeast	  cells	  (as	  described	  previously	  in	  chapter	  3).	  The	  release	  was	  very	  rapid	  and	  consequently	  the	  time	  points	  had	  to	  be	  taken	  every	  few	  seconds	  (Fig.	  4.4.8).	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Figure	  4.4.	  8.	  	  The	  plot	  shows	  the	  time	  course	  of	  the	  change	  of	  NR	  absorbance	  in	  the	  
supernatant	   of	   yeast	   cells	   pre-­‐loaded	   with	   the	   dye.	   Black	   squares	   represent	   the	  
absorbance	   of	   NR	   released	   in	   2%	   BSA	   in	   PBS	   after	   subtraction	   of	   the	   blank	  
(containing	   only	   2%	   BSA in	   PBS).	   Empty	   circles	   represent	   the	   absorbance	   of	  
samples	   in	  which	  NR	   loaded	  yeast	  cells	  were	  suspended	   in	  PBS	  alone.	   In	   this	  case,	  
data	  showed	  no	  statistically	  significant	  difference	  with	  time,	  from	  0	  to	  30	  min	  (1800	  












	  	  	  
	  
	  
Figure	  4.4.	  9.	  Release	  profile	  of	  NR	  in	  PBS	  containing	  2%	  fat	  free	  BSA	  solution	  at	  
37°C.	  Data	  is	  shown	  as	  average	  ±	  SD	  (n	  =	  4).	  The	  release	  process	  reached	  saturation	  
after	  only	  30s.	  



















	  The	   initial	   rate	  of	  NR	  release	  was	  extrapolated	   from	  the	   initial	  data	  points	  of	   the	  experiment	  in	  Fig.	  4.4.8	  and	  corresponded	  to	  11%	  per	  second.	  It	  was	  considered	  of	  interest	  to	  compare	  this	  rate	  with	  that	  extrapolated	  from	  the	  data	  reported	  in	  Fig.	  6	   of	   the	   paper	   by	   Shi	   et	   al.	   (2008),	   in	   which	   the	   experimental	   conditions	   were	  relatively	   similar	   to	   those	   employed	   here	   (Table	   4.4.1).	   	   Clearly,	   the	   rate	   of	   NR	  release	   was	   much	   higher	   than	   that	   of	   encapsulated	   resveratrol	   under	   the	  conditions	  of	  Shi	  et	  al.	  (2008).	  	  
Table	  4.4.	  1.	  Initial	  rate	  of	  release	  calculated	  for	  different	  compounds	  	  
	  *	  (Medina	  et	  al.,	  2010)	  	  Subsequently,	   the	   very	   hydrophobic	   retinyl-­‐palmitate	   was	   chosen	   to	   obtain	   a	  preliminary	  assessment	  of	  its	  release	  after	  efficient	  loading	  in	  DMSO-­‐treated	  yeast	  cells	   (see	   chapter	   4.4.2).	   Similarly	   to	   the	   experiment	   for	   the	   release	   of	   NR,	   the	  amount	  of	  retinyl-­‐palmitate	  encapsulated	  in	  yeast	  cells	  after	  DMSO	  treatment	  (cf.	  chapter	   4.4.2)	  was	   evaluated	   by	   HPLC	   and	   then	   the	   expected	   absorbance	   of	   the	  encapsulated	   compound	  was	   estimated	   from	   its	   extinction	   coefficient	   in	   ethanol	  (absorbance	  in	  water	  was	  not	  feasible	  because	  of	  its	  insolubility),	  shown	  in	  Figure	  4.8.3	  of	  Appendix	  B.	  For	  example,	   in	   the	  experiment	  of	  Fig.	  4.4.10	   the	  amount	  of	  encapsulated	  retinyl-­‐palmitate	  was	  2.4	  mg	  per	  60	  mg	  of	  yeast	  cells,	  from	  which	  the	  total	  Absorbance	  was	  estimated	  to	  be	  36	  A	  by	  assuming	  that	  the	  extinction	  of	  the	  compound	  bound	  to	  the	  hydrophobic	  pockets	  of	  BSA	  would	  be	  comparable	  to	  that	  in	  ethanol.	  	  	  
Compound	  and	  conditions	   Initial	  rate	  of	  
release	  (%	  /	  s)	  
References	   LogP	  





















	  	  	  
	  
	  
Figure	  4.4.	  10.	  The	  time	  course	  of	  the	  release	  of	  retinyl-­‐palmitate	  from	  loaded	  yeast	  
cells was	  evaluated	  at	  37°C	  in	  PBS	  containing	  2%	  fat	  free	  BSA.	  The	  loading	  of	  retinyl-­‐	  
palmitate	  was	  undertaken	  after	  treatment	  of	  yeast	  cells	  with	  DMSO	  as	  described	  in	  
chapter	  4.4.2.	  Data	  are	   shown	  as	  averages	  ±	   SD	   (n	  =	  4).	  No	  detectable	  absorbance	  
was	  recorded	  in	  parallel	  samples	  without	  BSA	  (cf.	  Fig.	  4.4.8).	  	  
4.5 Conclusions 	  One	  aim	  of	   this	   investigation	  was	  to	  answer	  the	  question	  arisen	   from	  the	   finding	  that	  the	  encapsulation	  of	  hydrophobes	  in	  live	  yeast	  cells	  reaches	  a	  physical	  limit	  of	  around	  10%	  (chapter	  3).	  Namely,	  could	  this	  limit	  be	  overcome?	  Overall,	  the	  results	  obtained	   indicate	   that	   the	   approach	   introduced	   by	   Kilcher	   et	   al.	   (2008)	  significantly	   overcomes	   this	   physical	   limit	   of	   encapsulation,	   which	   is	   essentially	  imposed	  by	  the	  cell	  structures	  of	  intact	  cells.	  In	  particular,	  treatment	  of	  yeast	  cells	  with	  DMSO,	  followed	  by	  gradual	  re-­‐exposure	  to	  aqueous	  media	  strongly	  increases	  the	   encapsulation	   efficiency	   within	   yeast	   cells	   of	   pharmacologically	   relevant	  hydrophobes	  such	  as	  retinyl-­‐palmitate,	  prednisolone	  and	  naproxen.	  Interestingly,	  the	  enhancement	  effect	  of	  DMSO	   treatment	   is	   strong	  only	   in	  cells	  growing	   in	   the	  logarithmic	  phase	  (Fig.	  4.4.7),	  which	  have	  a	  more	  flexible	  and	  porous	  cell	  wall.	  	  Overall,	  the	  results	  obtained	  indicate	  that	  the	  approach	  introduced	  by	  Kilcher	  et	  al.	  (2008)	  can	  significantly	  enhance	  the	  encapsulation	  efficiency	  of	  pharmacologically	  relevant	   hydrophobes	   within	   yeast	   cells,	   overcoming	   in	   part	   the	   physical	   limits	  imposed	  by	  cell	  structures	  on	  the	  maximal	  capacity	  of	  encapsulation.	  	  
























	  The	   second	   part	   of	   this	   chapter	   has	   addressed	   the	   related	   question	   of	   how	   the	  encapsulated	  hydrophobes	  are	  then	  released	  in	  systems	  mimicking	  physiologically	  pertinent	  body	  fluids.	  A	  novel	  and	  effective	  method	  for	  evaluating	  this	  release	  from	  intact	  yeast	  cells	  has	  been	  developed	  and	  has	  shown	  that	  such	  a	  release	  is	  rather	  rapid,	  mediated	  by	  physiological	  hydrophobic	  carriers	  like	  serum	  albumin	  even	  in	  the	   absence	   of	   physical	   rupture	   of	   the	   yeast	   microcapsules.	   This	   applies,	  importantly,	   also	   to	   cells	   treated	   with	   DMSO,	   a	   procedure	   that	   has	   been	  conclusively	   shown	   here	   to	   enhance	   the	   encapsulation	   of	   hydrophobes	   in	   yeast	  cells	  (Figs.	  4.4.3,	  4.4.4)	  without	  disruption	  of	  the	  external	  cell	  wall	  (Fig.	  4.4.6).	  	  The	   results	   presented	   in	   this	   work	   indicate	   that,	   ultimately,	   the	   rate	   of	   release	  depends	  upon	  the	  hydrophobicity	  of	  the	  compounds	  encapsulated	  in	  yeast	  and	  the	  physicochemical	   environment,	   in	   the	   opposite	   direction	   of	   the	   driving	   force	   for	  their	   encapsulation	   within	   the	   empty	   yeast	   cells,	   which	   generally	   is	   directly	  proportional	  to	  the	  LogP	  in	  octanol/water	  (Dardelle	  et	  al.,	  2007).	  To	  sum	  up,	  DMSO	  treatment	  changes	   the	  modalities	  of	  encapsulation	  of	  hydrophobes	   in	  yeast	   cells,	  allowing	   the	   incorporation	   of	   substances	   that	   cannot	   be	   dissolved	   in	   water.	  Conversely,	   the	   same	   treatment	   does	   not	   significantly	   affect	   the	   rapid	   release	   of	  the	  encapsulated	  hydrophobes	  under	  physiologically	  pertinent	  conditions	  for	  drug	  delivery.	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4.7	  Appendix	  A	  	  Table	  4.7.1	  shows	  the	  different	  mobile	  phases	  used	  to	  elute	  each	  of	  the	  compounds	  that	  have	  been	  used	  in	  this	  chapter.	  	  	  
Table	  4.7	  1	  –	  HPLC	  settings	  for	  measuring	  substances	  extracted	  after	  loading.	  	  




Indomethacin	   MeOH:	  50	  mM	  H3PO4	  	  80:	  20	  (Singh	  et	  al.,	  1991)	  
Naproxen,	  	  1	  mg/ml	   270	   Indom:	  6.5	  ISD:	  4.6	  
Naproxen	   MeOH:	  50	  mM	  H3PO4	  	  80:	  20	  (Singh	  et	  al.,	  1991)	  
Indomethacin	  0.5	  mg/ml	   270	   Naprox:	  4.6	  ISD:	  6.5	  
Prednisolone	   MeOH:	  10	  mM	  K2HPO4	  70:30	  (Rouster-­‐Stevens	  et	  al.,	  2008)	  
Toluene,	  12mg/ml	   250	   Predni:	  4.5	  ISD:	  8.24	  
Retinyl	  
palmitate	  




4.8	  Appendix	  B	  	  The	  calibration	  curve	  of	  Nile	  Red	  (NR)	  absorbance	  was	  obtained	  in	  PBS	  containing	  2%	  BSA	   as	   follows:	  NR	   stock	   solution	   (0.1	  mg/ml)	   in	  MeOH	  was	  diluted	  50-­‐fold	  using	  PBS	  containing	  2%	  BSA	  in	  order	  to	  have	  a	  2%	  final	  concentration	  of	  MeOH	  to	  avoid	   potential	   denaturation	   of	   albumin.	   Subsequently,	   a	   serial	   dilution	   of	   this	  solution	   was	   undertaken	   and	   the	   absorbance	   was	   then	   measured	   at	   575	   nm	  (Figures	  4.8.1	  and	  4.8.2).	  	  
	  
	  
Figure	  4.8.	  1.	  Serial	  dilution	  of	  NR	  in	  PBS	  containing	  2%	  fat	  free	  BSA.	  	  The	  first	  vial	  
on	   the	   left	  was	  NR	  stock	  solution	   in	  MeOH.	   	  The	   labelled	  vials	  represent	   the	  serial	  
dilution	   by	   half	   the	   original	   stock	   solution	   of	   NR	   (left	   most	   vial)	   using	   PBS	  
containing	  2%	  fat	  free	  BSA. 	  	  


















NR calibration curve in 2% BSA
	  
Figure	  4.8.	  2.	  Calibration	  curve	  of	  NR	  in	  PBS	  containing	  2%	  fat	  free	  BSA.	  Absorbance	  























Figure	  4.8.	  3.	  Calibration	  curve	  of	  Retinyl	  Palmitate	  (RP)	  in	  EtOH.	  Absorbance	  was	  
measured	  at	  325	  nm	  with	  a	  96-­‐well	  plate	  reader. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  




















4.9	  Appendix	  C	  	   	  	   	  	  	  	  	  	  	  	  	   	   	  	  	   	  	  	  	  	   	  	  	  	  	  	  	   	   	  	  	  	  
Figure	  4.9.	  1.	  HPLC	  Chromatograms	  of	  retinyl-­‐palmitate	  (peak	  A)	  extracted	  from	  
yeast	  cells	  after	  encapsulation	  with	  different	  solvents.	  ISD,	  internal	  standard.
DMSO	  


































































4.4.6)	   to	   a	   large	   variety	   of	   commercially	   useful,	   as	  well	   as	   chemically	   valuable	  substances	  (e.g.	  compounds	  with	  a	  wide	  spectrum	  of	  LogP	  values).	  	  	  As	   a	   final	   conclusion,	   the	   work	   of	   this	   thesis	   has	   quantitatively	   clarified	  important	  aspects	  of	   the	  encapsulation	  process	  of	  hydrophobic	  substances	   into	  yeast	  microcapsules.	  Their	  loading	  capacity	  depends,	  ultimately,	  on	  the	  solubility	  of	   the	   substances	   in	   the	   medium	   used	   for	   their	   encapsulation.	   This	   new	  information	   will	   be	   of	   value	   in	   future	   commercial	   applications	   of	   yeast	  microcapsules	  as	  an	  economic	  biotechnological	  tool	  for	  drug	  delivery.	   	  
 
 
